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The purpose of this study was to evaluate the efficacy, safety and cost effectiveness of a 
0.005mg/kg, up to a maximum of 0.45mg, dose of intrathecal morphine in first-time single level 
spinal surgery. The study was conducted, and results apply, to a tertiary care public service 
hospital in South Africa. 
This experimental intervention was compared to the institutional standard of care being the 
use of intravenous morphine via a patient-controlled device, administering 1mg of morphine 
intravenously every 7 minutes as required. 
Efficacy was measured with reference to validated scoring systems which included the 
Oswestry disability index, Roland Morris questionnaire, EQ-5 score and visual analogue scale 
(VAS) to assess pain, analgesia and disability in the post-operative phase and subsequent 
follow up. A standardised physiotherapy regime was used to mobilize patients and the patients 
was discharged directly to their homes, specifically skipping a step-down facility. 
Safety was assessed by monitoring the known side-effects of morphine (nausea, vomiting, 
pruritis), oxygen saturation, respiratory rate and sedation during the stay in the ICU. Inter alia, 
blood gases were analysed on 11 occasions within the first 24 hours. General patient follow-
up occurred at 6 weeks, 3 and 6 months. 
The study was conducted in a prospective double-blind, randomized placebo controlled 
fashion.  
40 patients were enrolled (20 per group). The time to discharge for the intrathecal morphine 
group (IT) was statistically significantly shorter (3.68 days) compared to 5.61 days for the 
patient-controlled analgesia (PCA) group. This translated into a 43.5% saving for general ward 
stay costs.  
VAS was assessed when lying still and moving and the difference between these values was 
used to quantify the intensity of pain. A significant difference was noted at 24 hours favouring 
the IT group. Significantly less supplemental analgesia was used in the IT group during the 
first 24 post-operative hours. 
No significant difference in side-effects were noted between the groups. The initially elevated 
mean PaCO2 in the IT group demonstrated a significant decrease from 4 hours up to 24 hours. 
An increase in mean respiratory rate was demonstrated from 10 hours onwards in both groups. 
Seven incidents of hypoxia (PaO2 < 8kPa) were observed (IT=4, PCA=3). The 7 incidents 




proven by the A-a gradient. No overt sedation was clinically demonstrated at the time the PaO2 
was less than 8.0 kPa. 
Six week, 3-month and 6-month follow-up demonstrated significant improvement in all scoring 
modalities in both groups.  
The intrathecal use of morphine had a direct effect on the µ-receptors in the spinal cord 
resulting in segmental analgesia allowing the patients to mobilize faster compared to the more 
central acting analgesic effects offered by intravenous morphine. The proposed dose proved 
to be safe with minimal side-effects, all of which were comparable to the PCA group. The 
application will be particularly useful in obese patients where the calculation of a safe 
intravenous dose can be challenging because of excess adipose tissue. When using IT or 
PCA morphine, supplemental oxygen is suggested for the first 4 hours post-operatively and 
continuous monitoring of respiratory rate, saturation and sedation should be done. Finally, it 
is recommended that it will be safer practice to reset the minimum cut-off value for saturation 




















Die doel van die studie was om die effektiwiteit, veiligheid en koste-effektiwiteit van ‘n 
0.005mg/kg, tot ‘n maksimum van 0.45mg, dosering van intratekale morfien te evalueer in 
eerste operasie, enkel vlak lumbale spinale fusie chirurgie. Die studie is uitgevoer in en 
resultate relevant tot ‘n tersiere vlak publieke diens hospitaal in Suid Afrika. 
Die eksperimentele intervensie was vergelyk met standaard sorg vir hierdie tipe gevalle wat 
bestaan uit intraveneuse morfien toegedien deur ‘n pasient-beheerde toestel wat 1mg 
intravenuese morfien elke 7 minute toedien soos benodig. 
Effektiwiteit is gemeet deur gevalideerde evaluerings sisteme wat insluit die “Oswestry 
disability index”, “Roland Morris questionnaire”, “EQ-5” telling asook die “visual analogue 
score (VAS)” om pyn en ongeskiktheid te evalueer, beide post-operatief asook tydens opvolg 
besoeke. ‘n Gestandardiseerde fisioterapie regime was gebruik om die pasiënte te mobiliseer 
en pasiënte is direk tuis ontslaan, sonder enige rehabilitasie fasiliteit.  
Veiligheid is evalueer deur monitering van die bekende newe-effekte van morfien (naarheid, 
braking, pruritis), suurstof saturasie, asemhalingspoed en sedasie gedurende die intensiewe 
sorgeenheid verblyf. Bloedgas analises is gedoen op 11 geleenthede gedurende die eerste 
24 post-operatiewe ure. Pasiënt opvolg het geskied op 6 weke, 3maande en 6 maande. 
Die studie is uitgevoer as ‘n prospektiewe, dubbel-blind, gerandomiseerde placebo beheerde 
studie. 
40 pasiënte is ingesluit (20 per groep). Die tyd tot ontslag vir die intratekale morfien (IT) groep 
was statisties beduidend minder (3.68 dae) as die 5.61 dae in die pasiënt-beheerde analgesie 
(PCA) groep. Dit het gelei tot ‘n 43.5% kostebesparing in algemene saal verblyf. 
VAS was gemeet beide as die pasiënt stil lê en as hulle beweeg. Die verskil in die waardes is 
gebruik om intensiteit van pyn aan te dui. ‘n Statisties beduidende verskil is op 24 uur 
identifiseer ten gunste van die IT groep. Betekenisvol minder reddings-analgesie is gebruik in 
die IT groep oor die eerste 24 uur. 
Geen beduidende verkil in newe-effekte kon identifiseer word nie. Die aanvanklike verhoogde  
gemiddelde PaCO2 in die IT groep het ‘n statisties betekenisvolle uur tot uur daling getoon 
vanaf 4 tot 24 uur. Beide groepe het ‘n gemiddelde asemhalingspoed verbetering getoon vanaf 
10 ure post-operatief aanwaards. Sewe insidente van hipoksie (PaO2 < 8kPa) is identifiseer 
(IT=4, PCA=3). Die 7 insidente kon verduidelik word deur of ‘n lae FiO2, of ‘n lae funksionele 
residuele kapasiteit aangedui deur die A-a gradient. Geen sedasie was assosieer met die 




Die 6 weke, 3 maande en 6 maande opvolge het statisties beduidende verbetering getoon in 
al die evaluerings sisteme. 
Die intratekale gebruik van morfien het ‘n direkte effek op die µ-reseptore in die spinal koord 
wat lei tot segmentele analgesie wat die pasiente vinniger laat mobiliseer vergeleke met 
intraveneuse morfien wat ‘n meer sentrale meganisme van werking het. Die voorgestelde 
dosis is bewys as veilig met minimale newe-effekte vergeleke met die PCA groep. Dit is veral 
van belang in obees pasiënte waar dosis bepaling uitdagend is met die addisionele vetweefsel 
wat teenwoordig is. Supplementele suurstof word aanbeveel vir die eerste 4 ure vir beide 
groepe, met volgehoue monitering van asemhalingspoed, saturasie en sedasie. Laastens sal 
dit veiliger wees om die minimum aanvaarde waarde vir saturasie op ‘n hoër vlak te stel as 
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1. Literature review 
Modern anaesthetics are constantly searching for ways in which to optimise analgesia during 
surgery, especially in the post-operative period. The shift in focus, from systemic opioids to 
more regional analgesic, underlines the efforts being made to overcome the side-effects of 
opioids such as respiratory depression, sedation, nausea, vomiting and decreased bowel 
mobility (Raffaeli, 2006). This constant drive to optimise analgesia, yet minimise side-effects, 
leads to innovative research in pain relief. 
 
1.1 Morphine  
The first opioid approved for neuraxial use by the United States Food and Drug Association 
(FDA) was morphine (DeSousa, 2014). It has several possible routes of administration with 
the most popular being intravenous. The intrathecal route provides the opioid with direct 
access to the neural structures, however, due to its many perceived dangers which include 
cerebrospinal fluid leakage from the access point as well as respiratory depression, this route 
of administration is not very popular (Raffaeli, 2006). Irrespective of the route of administration, 
a portion, if not all of the morphine will enter the bloodstream, be metabolised in the liver and 
ultimately cleared via the kidneys (Fukuda, 2009). 
 
1.1.1 Mechanism of action 
Opioids are effective as they directly inhibit the painful stimuli which ascend in the spinal cord. 
Concurrently descending pain control circuits, arising in the midbrain, are activated in the 
dorsal horn in the spinal cord by means of opioid receptors found in both pre- and post-
synaptic neurons (Fukuda, 2009). Opioids can reach these sites by several different means of 
which intravenous administration is most commonly employed. 
The opioid receptors are G-protein linked and specifically located in laminae I and II of the 
dorsal horn. Once bound to the receptors, calcium channels close and potassium channels 
open which reduce the level of intracellular calcium. Subsequently there is a reduction in 
excitatory transmitters (substance P and glutamate) from the pre-synaptic C-fibres and, 
although A-fibres are not affected, the result of these actions is a reduction in nociceptive 






1.1.1.1 Intravenous morphine 
Once administered, intravenous morphine is metabolised in the liver. Compared to other 
opioids, morphine has a relatively low lipid solubility and its penetration in and out of the central 
neural tissues (thus crossing the blood-brain barrier) is presumably slower (Fukuda, 2009). 
Its main metabolites are Morpine-3-Glucuronide (M3G), which is inactive, and Morphine-6-
Glucuronide (M6G), which has a similar potency to morphine itself regarding its binding to the 
µ-receptors in neural tissue (Linares, 2009). The kidney is mainly responsible for the clearance 
of morphine and thus renal failure is a major risk factor for persistent morphine effect, both 
from morphine itself and M6G. 
The intravenous administration of morphine faces several obstacles. To calculate the dosage 
needed, a dosage per total body weight will be accurate for a lean individual. However, the 
modern epidemic of obesity in the developed world (World Health Report, 2013) has resulted 
in body weight not being the only factor which needs to be considered.  
The amount of adipose tissue in the body, partly due to its poor blood supply (Wulfsohn, 1969), 
does not resort under pharmacologically active mass but does, however, add significantly to 
total body weight. At the same time the increase in weight, due to the deposition of adipose 
tissue, is non-linear to the relative increase in muscle bulk and other organs (Coetzee, 2010). 
The accurate calculation of morphine requirements in the overweight patient is thus a 
challenging exercise. The inability to calculate a safe and optimum dose across the spectrum 
of differing weights creates the risk of undertreating pain but also the potential for overdosing 
with life-threatening results. 
The more hydrophilic nature of morphine results in its crossing the blood-brain barrier slower 
than in the case of its more lipophilic counterparts, prolonging time to effect and resulting in 
more unpredictable outcomes when delivered intravenously. Green et al. (Green, 2010) 
concluded that total body weight can be used for dosage calculation of highly lipophilic drugs 
when these are given acutely (e.g. during anaesthesia) as these drugs are easily and quickly 
taken up due to the high lipid content of target cell membranes. However, once a drug is more 
hydrophilic (as with morphine), both the time to effect and dosage calculations become 







1.1.1.2 Intrathecal morphine 
The identification of opioid receptors in the brain by Pert and Schnyder in 1973 (Pert, 1973) 
and, subsequently in the spinal cord in 1976 (LaMotte, 1976), heralded the use of intrathecal 
morphine for analgesia. This concept was successfully tested in the animal model in 1976 
(LaMotte, 1976). A study by Yaksh et al., published in Science in 1976, similarly concluded 
that narcotics acting only at the spinal level changed cord function to block not only spinal 
reflexes but also the operant response to painful stimuli (Yaksh, 1976).  
Dorsal horn opioid receptors were identified by radioligand techniques and this subsequently 
led to further animal studies (DeSousa, 2014). A dose of 0.25ug morphine was intrathecally 
injected into rats by Wang et al. in 1976 (Wang, 1977). They concluded that intrathecal 
morphine provided potent analgesia which could be reversed with the administration of 
Naloxone. This paved the way for human application, a domain first studied by Wang in 1979.  
He successfully showed that the concept was valid in eight patients with genitourinary 
malignancy (Wang, 1979). Since then, intrathecal morphine has become widely used in an 
array of surgeries.  
Studies by McQuay et al., published in 1989, demonstrated an inverse relationship between 
the lipophilic nature of the opioid and the potency thereof based on the ability of the opioid 
drug to cross the blood-brain barrier (McQuay, 1989).  
Morphine administered intrathecally shows a high affinity for dorsal horn receptors. However, 
it does not exhibit the same characteristic for non-receptor sites in the myelin and white-matter 
(Hindle, 2008). This leads to a high concentration of morphine in the cerebrospinal fluid which 
is sustained by the more hydrophilic nature of morphine as opposed to other opiates, such as 
Fentanyl, which is much more lipophilic in nature and will thus cross the blood-brain barrier 
almost immediately (Fukuda, 2009). This then accounts for the spread of intrathecal morphine 
as well as the late, or later, onset of respiratory depression (Hindle, 2008). Said respiratory 
depression usually occurs after about 6 to 12 hours (Bujedo, 2012), once the morphine has 
spread more cephalad in the cerebrospinal fluid. A single dose of morphine, however, makes 
the timing and severity of respiratory depression more predictable and easier to avoid if safe 
dosages are applied, specifically when compared to continuous intravenous infusions and 
bolus intravenous doses (Bujedo, 2012). 
The intrathecal morphine will cause an effective band of analgesia in the proximity of the area 
of administration in addition to systemic effects (Bujedo, 2012). 
However, if the morphine dose is appropriate, it is possible to limit this cephalad spread and 




inherent lack of cephalad spread was proven by Kroin et al. in 1993 (Kroin, 1993). Results 
imply that it is possible to achieve a safe dose which would be almost completely risk free in 
terms of respiratory depression. Kroin noted a distinct decline in drug concentration in the 
cephalad region when cerebrospinal fluid was sampled from the cistern and lumbosacral areas 
(Kroin, 1993). This also confirmed that a direct intrathecal site of introduction, situated at the 
mid to lower lumbar area, would be associated with less ascent of the drug and thus curb its 
associated systemic, or central, effects. 
However, several factors aid in the cephalad spread of intrathecally delivered drugs (Hindle, 
2008). Cyclical thoracic pressure changes, associated with breathing, aid the flow of 
cerebrospinal fluid, both cranially and caudally. Brain expansion also occurs with the cardiac 
cycle and this, in turn, results in the flow of cerebrospinal fluid through the subarachnoid 
spaces. Both these mechanisms will thus aid in a lumbosacral delivered drug being distributed 
cranially, even if administered in lower concentrations (Hindle, 2008; Kroin, 1993).   
If a safe concentration could be achieved through direct delivery of the drug at a lumbosacral 
level and minimal spread occurs due to the low concentration of the drug being administered, 
it thus follows that the risk of respiratory depression should be low. 
An increase in the lumbosacral cerebrospinal fluid, adenosine, constitutes a further proposed 
mechanism of action. Adenosine opens potassium channels and subsequently decreases 
nerve fibre excitation due to hyperpolarisation which results in reduction of neural activity 
(Hindle, 2008; Kerchner, 2002). Intrathecally delivered morphine could also be taken up by 
the posterior radicular artery and this may result in its spreading to the brainstem. This 
mechanism was proven by autoradiographic studies in primates where an increased uptake 
of morphine in the respiratory centre was noted 60 minutes after it had been injected 
intrathecally (Hindle, 2008), even though the pharmacologically active amount of morphine 
had significantly diminished by then. 
Morphine will ultimately cross the blood-brain barrier (Bujedo, 2012), be taken up via the 
epidural venous plexus and then be metabolised in the liver. This amount will be small and, 
after a single intrathecal dose, deemed clinically insignificant.  
It was demonstrated in a pharmacokinetic study of intrathecal morphine in which the effect-
site concentration of the morphine was well maintained over the first 6 hours whilst minimal 
plasma concentrations were detected (Sjöström, 1987). This phenomenon can be ascribed to 
the hydrophilic nature of morphine. The subsequent clinical effect was dose dependent and a 





Intrathecal morphine has been widely adopted by several different surgical disciplines 
resulting in effective analgesia, without the addition of a local anaesthetic (Giovannelli, 2008). 
The American FDA approved preservative free morphine for intrathecal use in 1984 (Sultan, 
2011). 
 
1.2 Patient controlled analgesia  
As early as 1953 Keats et al. (Keats, 1961) highlighted the inadequacies of post-surgical pain 
control. Somerville, in 1982, once again emphasised this fact and claimed that insufficient 
treatment of pain should be tantamount to negligence and a violation of patients’ rights 
(Somerville, 1982; Brennan, 2007). The challenge, not only in high care settings but in general 
wards as well, was to address the delay in the initial administration of the drugs. A cycle of 
delayed administration was identified as a series of events initiated by the patient requesting 
pain medication. The nurse would take time to respond to the request, screen the patient, sign 
out the necessary medication, prepare an injection and finally administer it. This process, 
along with absorption time, resulted in a significant time interval to effect (Graves, 1983). The 
parenteral use of analgesia would facilitate a quicker response to medications and, having the 
patient administer the drug him/herself with certain safety measures in place, could break the 
cycle of delayed analgesia (Graves, 1983).  
Nursing staff’s influence on pain relief is dependent on their ability to assess said pain. Clarke 
et al., in a publication reporting on the impact of nursing characteristics and education on pain 
management, noted that the undertreatment of pain can be ascribed to nursing staff’s lack of 
understanding regarding addiction, tolerance and dependence. This incomprehension 
ultimately creates a fear of potential complications and, as such, it results in insufficient 
treatment (Clarke, 1996). Dalton et al. identified a proportional relationship between the 
treating nurse’s ability to assess pain and his/her years of nursing experience (Dalton, 1989). 
Holm also found that pain assessment, including emotional suffering and psychological 
distress, was significantly influenced by the nurse’s own personal experiences and perception 
of pain, thus potentially resulting in undertreatment of a patient (Holm, 1989). 
 
Patient-controlled analgesia (PCA) was first described in 1979 (Kranz, 1979) but PCA opioids 
only became universally accepted 15 years later. Today it is considered a valuable adjunct to 
post-operative analgesia because of its intravenous delivery of opioids and the lock-out period 




All patient-controlled analgesia devices operate in accordance with the same basic principles. 
The system comprises of an initial loading dose provided by the anaesthetist, a set demand 
dose which the patient will deliver themselves via the device, a lockout period which controls 
the amount provided and 1- and 4-hour dose limits (Grass, 2005). 
The safety of the PCA device, however, is closely linked to the careful training of both the 
patient and nursing staff (Coetzee, 2013). Mishaps that do occur are often as a result of 
inappropriate dose programming and/or accidental bolus administration during preparation 
(White, 1987). A further safety feature lies in the fact that if the opiates do result in cerebral 
depression, the patient will sleep and not self-request further PCA doses. 
Coetzee indicated, in his review on PCA usage, that education forms the cornerstone of 
achieving successful analgesia (Coetzee, 2013). As such, the patient needs to first understand 
the principles of PCA as well as the fact that despite the PCA device, pain will probably not be 
completely controlled. Monitoring of the patient will require waking him/her regularly to assess 
sedation and the patient should also be informed of this practice.  Instruction should take place 
via interpersonal communication and a printed handout should also be supplied for perusal at 
the patient’s leisure. Education should take place outside the theatre environment and during 
a pre-operative visit. Similarly, intensive care unit or general ward nursing staff must be aware 
of patients’ monitoring requirements as well as the clinical signs of an overdose which include 
depression of consciousness, sedation and hypoventilation. Nursing staff should also be well 
versed in immediate treatment options if this should occur (Parker, 1991). 
Greater efficacy of PCA has been demonstrated when a background infusion is run 
concurrently. This approach has, however, not been consistently described throughout the 
literature and has proven to be dangerous. Parker et al. studied 230 patients and their results 
could not demonstrate a difference in analgesia between 0.5, 1 or 2mg/h infusion rates running 
concurrently with on-demand PCA morphine delivering boluses of 1 - 2mg (Parker, 1991).  
Sam et al. (Sam, 2011) assessed the pharmacokinetics of morphine and its metabolites (M6G 
and M3G) during PCA. Results clearly indicated that the effect-site concentrations increased 
with an increase in background infusion rates. Peak levels were achieved 8 to 24 hours after 
the infusion had started with the highest peaks occurring when a 2mg/hour infusion was used. 
Across the groups, the peak M6G concentration was measured at 25 hours after the infusion 
was started with the 2mg/hour infusion again yielding the highest levels. The initial peak at 8 
hours was attributed to increased patient PCA usage immediately post-operatively in an 
attempt to achieve effective analgesia. The authors concluded that monitoring of patients with 
PCA devices, especially with a concurrent background infusion, should extend beyond 24 




respiratory depression occurs when PCA analgesia is supplemented with a background 
infusion. They noted that adverse events usually occur in the first post-operative day rather 
than immediately post-surgery and, as such, the need for monitoring beyond the perceived 
high-risk period, immediately post-operation, was stressed (Flisberg, 2003). 
The concern is that increasing the total dose of morphine will increase the risk of respiratory 
depression (Sam, 2011). Sidebotham et al. reviewed more than 6 000 patients who were 
treated with a PCA device after surgery. Their overall incidence of life-threatening 
complications was low at 0.28%, thus confirming the safety of the device (Sidebotham, 1997). 
A subgroup, however, was managed with a background infusion (n=276). When closely 
examined this subgroup revealed significant incidences of overdose related complications.  
Similarly, Sidebotham et al. demonstrated that the PCA device was most frequently used in 
the first 24 hours after surgery. Thereafter a rapid decline in use was noted over the following 
48 hours, irrespective of the type of surgery which had been performed (Sidebotham, 1997). 
The volume of morphine distribution is 2 - 5L/kg which implies that it will not be contained in 
the plasma alone but that it will be distributed to other tissues as well (Linares, 2009). This 
might result in PCA morphine being ineffective and therefore prompt increased use or even a 
request for rescue analgesia. The preceding combination elevates the risk of respiratory 
depression and other opioid related side-effects occurring later than generally expected 
(Green, 2004). It would therefore be beneficial if the risk could be contained with the 
administration of a single dose, for instance intrathecally, rather than exposing the patient to 
an increased risk associated with the accumulation of morphine after repeated doses. 
Coetzee, in his review on the safety of PCA devices (Coetzee, 2013), concluded that once a 
patient has recovered after surgery, it is the responsibility of the anaesthetist to titrate a volume 
of morphine to facilitate a starting point of very little to no pain prior to commencing the PCA. 
This process requires the doctor to exercise patience as the complete effect of a dose of 
morphine may only be demonstrated up to 45 minutes after titration. 
Intravenous morphine might also have a sedative effect and although this is the fundamental 
concept on which the safety of the PCA method relies it may, on the other hand, compromise 
the effective use of the PCA device (Fukuda, 2009). 
A further consideration in gauging the success of patient-controlled analgesia is the patient’s 
willingness to use the PCA pump when prompted by their experience of pain. If the patient’s 
expectations of post-operative pain were not properly discussed, inappropriate usage may 
ensue in which the patient will use the device constantly to prevent pain rather than in 




programmed maximum dose over any given period of time should limit this risk.  Similarly, 
some patients may underutilise the PCA. This may be prompted by a perception that pain 
should be accepted and endured and/or a perceived risk associated with the PCA (Ferrante, 
1988). In both these situations, training is paramount to ensure successful use of PCA. Patient 
compliance, however, can vary significantly (Coetzee, 2013). 
 
1.3 Lower backache and spinal surgery 
Lower backache is a condition which exerts a crippling effect on individual patients as well as 
economies worldwide. Not only does it negatively affect an individual’s ability to earn an 
income, but the pain in itself demoralises and significantly reduces quality of life. The 
economy, in turn, is affected by loss of work days and the subsequent impact on productivity 
(Ekman, 2005). The prevalence of lower backache, as reported in different studies and quoted 
in a meta-analysis by Dagenais et al., varies from 5 - 65% with a mean of 18.7% (Dagenais, 
2005). The impact of this condition is thus directly experienced by the patient, by virtue of 
direct costs accrued, and indirectly due to lost work days and the effect thereof on the broader 
economy (Dagenais, 2005). Direct costs involve peri-operative interventions which include 
chiropractors, physical therapists, peri- and intra-operative pharmacy costs, surgical cost 
(including anaesthetic, surgeon and facility costs), imaging ward costs and out-patient visits 
(Dagenais, 2005). These direct costs are generally easy to calculate as accounts and record 
keeping enable one to make a comparison across patient groups. Indirect costs, however, are 
more challenging to calculate and include factors such as impact of continual absenteeism on 
company and/or work productivity, early retirement, impact on the household, inactivity and 
sick leave (Dagenais, 2005). 
Katz et al. attempted to assess the socio-economic impact of lower backache in the United 
States (Katz, 2006). They found that in 2005 the American Worker’s Compensation 
expenditure exceeded 20 billion dollars for musculoskeletal disorders of which backache was 
noted as most prevalent. Lower back pain accounted for a loss of productivity equal to the 
bulk of 50 billion dollars. The total cost of lower back pain amounted to between 100 and 200 
billion dollars for the year 2005 (Katz, 2006). Frymoyer reported this cost to be between 50 
and 100 billion dollars per year in 1991 (Frymoyer, 1991).  
Due to certain socio-economic, psychological and work-related reasons, some individuals 
unfortunately often settle on backache as a diagnosis of convenience. A reliable diagnosis is 
consequently a challenging task and the overall indirect cost nearly impossible to calculate 
(Andersson, 1999). At the same time, degenerative conditions of the spine are most likely to 




latter part of their careers or who are approaching retirement (Andersson, 1999). The 
diagnosis of backache can thus either lead to or act as an incentive for early retirement. Hunter 
et al. studied 178 railroad workers with lower backache and, based on their observations, 
implemented a multidisciplinary rehabilitation programme (Hunter, 1998). The study recorded 
patient improvement in both subjective and objective measures, yet no impact was noted on 
long-term work status. These findings seem to imply that other factors, such as financial 
considerations, played a significant role.  
Once neurological cause, malignancy or infective process has been excluded from the work-
up of the chronic backache patient, the degenerative realm of disease comes to the fore 
(Chou, 2007). The afore-mentioned group resorting under malignancy and neurological fallout 
make up only 5% of lower backache patients (Wassenaar, 2011). The gold standard in lumbar 
spine imaging is the magnetic resonance imaging scan (MRI) which provides accurate soft 
issue information of the spinal nervous and ligamentous structures. It is the clinical correlation, 
however, that remains challenging. Wassenaar, in a systematic review pertaining to the 
correlation of MRI findings to lower backache in the absence of malignancy, infections or nerve 
root pathology (thus the chronic backache group), found that MRI findings were only 75% 
sensitive and 77% specific to clinical findings of spinal stenosis or degenerative disease and 
that a significant number of patients were over-diagnosed based on the MRI findings alone 
(Wassenaar, 2011). Sirvanci et al. attempted to ascertain a correlation between MRI findings 
and the Oswestry Disability Index (ODI) which is a validated scoring system used to define 
disability due to degenerative spinal pathology (Sirvanci, 2008). They could demonstrate no 
significant correlation between image findings and the ODI scores. However, the scan is 
almost routinely requested by clinicians prompted by a fear of missing some serious 
underlying pathology and/or in an effort to reassure patients (Ash, 2008). 
 
1.3.1   Instruments to measure backache and disability 
There are several scoring systems used to quantify backache and monitor the progression 
thereof. These scoring systems are also used to quantify the impact of the condition on daily 







1.3.1.1 The Visual Analogue Scale  
The visual analogue scale (VAS) is one of the most popular measuring tools used in spinal 
pathology and spinal surgery (Gould, 2001). It is performed by evaluation of a horizontal line, 
typically 10cm in length, with word descriptors at both ends namely no pain and worst pain 
ever. The patient is required to indicate his/her current experience of pain upon the continuum 
scale. The result is filed enabling comparison to past tests, using the same scale.  
Although the instrument can directly measure pain, it is reliant on the patient’s perception and 
understanding of the instrument. This implies that the number allocated to a specific degree 
of pain cannot be compared to another patient’s experience as perceptions of pain are unique 
to each individual. However, the trend of decreasing or increasing pain is relevant and will be 
indicated in terms of consecutive determinations of the scale. The patient quantifies his/her 
own pain and will then compare this experience at a specific time using a similar standard of 
interpretation.  
The scale involves a horizontal line marked 0 to 10. The length of the horizontal line should 
exceed 10cm as a shorter line exerts an impact on scoring variance (Scott, 1976). Similarly, 
the ends of the line should have vertical bars to clearly delineate the borders of the scoring 
tool and so prevent patients from marking outside the scoring parameters (Huskisson, 1983).   
The Visual Analogue Scale (VAS) was validated in 1983 (Price, 1983) and reviewed by 
Wewers et al. in 1990 (Wewers, 1990). It is a quick and easy-to-use tool which, in busy 
practices especially, can act as a handy guide to help the physician formulate an opinion as 
to the progress of a patient or the efficacy of an intervention. The VAS gives expression to an 
important fact that pain is a subjective experience and, as such, it allows for every individual 
to express his/her unique perception. The change in scoring can be reproduced reliably and 
measured across a study population. 
The minimal clinical important difference was found to be 19mm, or two vertical lines as seen 
on Figure 1.1 (Hägg, 2003). Hägg concluded that a 19mm difference, or more, in scoring at 
two separate intervals can be accepted as indicative of a clinically significant change. 
A variation of the VAS score exists in which the same line is used, but numbers ranging from 
0 to 10 are spaced evenly in between the ends. In this way the scale is converted into a so-
called numeric rating scale (NRS), or segmented numeric version of the VAS, as per Figure 
1.1. The NRS differs very little from the traditional VAS score. A numerical value on the 
horizontal line, which correlates easily to pain, indicates the degree of pain being experienced 
by the patient (Hawker, 2011). The extremes of pain are also defined as per the VAS. The 




analgesia or post-operatively in spinal surgery) or is experiencing challenges in making a mark 
on the line depicting their pain (e.g. intravenous lines on the writing hand). The NRS can be 
conducted verbally (Jensen, 1986). Its validity has a high correlation with the VAS, and 




Figure 1.1: The numeric rating scale (NRS) (Jensen, 1986)  
 
 
1.3.1.2 The Oswestry Disability Index 
The Oswestry Disability Index (ODI) (Figure 1.2) is a condition specific outcome measuring 
tool aimed at spinal disorders. It is one of the most frequently used tools to estimate disability. 
It was first proposed in 1980 (Fairbank, 1980) and disseminated in 1981 at the International 
Society for the Study of the Lumbar Spine (ISSLS) meeting held in France. It contains 10 
categories of activities associated with everyday living. Each activity has 6 possible options 
from which the respondent can choose with the best option (or top) scoring 0 and the worst 
option (or bottom) scoring 5. The total is multiplied by 2 (Fairbank, 2000). The result is 
categorised and interpreted in terms of a score where 0 reflects the best possible and 100 the 
worst possible state of health.  The degree of disability is expressed in increments of 20 with 
0 - 20% implying minimal disability, 20 - 40% moderate disability, 40 - 60% severe disability, 
60 - 80% crippled and 80 - 100% bed-bound (Fairbank, 2000). It has been translated into 
numerous languages. 
The daily living categories denote everyday activities to which patients can easily relate. These 
categories include: personal care, walking, standing, sitting, lifting, sex life, travelling, social 
life, sleeping and a personal interpretation of pain. It is condition specific to the degenerative 




understood by the patient. The assessment takes less than 5 minutes to complete and less 
than 1 minute to score (Sirvanci, 2008). The patient need only tick the appropriate option in 
each category and is not privy to the score associated with that option. 
This instrument was also intended for use at different time intervals, particularly to evaluate 
the effect of an intervention. It correlates significantly with the VAS (p<0.01) (Gronblad, 1997). 
Gronblad demonstrated increased VAS scores in relation to everyday activities whereas the 
ODI demonstrated a decrease in these activities, thus implying comparative conclusions in 
both scoring systems (Gronblad, 1997). The significant correlation was demonstrated in both 
females and males which confirmed that disability associated with degenerative spinal 
conditions is painful.  
The inclusion of basic activities in the assessment makes this scoring system applicable to 
any individual, irrespective of facilities or social support structures, as it represents the 
impact of pain on the basic qualities of life. The ODI is easy and convenient to use in busy 
clinical environments seeing that it is reliable, short, reproducible and internally consistent 




























1.3.1.3 The Euroqol-5D 
The Euroqol-5D (EQ-5D) scoring system, as per Figure 1.3, combines the clinical and 
economic impacts which an intervention, or disability, exert on a patient (The EuroQOL Group, 
1990).  
This scoring system tests 5 dimensions (mobility, self-care, activities of daily life, pain and 
anxiety/depression) with each dimension only allowing 3 options (no; mild to moderate; 
severe). The patient is requested to place a tick next to the sentence which best describes 
his/her condition at the time, allowing for comparison at a later stage. The scoring system can 
be applied to a great variety of conditions and is frequently used, and has been validated for 
use, in spinal surgery (The EuroQOL Group, 1990, Solberg, 2005). Each dimension has 3 
options and thus 3⁵ or 243 possible state of health combinations exist (Brooks, 1996). Apart 
from its ability to measure clinical and emotional improvement, or deterioration, the principle 
holds that a value can be allocated to a condition at a specific time (Williams, 1995).  
Jansson et al. reported on 230 spinal stenosis patients in 2009 (Jansson, 2009). The EQ-5D 
scoring system was accurate in indicating both quality of life and clinical improvement in this 
patient cohort.  
Solberg et al. attempted to assess the reliability, validity and responsiveness of the Euroqol 5-
D in a prospective study assessing 326 patients undergoing spinal surgery for degenerative 
spine conditions (Solberg, 2005). They compared their results to the ODI and concluded that 
the EQ-5D was responsive, valid and reliable in the assessment and follow-up of patients 
undergoing lower back surgery. 
The instrument was further validated for use in lumbar spinal pathology by Mueller et al. 
(Mueller, 2013). They concluded that it correlated well with existing validated scoring systems, 
such as the ODI, and ascertained that it could serve clinicians well as an effective measure of 
state of health and clinical outcome. The EQ-5D combines individual aspects, such as self-
care and mobility, but also identifies patients’ perception as to their activities, mobility and 
mood. The test does not take long to perform, and its worth lies, inter alia, in the fact that it 























1.3.1.4 The Roland-Morris disability questionnaire  
The Roland-Morris disability questionnaire (RM) is specifically designed to detect physical 
disability as a result of lower back pain (Roland, 2000). It is a useful patient-friendly tool for 
monitoring progress, in both clinical practice and clinical trials, as it is short, easy to understand 
and can be completed quickly. The questionnaire originally contained 24 questions, all starting 
with the phrase “Because of my backache…” but as certain questions were viewed as 
redundant, it was later reduced to 18 questions (Stratford, 1997). Its successful application 
was evident in instances of short-term improvement in backache, often achieved through 
primary care level interventions. The questionnaire is thus a particularly useful tool when trying 
to assess the improvement, as experienced by the patient, after an intervention had been 
performed on the lower back. The score has little or no association with the sex and/or age of 
the patient. Patients presenting to primary care facilities typically achieved median scores of 
11 (Roland, 1983). The score correlated well with other questionnaires, such as the ODI, used 
in assessing physical function (Stratford, 1994). The ODI and RM are complementary in 
tracking patients’ improvement at follow-up (Beurskens,1996). A difference in scoring of 5 is 


















Roland Morris Questionnaire: 
When your back hurts, you may find it difficult to do some of the things you normally 
do.  Mark only the sentences that describe you lately 
1. [ ] I stay at home most of the time because of my back.  
2. [ ] I walk more slowly than usual because of my back.  
3. [ ] Because of my back, I am not doing any jobs that I usually do around the house.  
4. [ ] Because of my back, I use a handrail to get upstairs.  
5. [ ] Because of my back, I lie down to rest more often.  
6. [ ] Because of my back, I have to hold onto something to get out of an easy chair.  
7. [ ] Because of my back, I try to get other people to do things for me.  
8. [ ] I get dressed more slowly than usual because of my back.  
9. [ ] I stand up only for short periods of time because of my back.  
10. [ ] Because of my back, I try not to bend or kneel down.  
11. [ ] I find it difficult to get out of a chair because of my back.  
12. [ ] My back or leg is painful almost all of the time.  
13. [ ] I find it difficult to turn over in bed because of my back.  
14. [ ] I have trouble putting on my socks (or stockings) because of pain in my back.  
15. [ ] I sleep less well because of my back.  
16. [ ] I avoid heavy jobs around the house because of my back.  
17. [ ] Because of back pain, I am more irritable and bad tempered with people than usual.  
18. [ ] Because of my back, I go upstairs more slowly than usual. 
 







1.3.2 Psychiatric disorder and spinal pathology 
Of very real concern is the effect of social and psychiatric conditions on pre-operative 
presentation of patients with lower backache as well as on outcome, should surgery be 
performed. Menendez et al. described the effect of psychiatric conditions on major spinal 
surgery outcomes and concluded that pre-operative psychiatric conditions, such as major 
depression, schizophrenia, anxiety disorders and dementia, were associated with higher rates 
of peri-operative adverse events whilst only dementia had an effect on mortality (Menendez, 
2014). Anxiety and depression are very real concerns in modern society and are estimated to 
affect 7.3% and 6 - 10% of the global population. Slover et al. observed 3 482 patients 
undergoing lumbar spinal surgery and ascertained that the impact of depression was 
statistically significant when using the Oswestry Disability Index at both 1 and 3 years (Slover, 
2006). They highlighted the fact that researchers and clinicians need to be mindful of the 
deleterious effect that depression has on clinical outcomes.  
Chronic pain due to lumbar pathology has a negative effect on patients’ social and professional 
lives. Demyttenaere et al., in a World Mental Health Survey, indicated that mood and anxiety 
disorders were more prevalent in patients who suffered from chronic lower back or neck pain 
(Demyttenaere, 2007). Population surveys from 18 countries, including South Africa, were 
used to specifically assess the consistent association of mood and anxiety disorders with 
chronic backache. From a total of 85 088 patients surveyed, the results indicated that patients 
suffering from chronic backache had a 2.2 times increased likelihood of suffering from anxiety 
disorder and a 2.3 times increased likelihood of suffering from a mood disorder. The pattern 
of disorder prevalence was consistent across developed and developing countries. 
It is therefore important to determine whether a patient is being treated for depression, 
schizophrenia or anxiety disorder prior to enrolling him/her in a clinical trial (Slover, 2006) as 
this will impact the post-operative course and outcomes. 
 
1.3.3 Physiotherapy 
Several studies have proven that physiotherapy and a structured rehabilitation programme 
have a significant impact on spinal surgery outcomes. As early as 1964 Hansen described the 
benefits experienced by a physiotherapy trained group in comparison with an untrained group 
(Hansen, 1964). The results indicated improved outcomes after spinal surgery in the trained 
patients who, as a result of trunk extensor strengthening, presented with quicker post-




Another study, evaluating patients undergoing spinal surgery, divided the patient cohort into 2 
groups: those undergoing regular physiotherapy and those subjected to a regime of intense 
post-operative physiotherapy. The results indicated that the latter outscored their counterparts 
(i.e. the normal physiotherapy group) and thus highlighted the positive effects of intensive 
physiotherapy for patients subjected to spinal surgery (Manniche, 1993). 
Patients find it difficult to do strengthening exercises when inhibited by backache, albeit from 
surgery or degenerative pathology. The performance of the group which underwent the 
intense regime is thus all the more remarkable as they had no fear of activity, even after having 
recently undergone spinal surgery. Unfortunately, most patients struggle to commit to a 
programme of strengthening exercises after surgery and this limits the practical 
implementation of an intense post-operative regime, especially when pain is not well 
controlled. 
Scrimshaw et al., in a prospective study, attempted to add neural mobilisation techniques to 
already established and proven physiotherapy muscle strengthening regimes in the post-
operative period to see whether this would further benefit the spinal surgery group 
(Scrimshaw, 2001). At 12-month follow-up no improvement in objective scoring or clinical 
analysis could be demonstrated. These results suggest that muscle strengthening, and 
training remains central to the basic advantages associated with physiotherapy after spinal 
surgery.  
The immediate goal-orientated active mobilisation regime after spinal surgery has been 
proven to aid in initial rehabilitation as well as improve short- and long-term outcomes (Kjellby-
Wendt, 1998). This regime is initiated in hospital and can be continued by the patient at home. 
The goal-orientated programme encourages the patient to initially sit, stand and walk and then 
to participate in daily activities such as showering and climbing the stairs as per Figure 1.5. 
Once mobile, the patient is discharged and issued with exercises which he/she has to perform 














Physiotherapy progress sheet: 
(Mark with an X in each column if achieved on that day) 
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Obesity has been officially defined as a disease (ICD-10 E66.0). This condition refers to an 
abnormal accumulation of body fat, in excess of 20% of the normal ideal body weight, or a 
body-mass-index (BMI) of 30 or above. Morbid obesity is defined as a BMI of 40 or above 
(Agha, 2017). 
The incidence of obesity is increasing across the world. In 1986 morbid obesity was observed 
in 1 in 200 adults in the United States. This figure escalated to 1 in 50 in 2004 and, by 2017, 
it had dramatically increased to 1 in 5 (Agha, 2017). 
The use of opioid based analgesia in obese patients is complex and adverse effects are more 
often reported. 
The risk of respiratory depression is generally increased in obese patients with a higher 
incidence (60 - 90%) of sleep apnoea syndrome (Rose, 1994, Benumof, 2001). The latter is 
due to the increased deposition of adipose tissue in the pharyngeal space which results in a 
smaller cross sectional total pharyngeal area. Should the upper airway muscles relax, the 
pharyngeal patency will be compromised earlier in obese patients (Benumof, 2001). Opioids 
diminish the action of pharyngeal dilator muscles, thus promoting collapse of the airway in 
obese patients with a fat-laden pharyngeal wall. In addition, this mechanical obstruction will 
further limit the ventilatory effort should hypercapnia and hypoxemia ensue once central 
respiratory depression occurs (Benumof, 2001). 
Volume of distribution (VD) of a drug is defined as the degree to which a drug is distributed in 
body tissue rather than the plasma itself. Thus, a higher VD implies a greater distribution in the 
tissues. The VD of morphine is 2 - 5L/kg body weight implying that it is widely distributed 
throughout the body as opposed to a drug with a smaller VD which would imply that the drug 
is distributed in plasma and extracellular fluid only (Linares, 2009). 
Considering morphine’s mostly hydrophilic, yet also lipophilic properties, its distribution into 
tissues is affected by total body water, regional blood flow and body composition. In obese 
patients, the increased adipose tissue is associated with increased blood volume and cardiac 
output. In lean patients, total body water is distributed 35% extracellularly and 65% 
intracellularly. In obese patients, however, an expansion of the extracellular compartment 
relative to the intracellular compartment is noted which would consequently affect the VD of 
morphine (Linares, 2009).  
Glomerular filtration rate is also affected by obesity. A larger glomerular planar surface, which 




more hydrophilic in nature, more frequent parenteral administration is required if the drug is to 
remain effective (Linares, 2009). 
Should a drug be purely hydrophilic, lean body mass could be used to calculate the dose as 
it would have little affinity for the excess adipose tissue in obese patients. Hence it has less of 
an effect on the VD. If the drug has lipophilic properties, such as morphine, the total body 
weight should be considered as a parenteral route will lead to the drug being exposed to 
adipose tissues (Linares, 2009). It must be noted that although morphine is generally regarded 
as more hydrophilic and less lipophilic, it does have some lipophilic characteristics i.e. the 
lipophilic tendency is not zero. 
Should a drug such as morphine, with a largely hydrophilic nature, be delivered intrathecally, 
its general kinetics will differ quite significantly from morphine administered parenterally in the 
obese patient. The hydrophilic nature of morphine, the smaller dose used and absorption into 
the spinal cord (myelin) will ensure a relatively constant cerebrospinal fluid concentration over 
time. Opposed to this, a systemically administered opiate in the obese patient will be widely 



















1.4 Peri-operative pain 
A patient’s recovery is adversely affected if post-operative pain management is not effective 
(McGuire, 2006). There are several options available and, depending on comorbid conditions, 
combinations of these are used for different surgeries and patient populations. The 
conventional approach includes non-steroidal anti-inflammatory drugs, local anaesthesia, 
Paracetamol and the opioid family of drugs, either administered alone or in combinations.  
When instrumented spinal fusion surgery is considered, several factors could affect the 
outcome. With regards to the lumbar spine there are three general indications for surgery: 
neurology, instability and deformity (Weinstein, 2007). Should a patient be suffering from a 
neural compressive condition, the decompression surgery might affect the stability of the 
lumbar spine which would result in a fusion procedure. At the same time, an acquired 
degenerative instability might cause dynamic compression of a nerve in which case the 
instability becomes the primary indication for surgery which, in turn, would also require a fusion 
procedure (Weinstein, 2007; Eismont, 2014). The technique itself can be executed in many 
ways, yet the gold standard remains a midline approach with open, direct decompression of 
the neural structures and pedicle fixation with bone-graft augmentation of the fusion (Eismont, 
2014; Watter, 2009). It is this bone graft on which a great deal of the outcome depends (Watter, 
2009; Greenwald, 2001). The instrumentation merely acts as a scaffold to facilitate the 
formation of the new bone which would then, ultimately, stabilise the new construction and 
maintain the decompression (Greenwald, 2001). Should this new bone formation not be 
successful, failure of the construct and patient morbidity would ensue. 
With this in mind, several considerations influence the choice of post-operative analgesia. 
Despite having been proven very efficient in the post-operative period in spinal decompression 
and fusion surgery (Nissen, 1992; Reuben, 1997), the non-steroidal family of drugs has an 











1.4.1 Non-steroidal anti-inflammatory drugs  
 
 
Figure 1.6: Diagram illustrating the formation of leucotrines, thromboxane, prostacyclin and 
prostaglandins from the pre-cursor arachidonic acid 
 
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the enzyme cyclo-oxygenase (COX) 
which is essential in the formation of thromboxane, prostacyclin and prostaglandins from the 
arachidonic acid pre-cursor as per Figure 1.6.  
Two forms of the COX enzyme exist namely: cyclo-oxygenase 1 (COX 1) and cyclo-
oxygenase 2 (COX 2). COX 1, which is involved in everyday homeostasis, is found in nearly 
all tissues of the body yet most notably in the small intestine, stomach and platelets (Vane 
1998). The COX 2 enzyme is mostly found in tissues of the musculoskeletal system, including 
bones and joints. Drugs which inhibit the enzyme are thus effective in managing 
musculoskeletal pain, especially considering that the COX 2 enzyme increases up to twenty-
fold during an inflammatory state (Thaller 2005).  
The response to inflammatory mediators, such as tumour necrosis factor, interleukin 1 and 
platelet derived growth factor, causes induction of the COX 2 enzyme in osteoblasts, 
chondrocytes, synoviocytes, monocytes and macrophages. Traditional NSAIDs, such as 




effectively address musculoskeletal pain, but would also explain the gastro enteral side-effects 
of abdominal discomfort and gastritis, especially during prolonged use. 
The prostaglandins involved in bone metabolism, and which are primarily affected by the 
inhibition of the COX enzymes, are prostaglandin E1 and prostaglandin E2. They play an 
important role in both bone resorption and formation and the net gain of bone is negatively 
affected by the inhibition of these prostaglandins (Thaller, 2005). This inhibitory effect is used 
to advantage in arthroplasty surgery where heterotopic ossification is prevented by NSAID use 
in the post-operative period of hip replacement surgery (Fransen, 2013). However, it would 
lead to poorer outcomes if bone formation is an important factor in the final outcome of a 
procedure such as spinal fusion surgery. 
Bone healing and new bone formation has been divided into three phases: the initial 
inflammatory phase, the reparative phase and the remodelling phase (Riew, 2003). The 
deleterious effect of anti-inflammatory drugs would potentially be most pronounced in the initial 
inflammatory phase. Riew et al. confirmed that the inflammatory phase occurs within the first 
week after surgery. In addition, they affirmed that this initial inflammatory phase was 
significantly affected if NSAID were used (Riew, 2003) with a trend towards non-union which 
persisted throughout the reparative and remodelling phases. However, the observed 
differences were not statistically significant. 
Reuben et al. retrospectively studied the effect of Ketorolac on the fusion rate of 434 patients 
(Reuben, 2005). They concluded that a high dose of non-steroidal anti-inflammatory drugs 
impacts negatively on bony union and that it should therefore be avoided. They also identified 
smoking as a common co-factor in the development of non-union. The combination of these 
two factors seems to be a significant inhibitor to bone healing (Reuben, 2005). Interestingly, 
this is the same author who eight years previously had advocated the addition of Ketorolac to 
the immediate post-operative pain relief regime (Reuben, 1997). However, he subsequently 
changed his practice in the light of the research revealing non-union complications (Reuben, 
2005). 
Reuben’s work is echoed by Glassman et al. who, already in 1998, published results garnered 
from 288 patients receiving non-steroidal drugs in the post-operative period after spinal fusion 
surgery (Glassman, 1998). They concluded that the non-steroidal drugs significantly reduced 
fusion rates. In addition, they noted increased non-union rates in all subgroups (men, women, 
smokers and non-smokers), thereby implying that NSAID were the most significant deterrent 
to bone fusion.  
It is in the first post-operative week that analgesia is most needed, yet, the same inflammatory 




foundation for successful fusion. Inhibition of this process might result in improved pain control, 
but the long-term effects could include failure of the procedure resulting from non-union of the 
fusion construct (Riew, 2003).  
A meta-analysis on the effect of NSAID and spinal fusion rates concluded that there is a 
duration- and dose-dependent relationship (Sivaganesan, 2017). 
Alternative therapy should thus be considered, and the emphasis falls on the use of opioids. 
  
1.4.2 Opioids 
The use of opioids in the post-operative setting is challenging. This family of drugs has many 
side effects albeit being an effective therapy.  The secret lies in balancing the analgesic effects 
with possible side effects as the latter could not only significantly impact the patient but also 
give rise to financial implications (Rathmell, 2005; Raffaeli, 2006). The side-effect which is 
most dreaded is significant respiratory depression which is associated with hypoxia and 
permanent brain injury. 
 
1.4.2.1 Respiratory depression 
Despite this potentially devastating complication being well-known and a primary 
consideration, the incidence of significant respiratory depression remains around 0.1 - 1% in 
the peri-operative period, irrespective of the route of administration (Etches, 1994). Cashman 
et al. concurred with these findings and concluded that progression to death is rare (Cashman, 
2004). This does not, however, exclude significant morbidity related to the event. Considering 
the vast number of patients treated with opioids in various forms, the figure of 1% adds up to 
a significant absolute number.  
The pathophysiology was originally perceived to be linked to the interaction between the opioid 
and µ-receptors in the medulla. The pre-Bötzinger complex, situated in the medulla, has now 
been identified as the main cause of decreased respiratory drive after opioid usage 
(Montandon, 2011). 
It should be understood that opioids cause dose dependant respiratory depression. Hence, 
once opioids have been selected, there will be some effect on the respiratory control 
mechanism. However, the risk lies in significant respiratory depression which may result in 






Respiratory depression can occur via any of the following three mechanisms:  
• Central respiratory depression leading to decreased respiratory drive and associated 
alveolar hypoventilation; 
• Decreased genioglossus or tongue muscle tone causing obstruction of the upper 
airway;  
• The sedative effect of opioids resulting in a decreased response to stimuli (Coetzee, 
2013). 
The fear of respiratory depression often results in insufficient analgesia being prescribed. This, 
in turn, leads to the under-treatment of pain which impacts upon length of hospital stay and 
the overall recovery of the patient (Rathmell, 2005; Brennan, 2007).  
The challenge when using opioids, in the absence of other forms of analgesia, is to minimise 
the side-effect profile yet optimise analgesia to the patient. In addition, pain stimulates 
respiration and, by inference, once analgesia is effective the desired effect of pain relief may 
well accentuate the side-effect of respiratory depression (Borgbjerg, 1996). Dahan et al. used 
an integrated pharmacodynamic-pharmacokinetic model to simultaneously assess the 
analgesic effect of morphine and respiratory depression (Dahan, 2004). The study design 
involved four groups of healthy volunteers receiving a bolus of intravenous morphine, or 
placebo, at 09:00 and 18:00 to also evaluate sleeping hours (23:00 - 07:00). They concluded 
that despite inadequate pain relief, respiratory depression is still possible based upon the 
interaction of morphine and the µ-receptor. In addition, this unwanted side effect can occur 
later than what was generally anticipated. 
The most common risk factors for acute and short-term opioid induced respiratory depression 
include: advanced age, high opioid blood and effector site concentration (either excessive 
dose per se or too short interval between administrations), respiratory acidosis as well as 
combined use with Benzodiazepines, or other central nervous system depressant drugs.  
Due to the renal clearance of morphine and its metabolites, renal failure should also be 
considered as a known risk factor in cases where opioids are being used in repeated dosages. 
This becomes a significant consideration when the dose is constantly being topped up with a 
PCA device (Fukuda, 2009). 
Delayed respiratory depression after morphine use, specifically with intrathecal administration, 
can be ascribed to the hydrophilic nature of the opioid (Sultan, 2011). Its slow rostral spread 




than 6 hours post-administration. Its hydrophilic nature facilitates its strong affinity to the µ-
receptors found at the dorsal horn in the spinal cord at the intrathecal injection site. It is, 
however, not absorbed into the white matter of the spinal cord and thus maintains a relatively 
constant concentration in the CSF (Hindle, 2008). In time, some cranial distribution does 
occur.  
Methods used to monitor the side effects of the opiates include: 
• The use of an opioid induced sedation scale is a valuable aid to guide the monitoring 
of patients with either intrathecal or patient-controlled intravenous morphine. As per 
Figure 1.7, the Pasero scale involves assessing the patient over a period of time (8, 
24 and 48 hours) and is based on clinical parameters of sedation (Pasero, 2004). The 
sedation scale allows for the following manifestations: sleeping, awake and alert, 
occasionally drowsy but easy to rouse, frequently drowsy and drifts off to sleep or being 
somnolent and having minimal response to painful stimuli (Coetzee, 2013). This 
approach is valuable in the acute setting as less opioids are required to cause sedation 
than respiratory depression and sedation can thus act as an early marker for the risk 
of respiratory depression. 
• Other clinical observations can provide additional valuable information regarding the 
deleterious effects of morphine. The most common reported finding indicative of 
significant respiratory depression in published literature is an oxygen saturation 
measurement less than 90%, especially in a patient who previously showed normal 
saturation (Cashman, 2004). They concluded that blood gas analysis, although 
accurate, is less frequently used due to its invasiveness than routine peripheral oxygen 
saturation measurement.   
•  Other clinical observations include respiratory frequency with a rate less than 10 
breaths per minute commonly indicating significant respiratory depression (Cashman, 
2004). The accuracy of respiratory rate as an indicator for respiratory depression has 
both been advocated and disputed. Camporesi et al. investigated the relationship 
between respiratory depression and CO2 after both intravenous and epidural morphine 
administration in healthy volunteers (Camporesi, 1983). They demonstrated that 
blunting of the CO2 response peaked at 10 hours post-intervention and could last up 
to 22 hours in the epidural group. This finding has to be considered within the context 
of the absence of painful stimuli, such as would typically occur after surgery. Although 
the pain will enhance respiratory drive, in principle, the observed length of potential 
respiratory depression is important for the post-surgical care environment. Camporesi 




depression. They reported on several cases of respiratory rates of 14 - 15 having 
sudden prolonged spells of apnoea. 
Overdyk highlighted the challenges of counting respiratory rate noting that it is done 
intermittently and an episode of bradypnea could therefor easily be missed (Overdyk, 
2007). In addition, Catley et al. documented short-lived ventilatory pattern changes not 
identified by routine counting of respiratory rate (Catley, 1985). Furthermore, Overdyk 
found that supplemental oxygen could potentially mask desaturation in respiratory 
depression. He noted that in those patients, desaturation occurred along with 
bradypnea lasting a longer period, three minutes or longer. These findings were similar 
to reports by Fu et al. who ascertained that oximetry could be a late indicator of 
respiratory depression if oxygen is supplemented (Fu, 2004). In addition, nursing 
response to audible alarms adds another dimension to the time delay factor, more so 
in the general ward setting. Pin-point pupils is an indication of a significant opioid effect 
(Coetzee, 2013). 
 
In order to be effective, these observations need to be repeated at close intervals. Patients 
should thus be cared for in a high care environment to ensure effective and repeated 
monitoring. In addition, the physician has to rely on the nursing staff’s accurate monitoring 
and, given the ever-increasing pressure in health care environments, this is becoming more 
and more difficult. A combination of these observations, rather than any single parameter, 
would increase the early detection of opiate side effects. Macintyre emphasised this by stating 
that, despite monitoring clinical parameters, all patients receiving opioids should at least be 
monitored with the use of sedation scores (Macintyre, 2011). 
Further morphine related side-effects include nausea, vomiting, pruritus and urinary retention. 
Post-operative nausea and vomiting remain one of the most common complaints, or 
complications, encountered in the post-operative recovery room setting (Hines, 1992, Habib, 
2004). Although not conventionally life threatening, it is extremely uncomfortable and can 
result in significant morbidity. 
The options for administration of opioids in the post-operative period include: 
• intravenous (typically through a patient-controlled device);  
• intrathecal morphine (delivered to the patient during the procedure);  
• intramuscular administration; 
• oral medications, although these are discouraged in the immediate post-operative 








S Sleep, easily aroused 
1 Awake and alert 
2 Occasionally drowsy, easy to rouse 
3 Frequently drowsy, rousable, drifts off to sleep during conversation 
4 Somnolent, minimal or no response to stimuli 
 
Figure 1.7: Pasero’s opioid-induced sedation scale (Pasero, 2004) 
 
1.4.2.2 Pruritus 
Pruritus is defined as an unpleasant irritation, or sensation, resulting in an urge to scratch. 
With opioid use it typically presents in areas innervated by the trigeminal nerve due to an 
abundance of opioid receptors in its spinal nucleus which is the origin of pain and temperature 
perception in the face (Korhonen, 2003). 
Pruritus, after the use of neuraxial opioids, can be explained by the following possible 
mechanisms (Gulhas, 2007): 
• It is theorised that pruritus and pain are transmitted by the same sensory 
neurons (small unmyelinated nerves or C-fibres). It is these fibres that are 
affected by prostaglandin release (PGE1 and PGE2) which enhances the 
transmission of C-fibres to the central nervous system and potentiate pruritus.  
• During neuraxial opioid delivery, cephalad spread of the drug occurs and the 
opioids act on the 5 Hydroxytryptamine (5HT3) receptors causing pruritus. 
The incidence of pruritus after neuraxial use has been reported in the range of 20 to 100% 
(Ganesh, 2007). The high incidence has been ascribed to the interaction between eostrogen 
and the opioid receptors leading to a much higher incidence of pruritus in pregnant patients 
(Kumar, 2013; Charulaxananan, 2000). When excluding pregnant patients and assessing 
orthopaedic patients separately, the reported pruritus incidence ranges from 30 to 60% 
(Kumar, 2013) after intrathecal opioid use. This is comparable to the reported incidence of 10 




It is the more direct and immediate exposure to opioid receptors, via the intrathecal route, that 
could lead to a quicker onset of pruritus. The overall incidence between intrathecal and 
intravenous administration, however, is comparable in the non-pregnant group of patients 
(Gulhas, 2007). 
Various drugs, the most successful being 5HT3 antagonists such as Ondansetron, have been 
used to decrease, or treat, pruritus after both neuraxial and parenteral opioid use. However, 
contradictory results regarding efficacy persists in literature. Korhonen et al. failed to 
demonstrate a decrease in pruritus in patients receiving intrathecal Fentanyl compared to 
placebo, yet they used only a small amount of intrathecal Fentanyl and postulated that it did 
not have significant cephalad spread to interact on 5HT3 receptors in the trigeminal cervical 
nucleus (Kerhonen, 2003). Gulhas, in turn, demonstrated a significant reduction in pruritus 
incidence when 8mg Ondansetron was administered intravenously within the first 24 hours 
after surgery (Gulhas, 2007). Considering its low side-effect profile, 5HT3 antagonist group of 
drugs are considered the drugs of choice in treating opioid related pruritus. 
NSAIDs, due to their inhibitory effect on prostaglandin formation, could be effective in treating 
post-operative pruritus but they cannot be used in fusion surgery due to the deleterious effect 
on bone formation (Riew, 2013). 
 
1.4.2.3 Nausea and vomiting 
Nausea and vomiting can be caused by opioids and, as such, they count amongst the most 
distressing side effects associated with opioids in the post-operative period. The incidence of 
nausea is reported to be 20 to 33% with vomiting affecting more or less half of those patients 
(Smith, 2014). It appears, although the mechanism is not yet clear, that opioid stimulation of 
the vestibular apparatus chemoreceptor zone could trigger nausea and vomiting. 
Ali et al. demonstrated that in patients undergoing major thoraco-abdominal surgery, opioid 
epidural analgesia provided better analgesia and improved short-term quality of life in 
comparison to PCA (Ali, 2010). They concluded that this short-term advantage was due to the 
lower incidences of nausea, vomiting and pain which then resulted in patients sleeping better. 







1.4.2.4 Opioid induced hyperalgesia 
This side-effect of opioid use is defined as a paradoxical increase in painful sensation, despite 
the optimal usage of opioids (Lee, 2011). This sensitisation to noxious stimuli often leads to 
increased rescue dosages of opioids which, in turn, could lead to more severe side-effects 
such as respiratory depression. Respiratory depression, it has been proven, is linked to the 
interaction of opioids with the pre-Bötzinger complex in the medulla (Sultan, 2011). The 
paradoxical response in analgesia does not exhibit heightened respiratory depression yet, if 
safe opioid doses are exceeded, the standard risk regarding depression of ventilation still 
applies. 
The mechanism of action is related to the interaction of opioids with the central glutaminergic 
system. The neurotransmitter N-methyl-D-aspartate (NMDA), which is excitatory in nature, is 
activated in the central nervous system and can trigger post-operative hyperalgesia. It has 
been shown that intra-operative use of Remifentanil is linked to opioid induced hyperalgesia 
due to the stimulation of these NMDA subunits (Joly, 2005). This phenomenon can be avoided 
with the use of a small Ketamine dose intra-operatively. The latter, in turn, increases the 

















1.5 Intrathecal morphine in spinal surgery 
Spinal surgery, especially fusion surgery with extensive tissue mobilisation and bone work, 
results in significant pain in the immediate post-operative period. The analgesic modalities 
available need to be safe for the patient and not deleterious to the bony construct created 
and/or the fusion mass which needs to form. It is in this situation where opioids, when used 
safely and effectively, could assist in early mobilisation and rehabilitation. 
Literature regarding the use of intrathecal morphine in spinal surgery provides several 
guidelines. Potentially good studies have, however, often been flawed by poor study designs 
and an incomplete understanding and interpretation of already published results. 
O’Neill randomised 46 patients to 1mg intrathecal morphine, or no injection, after lumbar spinal 
surgery (O’Neill, 1985). The control group received the same analgesia used as rescue 
analgesia for the intrathecal group namely Papavaretum 15 to 20mg intramuscularly every 4 
to 6 hours, as required. On all pain scoring modalities, the intrathecal group did significantly 
better up to 20 hours after which the difference in pain perception was not considered 
statistically significant any longer. This loss in significance was not addressed by the authors. 
It can be theorised, however, that the surgical procedures did not require extensive muscle 
dissection (no fusion-type surgeries were performed) which leans itself to less pain post-
operatively and pain could therefore be treated effectively with intramuscular analgesia. The 
only side-effect noted was an increased tendency towards pruritus in the treatment group. The 
authors acknowledged the risk of respiratory depression in their discussion and commented 
that suggested doses for intrathecal use were, at that time, not yet firmly established. They 
cautioned that intrathecal opioid use was investigational and that the risk of respiratory 
depression should be weighed against intramuscular options to provide analgesia. A dose of 
1mg of intrathecal morphine was given across the study population with no consideration to 
patient weight. Remarkably few complications were recorded, especially considering this high 
dose of morphine. The study thus proved the efficacy of the concept of intrathecal morphine. 
Blacklock subsequently reported on 5 patients undergoing lumbar procedures who received 
1mg of intrathecal morphine (test group). This patient cohort was compared to 10 control 
patients who received any of the following analgesics at the discretion of the nursing staff: 
intramuscular Meperidine (50 to 100mg), an oral Acetominophen and codeine combination, or 
Acetaminophen alone (Blacklock, 1996). He noted that, in the test subjects, affective analgesia 
resulted from the administration of intrathecal morphine with hardly any supplemental 
analgesic requirements. However, the test group used twice as much supplementary 
intramuscular narcotics (which were not named, nor were doses provided) after 24 hours when 




both groups were comparable over the 5 days studied. However, procedures performed in the 
test and control groups did not include any fusion procedures, which require more muscle 
dissection and is intuitively more painful. This study also demonstrated that vigilance is 
required after the effect of the intrathecal morphine has worn off and that additional effective 
analgesia might then be needed. 
Of significance was the finding that urinary retention, which lasted 24 to 36 hours, was noted 
in all 5 test subjects. No urinary retention was noted in any of the patients in the previously 
mentioned study published by O’Neill, despite the same dose of 1mg intrathecal morphine 
being used (O’Neill, 1985). 
Blackman et al. studied the use of intrathecal morphine in a younger population (ranging from 
11 to 16 years) in 1991 (Blackman, 1991). The study specifically addressed the issue of the 
efficacy of intrathecal morphine in scoliosis surgery as well as evaluating the risk of respiratory 
depression. Thirty-three patients were assessed, and it was concluded that efficient pain relief 
lasted between 8 and 40 hours (the patients thus required no supplemental analgesia). 
However, 2 patients reported no pain relief which could imply a technical failure in the delivery 
of the intrathecal morphine, most likely leakage through the small puncture in the dura. 
Significant respiratory depression in this study was defined as PaCO₂ equals to or more than 
60mm Hg. 
Four patients demonstrated PaCO₂ of more than 60mm Hg and were subsequently treated 
with intravenous Naloxone 6 hours after anaesthesia in order to reverse the opioid effect. All 
4 patients had normal respiratory mechanical parameters and blood gas analysis, 30 minutes 
after extubating, diagnosed the respiratory depression. The literature does not state whether 
any of the patients were awake and responding to commands. There is also no reference to 
the PaO₂ level, or saturation, or the number of blood gas analyses done on each patient. The 
increased PaCO₂ could, in the author’s opinion, have been easily managed by instructing the 
patient to breath deeper, or faster, or by increasing the inspired oxygen concentration.  
However, respiratory depression is a known side effect of opioids and nothing turns on this 
provided it does not result in hypoxia or somnolence i.e. the PaCO2 level becomes very high. 
The absence of saturation data therefore limits the understanding of the respiratory risk 
associated with intrathecal opioids.  
The authors concluded that intrathecal morphine provided noticeable pain relief in younger 
spinal fusion patients. They further asserted that possible side effects are easily recognisable 




The dose used was described in the materials and methods section as 0.01mg/kg with an 
added reference that the dose was varied to determine whether it changed the response. The 
doses ultimately used ranged from 0.007 to 0.019mg/kg which makes it difficult to draw a 
definite conclusion as to an effective dose and dose-related side-effects. One patient had to 
be ventilated for more than 24 hours. Scoliosis surgery is significant spinal surgery and the 
resultant effective analgesia achieved by intrathecal morphine in this study strongly suggests 
that the approach holds promise in terms of analgesia. The study, however, also highlights 
the important risks associated with intrathecal opiates.  
Ross et al. reported on the use of intrathecal morphine in spinal surgery (Ross, 1991). They 
randomised patients to doses of 0.125, 0.25 and 0.5mg and compared this to a placebo group 
receiving normal saline intrathecal injection (placebo). The results showed that the 0.125mg 
and placebo group experienced similar degrees of pain relief and that the 0.25 and 0.5mg 
groups both showed improved pain scores and shorter hospital stays. The rescue analgesia 
of choice was subcutaneous morphine. Their protocol required clinical respiratory frequency 
measurements every 30 minutes for 12 hours in a high care environment and no respiratory 
complications were noted. No blood gas analyses were done to support any potential 
respiratory complications. It is now accepted that reliance on respiratory rate, as an indication 
of opioid respiratory depression, is neither accurate nor safe (Coetzee, 2013). 
Generally, the study was well designed and proved the efficacy of the 0.25 and 0.5mg doses. 
However, the surgical procedures were not standardised, nor equally distributed amongst the 
groups. No fusion procedures were performed in this study. These observations raise 
questions regarding the randomisation of the study. None of the procedures performed (which 
included discectomy, hemilaminectomy, laminectomy and foraminotomy) required significant 
muscle stripping as part of the surgical intervention. This is important as muscle stripping is a 
significant contributor to post-operative pain in many surgical procedures performed on the 
spine. The amount of surgical levels operated on were also unequally spread, as some 
procedures, such as discectomy and hemilaminectomy, will require no more than two days 
hospital stay in conventional spinal surgical practice. This normal post-operative course could 
have significantly influenced the authors’ conclusions regarding reduced hospital stay and 
improved pain scores as baseline expectation was neither severe pain nor extended hospital 
stay. The randomisation apparently did not address this variable.  No body-weight adaptations 
of the doses were used, an approach which could have skewed the results and influenced 
potential respiratory complications. The time to first supplemental narcotic was 20 hours in the 
0.5mg group compared to 13.5 hours in the 0.25mg group. Despite having no respiratory 
complications, the authors still recommended a regime of intensive post-operative respiratory 




insufficient to ignore the potential risk of respiratory depression. Finally, the authors did not 
express an opinion regarding the safety of the 0.5mg intrathecal morphine dose. They 
recommended that the treating physician should decide whether he/she wanted to perform 
intensive monitoring on the patient for the added benefit of longer and improved analgesia. 
The studies by Blackman (Blackman, 1991) and Ross (Ross, 1991) evaluated respiratory 
complications associated with the use of intrathecal morphine. Despite comparable dose 
regimes, conflicting results were reported. This difference could be ascribed to the fact that 
Ross did not study arterial blood gases and relied on respiratory rate. There is a right shift in 
the minute ventilation vs PaCO2 response curve which confirms the notion that opioids depress 
respiration, but this may not necessarily find expression in the respiratory rate (Loeschke, 
1953). It is well known that a reliance on respiratory rate as an index of respiratory depression 
associated with morphine, is unreliable and even unsafe. In addition, the study by Ross did 
not use a weight-calculated dose, complicating any conclusion regarding safety. Both studies 
were promising inasmuch as effective analgesia was achieved but they failed to provide 
specific information regarding effective vs safe doses. 
Two years after Ross et al. reported on their experience with intrathecal morphine, Bernard et 
al. published their experience comparing an intrathecal morphine dosage of 0.3mg to a 
continuous intravenous infusion of Clonidine and Fentanyl. Patients undergoing major spinal 
surgery (scoliosis correction) were randomly assigned to groups in a double-blinded fashion 
(Bernard, 1993). A standardised anaesthetic regime was used. All patients were kept 
intubated after surgery and were only extubated approximately 4 hours after administration of 
the drugs. The study design identified a PaCO₂ of 50mm Hg as trigger to reverse the opioid 
effect with Naloxone. A rise in PaCO₂ was noted in the first 2 hours after extubating in the 
intrathecal morphine group with 4 patients reaching PaCO₂ levels in excess of 50mm Hg. 
Although no hypoxia was recorded, the authors concluded that a significant respiratory 
depression risk exists with the use of intrathecal morphine. Similarly, no decrease in saturation 
below 90% was noted in either group. The PaO₂ and saturation remained at control values 
between the 2 groups for the duration of the study and no patient’s respiratory rate decreased 
below 10 breaths per minute. All patients received a facemask oxygen (FiO2 0.4) and all 
patients were reported to be easy to rouse post-operatively. No significant difference could be 
demonstrated between the 2 groups with regards to analgesia. The intrathecal dose of 0.3mg 
was used in all the patients although the Fentanyl and Clonidine infusions were adapted for 
weight, making it difficult to compare efficacy. All patients received Ketoprofen (NSAID) as 
rescue analgesia and its use in the groups was similar. However, the use of NSAID drugs in 
the post-operative period after spinal fusion surgery is deemed inappropriate. Further, the use 




France et al. published a comparative study of intrathecal morphine to intrathecal 0.9% normal 
saline injection (placebo group) (France, 1997). All 77 patients in the study population received 
a PCA pump to control breakthrough pain. The intrathecal morphine dosage used was 
0.011mg/kg, implying that a 100kg patient would receive a single intrathecal dosage of 1.1mg 
morphine. This would be considered a high dose according to the literature at the time.  
The patient-controlled analgesia solution was not standardised, and 3 different drugs were 
administered non-randomly to provide additional analgesia. The drugs used were morphine, 
Demerol (Meperidine) and Dilaudid (Hydromorphone). The management of breakthrough pain 
was left to the discretion of the pain management team of the hospital thus making it difficult 
to draw reasoned conclusions regarding the findings. It would have increased the benefit of 
the study had a single drug been selected as PCA escape as this would have facilitated a 
comparison regarding the amount used over a specific time period. This was, however, not 
done. 
 All patients remained in ICU post-operatively and were monitored for apnoea. The study also 
evaluated hospital length-of-stay. 
Naloxone was administered to 3 patients as their respiratory rates decreased below 8 per 
minute. An additional 9 patients, all belonging to the intrathecal placebo group, were removed 
from the study as their PCA was changed to continuous infusion, implying ineffective analgesia 
associated with PCA as single treating modality. No blood gas analyses were done to 
objectively examine the respiratory effects of the intrathecal morphine. The frequency of 8 
breaths per minute as trigger for Naloxone administration was part of the study design, yet 
none of the 3 three patients who were given Naloxone showed any clinical signs of respiratory 
compromise, nor difficulty being roused. It is thus uncertain why Naloxone was administered.  
The authors did not evaluate other breakthrough pain analgesic options but recorded a 
decreased use of PCA in the group which had received intrathecal morphine by comparing 
post-surgical PCA volumes and attempted use (within the lock-out period) between the 
groups. No mention was made of a standardised anaesthetic and the intrathecal morphine 
injection was administered approximately 30 minutes before the surgical procedure was 
completed. The end of surgery was adopted as time zero i.e. the start of time-based data 
collection for this study. This being so, the type of anaesthesia, especially intra-operative 
opiate use, was of significant importance in the interpretation of their results.  
No difference could be demonstrated in the length of stay between the 2 groups. As regards 
the side-effects of morphine, the dose of 0.011mg/kg could be criticised due to the known 
respiratory effects associated with a higher dose of intrathecal morphine (Rathmell, 2005). 




minimal. Pruritus was documented in 8 intrathecal morphine patients and in 2 control patients. 
The authors described this as a “minor nuisance” and regarded it as not being significant.  
No pain scoring was done after 32 hours and no other analgesic regime, other than PCA, was 
used. Upon post-operative arrival in the intermediate care unit, the mean VAS was statistically 
significant in favour of the intrathecal group. However, this significance diminished towards 
the end of the first day (p=0.1) and a statistically significant reversal occurred in favour of the 
control group at 36 hours post-operatively. The authors highlighted the importance of 
breakthrough pain after 24 hours where the PCA demand exceeded that of the control group. 
The attempted PCA use was consistently lower in the intrathecal morphine group, initially 
coinciding with the better VAS scores. However, during the second 24 hours post-operatively 
the use increased to more than that of the control group which implied that the breakthrough 
pain regime was not fully effective. PCA as standalone entity could thus provide some 
analgesia, but not comparable to that of the intrathecal morphine.  
Boezaart et al. (Boezaart, 1999) attempted to provide a dose regime for analgesia after spinal 
surgery which would balance optimal analgesia with minimal side effects, specifically with 
reference to respiratory depression. Sixty patients, scheduled for spinal surgery, were divided 
into 3 groups of 20 patients each. At the end of surgery, before wound closure, 0.2, 0.3 and 
0.4mg morphine was intrathecally administered to the 3 groups. Pain was scored by means 
of the Visual Analogue Scale at 6, 12, 18 and 24 hours post-operatively. However, no 
randomisation occurred, and doses used were not based on body mass. The surgery itself 
entailed fusion-type procedures with, or without, a decompression. The time to wound closure 
as well as the time it took to wake the patient up was not recorded thus making it difficult to 
extrapolate a time to effective analgesia from the initial administration of intrathecal morphine. 
Also, the anaesthetic regime was not standardised. This implies that intra-operative opioids 
might have influenced the outcome, at least for the first few hours after the patient woke up. 
Diclofenac was prescribed and only required in the 0.2mg intrathecal morphine group where 
40% of the patients received the drug. The amount of times Diclofenac was used was not 
noted. In the initial 24 hours post-operatively, the ineffectiveness of the 0.2mg dose was 
notable. If an additional 24 hours had been studied, the dose to weight discrepancies (the 
doses were not scaled to body weight) in the higher intrathecal doses would probably have 
come to the fore. Effectiveness in the 0.3 and 0.4mg groups were comparable between groups 
and demonstrated for up to 24 hours. 
The changes in PaCO₂ were not significant across the groups and the highest single level 
measured was 6.4kPa (48mm Hg). All 3 groups followed the same overall trend of a 




hourly, no mention is made of PaO₂ or SaO₂. Respiratory rate was significantly less in the 
0.3mg group when compared to the other 2 groups, yet the lowest value was 13 breaths per 
minute. No comment was made regarding how easily these patients could be roused. The 
oxygenation status and level of sedation were important factors which informed the decision 
as to whether or not the respiratory depression, as gauged from the elevated PaCO2, was of 
clinical significance. 
Urban et al. also published results in 2002 on the use of intrathecal morphine in spinal surgery 
(Urban, 2002). Sixty-five patients were randomised into 3 groups and given a bolus of 10ug/kg, 
20ug/kg intrathecally or no intrathecal injection. All patients received morphine PCA post-
operatively for 72 hours and were monitored for respiratory depression. The authors defined 
oxygen saturation as less than 90% and sedation which was graded on a scale of 1 to 5 with 
1 being awake and 5 unconscious. The larger dose intrathecal morphine group remained pain 
free for the longest period of time followed by the group who had received 10ug/kg. The 
placebo group predictably used the PCA device most often. All groups were, however, 
comparable after 12 hours. 
The study adopted a standardised anaesthetic regime as guideline. However, the large variety 
of surgical procedures, and especially the length of surgery (not quantified, yet implied), 
exposes this part of the protocol to uncertainty. Neither the surgeon nor the ICU staff were 
blinded to the intrathecal morphine groups and although no respiratory complications were 
mentioned in the results, the discussion mentions that the author, as standard practice outside 
of this study, used Naloxone to treat perceived respiratory depression based on hypercapnia. 
The study design did not mention any threshold value used to initiate treatment for 
hypercapnia, neither did it address the role of PaO2, SaO2 and/or respiratory rate. Prolonged 
ICU stay was required for 15 patients, yet this was due to pre-existing pulmonary disease, 
extensive and prolonged surgery as well as ventilator support beyond the first post-operative 
night. The number of patients who required ventilator support were significantly more in the 
placebo group than the high dose intrathecal morphine group. Incidences of pruritis were 
higher in the larger dose group, yet instances of nausea and vomiting were similar, even in 
the placebo group.  
Ultimately this study design added no new information to the known literature regarding 
intrathecal morphine. It is this author’s considered opinion that the higher doses of intrathecal 
opiate potentially endangered the patients. The higher dose of intrathecal morphine provided 
a longer analgesic effect and Urban et al. commented on its efficacy in spinal surgery, yet the 
affirmation was not supported with appropriate pain scores. The discussion did not involve any 




Gehling et al. performed a multi-centre placebo-controlled trial between 2002 and 2003 on 
orthopaedic patients receiving spinal anaesthesia (Gehling, 2009). They postulated that 
patient-controlled devices could be avoided if intrathecal morphine was given in addition to 
the conventional spinal anaesthesia. They randomised patients into 3 groups: placebo (zero 
morphine), 0.1 and 0.2mg intrathecal morphine injections. These were administered in 
addition to the spinal anaesthesia of 15mg intrathecal Bupivacaine given to all 3 groups. An 
intravenous dose of 5mg morphine was prescribed for rescue analgesia and could be given 
every 10 minutes, if necessary. In addition, all patients received an intravenous infusion of 
1000mg Metamizol over 30 minutes which could be repeated according to protocol every 4 
hours to a maximum dosage of 6000mg.  
They concluded that the higher dose of intrathecal morphine resulted in longer post-operative 
analgesia and less additional opioid requirements, confirming the analgesic potency of 
intrathecal morphine. After 24 hours, additional opioids were required in 51% of patients who 
had received 0.1mg intrathecal morphine and 31% in those who had received 0.2mg. The 
placebo group, with only the spinal anaesthetic, had a 71% additional opioid requirement, 
predictably starting at around 6 hours post administration. Of all the patients who had received 
intrathecal morphine, only 40% required additional narcotics after 24 hours. All patients were 
kept in a high care facility (PACU) for 3 hours only and then transferred to a general ward once 
circulatory and respiratory parameters were deemed normal where hourly observations were 
performed.  
Of the 188 patients studied, no respiratory complications were reported. However, no blood 
gas analyses were done, and respiratory frequency was the only parameter used to assess 
respiratory complications with a rate of 10 breaths per minute as trigger for intravenous 
Naloxone to reverse the opioid effect. The intrathecal morphine dose was not adapted to 
weight, making it difficult to draw a final and definitive conclusion as to its effectiveness in 
relation to a specific dose.  By not subjecting the patients to general anaesthesia, this study 
eliminated intra-operative administration of opiates (as part of the anaesthesia) as a 
confounding factor. The authors proved the efficacy of intrathecal morphine. The lack of 
standardised surgical procedures and standard doses (scales to the patient size), however, 
once again makes it difficult to draw more specific conclusions besides confirming that the 
technique is, indeed, effective. 
Techanivate performed a prospective randomised controlled study on 40 patients which were 
allocated to 2 groups (Techanivate, 2003). All patients received spinal fusion procedures and 
were randomised to a morphine (0.3mg) intrathecal injection or intrathecal 0.9% normal saline 




breakthrough pain in the post-operative period. Their results indicated that less patient- 
controlled analgesia was required and longer time to first use of the PCA was present in the 
morphine group (131.7 to first use vs 29.6min).  Both groups had similar incidences of nausea 
and vomiting, and no respiratory depression was documented. No complications were noted 
regarding the dural puncture site for the intrathecal injections.  
Again, albeit indirectly, the authors confirmed that spinal opiate administration is effective. The 
lack of puncture site complications is comforting to those who fear cerebrospinal fluid leaks 
and complications thereof.  
A case report by Law et al. (Law, 2009) demonstrated severe respiratory depression in a post-
operative patient after an intrathecal morphine injection. The patient recovered after Naloxone 
had been administered. The patient received a dose of 0.4mg intrathecal morphine, which is 
lower than most guidelines available at the time. In particular, a patient group in the Boezaart 
study (Boezaart, 1999) received 0.4mg intrathecal morphine and no similar complications 
occurred. On closer analysis of this single case, it appears as if the patient received a dose of 
0.0068mg/kg which is indeed higher than what the literature at that time suggested (Boezaart, 
1999), although other studies used higher doses. Blackman et al. (Blackman, 1991) reported 
4 cases of respiratory depression in their series, but the doses used exceeded the dose used 
in the case report on by Law. In this case report, the intrathecal injection was combined with 
5mg Bupivacaine. A 3mg intravenous morphine bolus was administered at the end of surgery 
and a PCA device, charged with morphine, showed that 1.5mg was used in the first 5 hours 
post-operatively. In the absence of pain, the combined effect of the different morphine sources 
led to the respiratory depression. This publication highlights the risk of a fixed dose of 
morphine, in addition to the spinal morphine, rather than administering the additional morphine 
with a PCA only. The latter combination relies on the safeguard that the PCA cannot over 
administer and also, presumably, a PCA request cannot be delivered when the patient is 
deeply sedated by the morphine. This case report simply confirms what is already well known 
regarding the consequences of excessive doses of morphine being administered.  
Ziegeler et al. (Ziegeler, 2008) included 52 randomised patients undergoing spinal fusion 
surgery in a study where patients were then randomly allocated an intrathecal morphine 
injection or placebo 0.9% normal saline injection intrathecally. All patients in the study 
population received a PCA pump containing Piritramide for post-operative treatment. The 
study participants were administered a single dose of 0.4mg of intrathecal morphine, 
irrespective of weight, and all patients were prescribed an intravenous regime of 5mg 
Piritramide in bolus doses for breakthrough analgesia. All patients received 100mg Diclofenac 




post-operatively. Their results showed a significantly superior analgesia in the first 8 hours 
after surgery in the morphine group with the mean VAS scores being significantly better when 
compared to placebo (22 in the morphine group vs 30 in the placebo group). The PCA use 
was significantly more frequent in the placebo group when compared to the morphine group 
for the first 3 time periods up to 8 hours post-operatively. Between 8 and 20 hours the absolute 
PCA use was more frequent in the placebo group, yet this result did not achieve statistical 
significance. This could perhaps be attributed to the Diclofenac administered to all the study 
participants knowing that Diclofenac is very effective in managing musculoskeletal pain 
(Thaller, 2005.) Intravenous bolus use of Piritramide was higher in the immediate post-
operative period in the placebo group with 13 patients requiring additional doses compared to 
5 in the morphine group. The number of times it was required is not described.  
The authors could not detect statistically significant differences in the side-effect profile, which 
included respiratory depression. The latter was measured using PaO₂ and PaCO₂ at 3 time 
intervals post-operatively (30 minutes, 4 hours and 16 hours). All patients received 
supplemental oxygen via nasal cannula. The results indicated no difference in PaO₂ between 
the groups, however, the intrathecal morphine group at 4 hours had a statistically significantly 
greater change in PaCO₂ values (9.8mm Hg vs 5.2mm Hg). No clinically relevant respiratory 
depression requiring Naloxone was documented, yet the criteria used for Naloxone 
administration was not recorded in the study. No difference in saturation between the groups 
could be demonstrated. Other side-effects measured were: pruritus, cerebrospinal fluid 
leakage from the puncture site, nausea and vomiting and the use of antihistamine and 
antiemetic medication. No statistically significant difference could be detected in any of these. 
The single dose for intrathecal morphine (0.4mg, irrespective of patients’ size) could potentially 
be a dangerous dose for a smaller patient. The authors did attempt to standardise the 
anaesthetic regime and both study groups had access to PCA. Although the latter was 
necessary to provide for escape treatment, in this author’s opinion it makes for a difficult 
evaluation of the intrathecal morphine as treatment alone. The impact which Diclofenac had 
on the pain measurements is also not discussed. This study is comparable to that of France 
et al. (France, 1997) who reported similar results. The short post-operative study period of 20 
hours avoided the critical analysis of breakthrough pain. The PCA use was meant to 
demonstrate breakthrough pain but the 20 hours study period was too short to fully evaluate 
this phenomenon.  
Airamo Morselli et al. attempted to compare the efficacy of a fixed intrathecal dose of 100ug 
to a standardised intravenous regime of approximately 5mg intravenous morphine, 




Patients were observed for 24 hours (Airamo Morselli, 2017). No rescue analgesia was 
permitted in either group.  
A single anaesthetist managed all the cases with a standardised anaesthetic regime. The 
intrathecal dose, not calculated to weight, was given prior to commencing surgery soon after 
induction of anaesthesia. The intravenous dose was calculated to weight (0.06 - 0.08mg/kg) 
and given as a 24-hour infusion. The intrathecal group received a similar infusion of normal 
saline. All patients were observed in a general ward and transferred to ICU only if the 
respiratory rate was less than 8 breaths per minute.  
Fifty patients were recruited to take part in the study. The intrathecal group demonstrated 
statistically significantly lower VAS scores compared to the intravenous morphine group 
(mean VAS of 0.72 vs 3.08 at 6 hours, 0.72 vs 3.56 at 12 hours and 1.36 vs 3.64 at 24 hours). 
Eighteen patients in the intrathecal group underwent early mobilisation vs 10 only in the 
intravenous morphine group. This significant difference meant that the intrathecal group had 
a shorter hospital stay than the intravenous morphine group (3 vs 6.44 days). No nausea and 
vomiting, pruritis or respiratory depression was encountered in either group. Respiratory 
depression was defined as a respiratory rate less than 8 breaths per minute. 
The authors acknowledged the limitations of their study, including the small sample size and 
the inherent nature of the minimal invasive procedure, which in its own right is meant to be 
much less painful than open spinal surgery. However, one has to keep in mind that the placebo 
group had similar surgery and the comparison is therefor still valid. The reader can interpolate 
but can naturally not extrapolate to more painful surgery, such as conventional spinal surgery.  
Once again, no dose-per-weight calculation was made for the intrathecal group. This is a 
problem which occurs in many studies as it complicates the making of a comparison.  
 
In summary, with regards to the use of intrathecal morphine in lumbar spinal surgery, the 
available literature shows: 
1. Support for the efficacy of this approach.  
2. Significant variations occur as to the doses used. 
3. Significant variations occur as to possible side-effects. 
4. Variations often occur as a result of poor study design.  
5. The natural history of this technique shows that progressively smaller doses are being 
used. This approach is driven by the fear of complications, of which respiratory 




6. Multiple factors could influence the measurement of pain in the post-operative period. 
These include a non-standardised anaesthetic regime and non-standardised 
procedures which could result in variations regarding the amount of tissue dissected 
to perform the procedure, and ultimately how painful the procedure might be.  
7. PCA is mostly used in conjunction with intrathecal morphine which makes it difficult, if 
not nearly impossible, to make valid conclusions regarding dose and dose-related side 
effect.  
In view of the uncertainties, safety for effectiveness, a standardised evaluation of 
intrathecal morphine is necessary. The surgical and anaesthetic procedure must both be 
standardised; the dose of intrathecal morphine should be calculated to body weight and 
the post-operative management standardised with reference to escape analgesia and 
management of side effects. The presence and extent of respiratory depression need to 
be objectively quantified to properly gauge the perceived respiratory risk. The study 
























2. Materials and methods 
 
This study was conducted in the Department of Neurosurgery at Tygerberg Academic Hospital 
in the Western Cape province of South Africa. 
Ethical approval was obtained from the University of Stellenbosch’s Health and Ethics 
committee (REF:M15/09/039). 
Approval to conduct the research at Tygerberg Academic Hospital was obtained from the 
Provincial Government of the Western Cape (22/11/2018). 
Public healthcare patients presenting for surgery to the department were recruited via 
standard out-patient visits as first contact. Surgery was only offered once conservative 
measures had been exhausted. Inclusion criteria for the study were: patients should not have 
undergone previous spinal surgery and should be classified as American Society of 
Anaesthesiologists (ASA) grade I or II. 
At the last out-patient visit, prior to surgery, patients were educated regarding the use of the 
patient-controlled analgesia (PCA) device.  
Patients were admitted to hospital one day prior to surgery and informed consent was obtained 
for both the procedure and participation in the study.  
The surgical procedure, a first surgery single level fusion of 2 lumbar vertebrae, was performed 
in the elective operating room environment. 
Prior to administration of the anaesthesia, the anaesthetist received an envelope allocating 
the patient to either the intrathecal morphine or the PCA group. This information was only 
communicated to the anaesthetist and neither the surgeon nor the patient had insight as to 
allocation. The anaesthetist then prepared the appropriate solutions for both the intrathecal 
injection and the PCA. All patients received a PCA device and an intra-operative intrathecal 
injection with one containing the appropriate dose of morphine and the other normal saline, 
as determined by randomisation. Each patient was thus subjected to either morphine or saline 
injected intrathecally as well as a PCA containing either morphine or saline.  
Pre-operative scoring was conducted by the author and co-investigators. Post-operative 







2.1 Informed consent 
Informed consent for the study was obtained during admission for surgery. Informed consent 
for the surgical procedure was dealt with separately and procedural risks, benefits and 
possible complications were explained.  
Consent forms for the study, which all participants were required to sign, were made available 
in Afrikaans, English and Xhosa. It was explained that both methods of analgesia are effective 
and that the doses studied fall within the recommended doses for the drug morphine. Patients 
participated in the study of their own volition and were afforded the opportunity to ask 
questions related to the study, admission as well as the procedure.  
 
2.2 Randomisation 
As previously noted, patients were allocated to one of the study options per sequentially 
numbered envelope which contained a descriptor for the anaesthetist allocating the patient to 
either the intrathecal morphine (thus PCA normal saline) or intrathecal placebo or saline (thus 
PCA morphine) group. 
Randomisation was done by an independent third party. Block randomisation occurred 
allowing for 5 of each study group per 10 patients recruited. The unblinded information was 
filed and locked in a secure location in the departmental office, close to the ICU, should the 
necessity for unblinding arise during the study.  
 
2.3 PCA 
Depending on the group to which the patient had been randomised, he/she received a PCA 
device which contained either morphine, or normal saline. In the PCA morphine group, the 
device was loaded with a 1mg/ml concentration of morphine in normal saline. The 7 minute 
lock-out period allowed a maximum dose of 8 mg morphine per hour. 
In the immediate post-operative period, the anaesthetist titrated small doses (1 - 2mg) of 
morphine until the patient was pain free on his/her arrival in the recovery room. The patient 






2.3.1 PCA Education 
Patients who could not understand the principles of PCA analgesia, or how to use the device, 
were excluded from the study. 
PCA education took place on two occasions prior to the procedure: once pre-operatively on 
the day of admission and the second immediately pre-operatively, just prior to induction of 
anaesthesia. Post-operatively, once they had recovered form anaesthesia, patients were 
again reminded of the PCA facility. 
During the first PCA education session, which occurred in the ward on the day of admission, 
the device was shown to the patient and the mechanism of action was explained. Emphasis 
was placed on the lock-out period of 7 minutes between available dosages.  
The same education was re-emphasised in the induction room prior to anaesthesia being 
administered. Once the patient had been recovered and he/she was in the recovery room, the 


















2.4 Scoring systems 
 
2.4.1.  Oswestry disability index 
The patient was requested to complete an Oswestry disability index (ODI), as illustrated in 
Figure 1.2, pre-operatively and then again at the 6-week, 3-month and 6-month follow-up 
visits.  
2.4.2.  Visual analogue scale  
The patient was given a visual analogue scale (VAS), as per Figure 1.1. This instrument 
constitutes a horizontal line, at least 10cm in length, and marked from 1 to 10 with clear 
borders at 0 and 10 on an otherwise blank sheet of paper. The investigator explained that 0 
signifies a complete absence of pain whilst 10 indicates the worst pain imaginable. The patient 
was then requested to draw a mark at the number which most appropriately represented 
his/her current pain. This process was done pre-operatively, and then at 8, 24 and 48 hours 
post-operatively and thereafter every 24 hours until the patient was discharged.  
2.4.3.  Euroqol-5D 
This scoring system, as illustrated in Figure 1.3, was employed pre-operatively and then again 
at 6 weeks, 3 months and 6 months post-operatively.  
2.4.4.  Roland Morris 
The patient completed this scoring sheet, as per Figure 1.4, pre-operatively. The process was 
repeated at 6 weeks, 3 months and 6 months post-operatively. 
2.4.5.  Opioid induced sedation scale 
In conjunction with blood gas analysis, this scale is used to evaluate a patient’s state of 
sedation in the first 24 hours post-operatively. The evaluation process, as per Figure 1.7, is 
repeated every hour for the first 4 hours post-operatively, 2-hourly for the next 8 hours and 
then 4-hourly for up to 24 hours post-operatively. A total of 11 blood gas analyses was done 
per patient using the same machine in the neurosurgical ICU (Gem Premier 3500, 
Instrumentation Laboratory, Bedford MA, United States). The analyser has an auto-calibration 





2.5 General anaesthetic plan 
 
2.5.1 Pre-operatively   
The patient’s medical risk factors and fitness for surgery were optimised. 
Special investigations were directed by the patient’s underlying medical comorbidities but a 
full blood count (FBC), urea and electrolytes (U/E) and electrocardiogram (ECG) were 
recommended for all patients 40 years and older. 
An active crossmatch for all patients was sent to the blood bank in the event of an intra-
operative blood transfusion being required. 
Diabetics were to stop oral hypoglycaemic agents and were managed in accordance with a 
subcutaneous short-acting insulin sliding scale on the day before surgery. 
All anti-hypertensive medication and diuretics were continued pre-operatively, except 
Angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers which were 




No sedatives or anxiolytics were given to patients with anticipated airway difficulties or to 
patients suffering from obstructive sleep apnoea. 
 
All other patients received Midazolam 0.5mg/kg orally, to a maximum dose of 15mg 30 
minutes pre-induction, or Lorazepam 1 - 2mg sublingually 30 minutes pre-induction. 
Paracetamol 1g orally was given as a pre-medication as intravenous Paracetamol is not 
reliably available.  









Standard monitoring techniques were done. These included: non-invasive blood pressure 
measurements, oxygen saturation, 3 - 5 lead ECG, agent and oxygen analyser, expired 
carbon dioxide and core temperature (Carescape Monitor B650, Helsinki, Finland).  
As additional monitoring requirement, all study patients had an intra-arterial line insertion for 
haemodynamic monitoring and arterial blood gas analysis intra- and post-operatively in the 
ICU. This was inserted whilst the patient was under general anaesthesia and had specifically 
been consented to pre-operatively. 
Other monitoring requirements were dictated by the patient’s underlying physical/functional 
status and any concurrent medical co-morbidities. 
A single 16g/18g peripheral intravenous line with Ringer’s Lactate or Balanced Solution 
(Balsol) was placed to help maintain fluid requirements. 
A central venous catheter was not mandatory and placement of such was guided by the 
patient’s underlying medical co-morbidities, or if peripheral venous access proved to be 
difficult.  
An upper or under body forced air warming blanket (Bair Hugger) was used to ensure that the 
patient’s core body temperature was maintained at 36 to 37oC. 
 
2.5.4 Induction  
 
Intra-operative analgesia was provided by an effect site target-controlled infusion (Cet TCI) of 
50ug/ml (2mg in 40ml 0.9% normal saline) Remifentanil using the Minto pharmacokinetic-
pharmacodynamic model. (Minto, 1997) The aim was to achieve an induction effect site 
concentration of 4 - 6ng/ml.  A maintenance dose of 2 - 5ng/ml was titrated to the patient’s 
analgesic requirements intra-operatively.  
 
Depending on its availability, intravenous Paracetamol (Perfalgan) 15mg/kg IVI was infused 
slowly. This was done only if Paracetamol had not been administered as a pre-medication. 
 
Hypnosis was initiated with an intravenous dose of 1% Propofol/Propoven titrated slowly to 





Muscle relaxation was facilitated with a non-depolarising muscle relaxant, Rocuronium, at a 
dosage of 0.6mg/kg. Residual neuromuscular paralysis was monitored using a standard train 
of four count (TOF), aiming for a TOF count of 1 (NMT TOF module, GE Healthcare, Helsinki 
Finland).  
 
Cefazolin 25 - 30mg/kg was administered as prophylactic antibiotic, provided no allergic 
contraindication existed. If so, an alternative antibiotic was selected in consultation with the 
surgeon. 
 
Dexamethasone 8mg IVI was given to each patient to decrease the incidence of post-
operative nausea and vomiting (PONV).   
 
Anaesthesia was maintained using a volatile based technique with either Isoflurane or 
Sevoflurane, depending on availability, in an oxygen/air blend aiming for 0.8 - 1 minimum 
alveolar concentration (MAC), depending on the patient’s age and underlying 
comorbidities/functional class. The minimum inspired oxygen was 40%. Patients were 
mechanically ventilated using tidal volumes of 6-8ml/kg and adjusting the respiratory rate to 
ensure the expired carbon dioxide was 4 - 5%. 
The patient was hand ventilated and full muscle relaxation was achieved in about 2 to 3 
minutes. The trachea was then intubated using the appropriate size armoured endotracheal 
tube. The latter was securely fastened to ensure that it did not dislodge. An oral or nasal 
temperature probe was placed, and the patient’s eyes were adequately padded and closed 
using ophthalmic pads. 
 
A urinary catheter was inserted. 
 
The patient was placed in the prone position. Care was taken to not dislodge any lines or the 
endotracheal tube and to support the patient’s head and neck. The upper chest and pelvis 
were supported with a prone pillow allowing minimal pressure on the abdomen so as to not 
impede mechanical ventilation. The head and neck were kept in in a neutral position and the 
forehead was supported on a gel face pillow with no pressure being exerted on the eyes, nose 
or mouth. The temperature probe and endotracheal tube were positioned free from 
impingement on the patient’s facial tissues. The patient’s arms faced forward in a 90% flexion 
on arm boards resulting in minimal tension at the shoulder and elbow joints. Arm position was 
at the surgeon’s discretion. All pressure points were protected with gel/foam pads and the 
patient’s hips, knees and ankles were adequately supported. The urinary catheter was 





The haemodynamic goal during surgery was to maintain mean arterial blood pressure (MAP) 
within 20% of pre-induction baseline values. This was achieved using appropriate fluid therapy 
(crystalloid/colloid) to maintain euvolemia and appropriately directed vasopressor/inotropic 
support to maintain adequate myocardial contractility and afterload, as needed. 
 
Transfusion requirements were directed by the patient’s underlying starting haemoglobin level, 
co-morbidities (transfusion trigger), as well as indicators of inadequate delivery of oxygen and 
intra-operative blood loss. 
 
The surgeon delivered an intrathecal injection of preservative free morphine sulphate at a 
dose of 5ug/kg to a maximum dose of 450ug, or a placebo of normal saline (similar volume) 
under direct vision during surgery. The dose calculation was made based on the relationship 
of height to weight with the theory that the length of a person and thus the length of the spinal 
column will be related to the weight. However after 90kg, additional weight is theorised to be 
as a result of more adipose tissue, hence the upper limit of 450ug. 
 
A PCA pump primed with morphine sulphate 1mg/ml or normal saline placebo was attached 
to an independent intravenous cannula for post-operative use. 
 
2.5.5  Emergence  
 
Upon completion of surgery, the Remifentanil TCI was weaned timeously to a Cet of 1ng/ml, 
which allowed for adequate return of spontaneous ventilation on emergence from 
anaesthesia. 
 
Muscle relaxation was reversed using Neostigmine 25 - 50ug/kg in combination with 
Glycopyrrolate 4 - 6ug/kg or, for an average adult patient, 2.5mg Neostigmine with 0.5mg 
Glycopyrrolate. If Glycopyrrolate was unavailable, Atropine was used in a dose of 0.6 -1.2mg. 
 
Adequate muscle reversal is demonstrated when the TOF ratio T4:T1 is >95%. 
 
Upon adequate reversal, the volatile agent was terminated, and the patient woke up from 
anaesthesia. The patient’s oropharynx was adequately suctioned under direct vision and the 










The patient was transferred to the recovery room for further post-operative monitoring and to 
complete emergence. 
 
A face-mask oxygen with a FiO2 of 0.4 was administered to all study patients for the first 24 
hours post-operatively. 
 
Either the nursing staff or anaesthetist reinforced PCA pump function availability and its use 
as soon as the patient was fully awake.  
 
When fully awake and stable the patient was sent to the Neurosurgery Intensive Care Unit 
(ICU) for further care and monitoring of study variables which included: blood gas analysis, 


















2.6 Single level fusion 
Once general anaesthesia had been administered, the surgeon or assistant surgeon placed 
and secured a catheter. The patient was then placed in a prone position. Once prone, the 
surgical level was confirmed with fluoroscopy.  
Routine surgical site preparation followed which involved the cleaning of the site with an 
antiseptic solution by the surgeon, assistant surgeon or nursing staff. Thereafter a sterile 
draping was placed.  
A midline incision was performed, and the para-spinal muscles were stripped to the lumbar 
lamina. This dissection was then extended beyond the facet joints to expose the lateral gutters 
and transverse processes. Fluoroscopy was once again used to confirm the surgical level. 
This was followed by the placement of pedicle screws in the relevant pedicles (4 in total as it 
is a single level fusion). This involved intra-operative identification of the pars interarticularis, 
transverse processes and facet joints. Screw lengths were estimated pre-operatively and 
optimal lengths to use intra-operatively were guided by clinical probing of the pedicle, to 
ensure no breaches, and intra-operative fluoroscopy.  
This was followed by a laminectomy and decompression of the neural structures.  
A laminectomy or hemi-laminectomy was performed to access and decompress the relevant 
neural structures. Care was taken to preserve the interspinous ligament of the more cranial 
vertebra involved in the fusion construct.  
The use of a transforaminal lumbar interbody fusion (TLIF) was done at the discretion of the 
surgeon. This involved a facetectomy, discectomy and placement of an interbody cage. This 
added approximately 20 to 30 minutes to the total procedure time and caused no additional 
muscle trauma. 
Prior to insertion of the rods, the intrathecal injection was administered. The rods were placed 
in the screw heads and secured with locking caps. A locally harvested bone graft was placed 
in decorticated lateral gutters. A surgical site drain was placed, and the wound was closed 
using continuous, interrupted and subcutaneous sutures. Surgical site clips were used if 
deemed appropriate by the surgeon. 
The Intra-operative data captured included: surgical time, blood loss, complications, surgical 






2.7 Intrathecal injection 
Depending on the group to which the patient had been randomised, the anaesthetist prepared 
a solution containing 1mg/ml of morphine in normal saline or a placebo. The surgeon, using a 
sterile insulin needle, drew up the appropriate volume from the solution provided by the 
anaesthetist (Figure 2.1). If the patient had been randomised to the intrathecal group, the dose 
administered was 0.005mg/kg to a maximum dose of 0.45mg. The volume matched the total 
milligram in millilitres, thus 0.45mg was 0.45ml. If the patient had been allocated to the placebo 
group, the solution contained normal saline only, applying a similar volume calculation as per 
the weight of the patient. 
The intrathecal injection was performed at the most cranial point of the exposed dura mater. 
The dura mater at the caudal border of the lamina at the cranial end of the decompression 
was depressed using a blunt instrument. The spinal needle was then passed through the dura 
in the midline effectively under the cranial lamina. This technique provided a tamponade of 
the needle site with the lamina limiting a cerebrospinal fluid (CSF) leak and potential 
complication (Figure 2.2).  
Once the needle had been correctly placed, cerebrospinal fluid (CSF) was aspirated to ensure 
correct positioning of the needle within the thecal sac. The solution was then slowly 
administered. The needle was not removed until 30 seconds after the entire content had been 
delivered. This slow delivery aided the spread of the solution within the CSF space. 
Considering that the remainder of the surgical procedure involved placement of the rods, bone 
graft and closure of the wound, the intrathecal solution was administered roughly 30 to 45 
minutes prior to the end of the procedure. 
Time point 0 was fixed as the time of the patient’s arrival in the recovery room.  
 
2.8 Blood gas analyses 
Blood gas analyses were performed at the following time points for the first 24 hours post-
surgically: hourly for the first 4 hours, 2-hourly for the next 8 hours and 4-hourly for the next 
12 hours resulting in 11 samples in total. These arterial samples were analysed by the same 
calibrated blood gas machine. The parameters evaluated were: PaO2, PaCO2, oxygen 
saturation, FiO2, HCO3, TCO2 (total carbon dioxide), haematocrit, base excess, haemoglobin, 






2.9 High care unit 
Routine observations were performed and included: blood pressure, mean arterial pressure, 
pulse rate, oxygen saturation, respiratory rate, opioid induced sedation scale, urinary output 
and intravenous fluid use. 
 
2.10 Rescue analgesia 
Additional analgesia consisted of intravenous paracetamol (Perfalgan®) 6 hourly for 48 hours. 
An intramuscular dose of 5mg morphine was prescribed as rescue analgesia to be 
administered 4 - 6 hourly should the VAS score be 4 or above.  
 
2.11 Physiotherapy 
Physiotherapy was standardised throughout the study population with the same endpoints to 
be achieved and recorded. These endpoints included: log-roll and circulation exercise in the 
bed, sitting on the side of the bed, standing next to bed, mobilising a few steps next to bed, 
walking to the bathroom aided, walking to the bathroom unaided, mobilising independently 
and then discharge (Figure 1.5). These were recorded on the post-operative day that the target 
was achieved. 
 
2.12 Retrospective cohort 
A size matched retrospective cohort was enrolled from consecutive patients in the public 
sector who had their surgical procedures performed by the author and who were managed in 
the same neurosurgical unit where the prospective arm was conducted.  
The data collected in the groups included demographics (age, gender) and length of hospital 







2.13 Direct costs 
The length of stay of each patient was converted to a Rand value and a direct cost implication 
was calculated. Other factors which affected cost included: materials cost (e.g. PCA pump), 
drugs used and physiotherapy costs.  
 
2.14 Statistical analysis 
The statistical analysis was done by Ms Tonya Esterhuizen from the Biostatistics Unit, Division 
of Epidemiology and Biostatistics, Stellenbosch University with support from the Dean’s Fund. 
Group sample sizes of 37 and 37 was calculated to achieve 80% power to detect a change in 
mean duration of stay of 1.0 day between the PCA group and intrathecal morphine 
group.  Group standard deviations of 1.5 (a conservative estimate) were assumed for the 
purposes of the sample size calculation.  A significance level (alpha) of 0.05 using a two-sided 
Mann-Whitney test was used assuming that the actual distribution is uniform. 
IBM SPSS version 25 was used to analyse the data. A p-value <0.05 was considered as 
statistically significant. However, clinical significance was also considered in the interpretation 
of the results.  
Descriptive analysis:  
Continuous variables were analysed descriptively using means and standard deviations if data 
was normally-distributed and medians and interquartile ranges if the data was non-normally 
distributed.  95% Confidence intervals were presented for population means and medians 
were presented when appropriate.  Histograms were used to present the data 
visually.  Nominal data was presented using frequency distributions and bar charts.  95% 
Confidence intervals for binary proportions were presented.  Ordinal data was presented as 
medians and interquartile ranges.  
Hypothesis testing:  
Due to the randomisation of treatments in this study, where simple comparison of the 
outcomes between the two groups were required, a general framework of analysis was 
applied. The relationship between two nominal variables were investigated with contingency 
tables and likelihood ratio chi-square tests. Relationships between two continuous variables 
were analysed with regression analysis and the strength of the relationship measured with the 
Pearson correlation, or Spearman correlation, if the continuous variables were not normally 




input variables, multiple regression analysis was used, and the strength of the relationship 
was measured with regression coefficients. The relationships between continuous response 
variables and nominal input variables were analysed using appropriate analysis of variance 
(ANOVA). When ordinal response variables were compared versus a nominal input variable, 
non-parametric ANOVA methods was used. For comparison of non-normally distributed 
outcomes, for example volume of PCA used, between the two treatment groups, the Mann-
Whitney tests were used. Continuous normally distributed baseline variables were compared 
between the two treatment groups using independent t-tests,  
 
In accordance with good clinical practice regarding a prospective clinical trial, an interim 
analysis was performed once twenty patients per group were recruited.  
The primary objective of the study was to determine whether there is a decrease in the 
median duration of stay between the PCA and intrathecal morphine arms of the prospective 
groups. Assumptions of normality was tested using normal probability plots and found to be 
not normally distributed. Non parametric Mann-Whitney tests were used to compare median 
days to discharge as well other end points between the groups.  
Another important objective of the study was to test for differences in side-effects and 
efficacy (measured by VAS scores and mobilisation) between the groups.  Side effects are 
measured at 8, 24 and 48-hour post-operative time points as well as 11 blood gas analysis 
values in the first 24 hours post-operatively.  Repeated measures ANOVA models were 
employed, with time as a within-subjects factor and intervention group as the between-
subjects factor. Interactions between time and intervention group were interpreted as 
treatment effects.  Profile plots of mean outcome measures over time were shown by 
treatment group to visually assess the presence of an interaction or treatment effect. 
Assumptions of normality was tested using normal probability plots.  Similar analyses were 
carried out for pain questionnaires (e.g. ODI, RM, EQ-5 and VAS), however the measurement 






Figure 2.1: A sterile insulin needle was used to deliver the prepared solution intrathecally. 
The anaesthetist prepared the appropriate solution and the surgeon then drew it into the 





Figure 2.2: The thecal sac is depressed under the cranial lamina and the intrathecal solution 
is then delivered. When the syringe is removed, the lamina will tamponade the puncture site 













3.1 General remarks 
A sample size calculation was performed after 40 patients had been recruited. The total 
sample size resulted in the study being powered at 90% with a significance level of 0.01. 
The block randomisation allowed for 20 patients per group (PCA and IT). Three patients were 
withdrawn from the study for reasons detailed in the following section: 
• The first patient suffered a cardiac arrest whilst walking to the X-ray division for 
post-operative x-rays. The patient was successfully resuscitated and taken to 
cardiac angiography suite. Cardiac angiography demonstrated closure of a 
coronary vessel. The vessel was successfully stented, and re-perfusion 
occurred. The patient woke up and was transferred to the cardiac ICU. Later 
that evening she suffered another cardiac arrest and she could not be 
resuscitated. The case was reported as a serious adverse event (SAE) and 
was considered not related to the study. 
• The second patient suffered from cannabis withdrawal during the first post-
operative day. The patient pulled out all intravenous lines as well as the arterial 
line and needed sedation to control the withdrawal event. The patient, who had 
not disclosed any substance abuse or addiction prior to being enrolled, was 
subsequently withdrawn from the study.   
• The third patient had a misplaced screw identified on post-operative X-rays. 
This required another surgery during the same admission. The post-operative 
blood gas data obtained in the first 24 hours were analysed. Length of stay, 











3.2 Group demographics 
 
3.2.1 Intrathecal morphine group (IT group)  
This group contained 11 female and 8 male patients. Seven patients were actively working at 
the time of the surgery. Ten patients were unemployed and 2 were retired and/or pensioners. 
Sixteen patients in the group were treated pre-operatively with oral opioid drugs (Tramadol). 
  
3.2.2 Patient controlled analgesia group (PCA group) 
There were 16 female and 2 male patients in the group. Four patients were actively working 
at the time of the surgery. Nine patients were unemployed and 5 were retired and/or 
pensioners. Seventeen patients in this group were treated with oral opioid drugs (Tramadol) 
pre-operatively. 
 
3.2.3 Body mass index, body fat and muscle percentage  
The mean body mass index (BMI) in the IT group was 29.18kg/m². Eleven patients had a BMI 
of more than 30kg/m² (58%). The mean body fat percentage was 37.4% and the mean muscle 
percentage was 35.16%. 
The mean BMI in the PCA group was 34.31. Twelve patients had a BMI of more than 30 (67%). 
The mean body fat percentage was 44.65% and the mean muscle percentage was 32.37%.  
The median BMI in the PCA group was 33kg/m² and 30.9kg/m² in the IT group. 
There was a significant difference in mean BMI between the groups (p=0.011) and median 
BMI (p=0.033). 








BMI and Body fat % 
  Mean Std. 
Deviation 
p-value 
BMI (kg/m²) PCA 34.31 6.52 0.01 
IT 29.18 5.24 
Body fat % PCA 44.65 10.89 0.075 
IT 37.40 13.40 
Body muscle % PCA 32.37 9.23 0.06 
IT 35.16 7.02 
 
Table 3.1: BMI, bodyfat percentage and body muscle percentage in the intrathecal morphine 
and PCA groups 
 
3.3 Pre-operative scoring  
3.3.1 Quadruple Visual Analogue Score  
In the IT group the following average Quadruple Visual Analogue Score (QVAS) scores were 
recorded: 
Pain right now at 7.16 
Pain on average at 6.37 
Pain at its best at 3.37 
Pain at its worst at 9.42 
 
In the PCA group the following average QVAS scores were recorded: 
Pain right now at 6.05 
Pain on average at 6.00 
Pain at its best at 2.79 






The average Best/Worst imaginable health state, as measured out of 100, was 34.21 in the IT 
group and 36.05 in the PCA group. 
 
3.3.3 Oswestry disability index  
The average Oswestry disability index (ODI) percentage for the IT group was 63.79 and 63.47 
in the PCA. 
 
3.3.4 Roland Morris (RM) 
The mean total in the IT group was 16.11 and in the PCA group 16.37. 
 
 
 IT PCA 
QVAS Pain right now 7.16 6.05 
QVAS Pain on average 6.37 6 
QVAS Pain at its best 3.37 2.79 
QVAS Pain at its worst 9.42 8.84 
EQ-5 34.21 36.05 
ODI percentage 63.79 63.47 
RM 16.11 16.37 
 
Table 3.2: The mean pre-operative scores in the IT and PCA groups (no statistically significant 









3.4 Surgical detail 
The index procedure to be included in the study was first-time spinal surgery namely a single 
level lumbar fusion.  
The most common levels at which the procedure was performed was:  
L4/L5 (n=23, 62.2%) 
L5/S1 (n=10, 27%) 
L3/L4 (n=2, 5.4%) 
L2/L3 (n=2, 5.4%) 
The breakdown per study group for surgical levels is as follows: 








L2/L3 (n=1)  
 
For the IT group, the average intra-operative blood loss was 434.2ml and surgical time 129.2 
minutes. 
For the PCA group, the average intra-operative blood loss was 538.9ml and surgical time 
129.9 minutes. 
The average time from the intrathecal injection until closure of the skin was 29.58 minutes in 
the IT group and 28.83 in the PCA group. Overall, the average time was 28.21 minutes 





 IT PCA Overall 
Blood loss (ml) 434.2 538.9 486.55 
Surgical time 
(minutes) 
129.2 129.9 129.55 
Intrathecal 
injection until skin 
closure (minutes) 
29.58 28.83 28.21 
 
Table 3.3: Intra-operative detail in the IT group, PCA group and overall (no statistical 
difference between groups) 
 
3.5 Post-operative course 
The VAS scores were taken at 8 hours post-operatively both when the patient was lying still 
and when he/she was moving. Possible side-effects related to the intrathecal injection and 
morphine (itching, headaches, nausea and vomiting, feeling of heavy breathing) were 
recorded.  
The post-operative results are presented per each time point (8, 24, 48, 72, 96 and 120 hours 
post-operatively). A summary of the side-effects, VAS scores and supplementary analgesia 
used are presented as per each point in time.  
 
3.5.1 Eight (8) hours post-operatively 
3.5.1.1 IT group 
There were 4 incidences of itching, 3 cases of headache, 1 incident of nausea and vomiting 
and 1 incident of a feeling of heavy breathing (Table 3.5). 
The average VAS lying still was 2.26 and moving 4. The average difference between lying still 







3.5.1.2 PCA group 
There was 1 incident of itching, 3 incidences of headache, 0 incidences of nausea and 
vomiting and none of a feeling of heavy breathing (Table 3.5). 
The average VAS lying still was 2.68 and moving 4.79. The average difference between lying 
still and moving was 2.11. 
3.5.1.3 Supplemental analgesia 
 There was no supplemental analgesia required for either group. 
 
3.5.2 Twenty-four (24) hours post-operatively 
3.5.2.1 IT group 
There were 5 incidents of itching, 2 incidents of headache, 1 incident of nausea and vomiting 
and 0 incidences of a feeling of heavy breathing (Table 3.5). 
The average VAS lying still was 3.16 and moving 4.79. The average difference between lying 
still and moving was 1.63. 
 3.5.2.2 PCA group 
There was 1 incident of itching, 2 incidents of headache, 0 incidence of nausea and vomiting 
and none of a feeling of heavy breathing (Table 3.5). 
The average VAS lying still was 2.26 and moving 4.68. The average difference between lying 
still and moving was 2.42. 
3.5.2.3 PCA volume used 
The volume of PCA used was calculated for both groups. The volume used in the IT group 










 PCA IT p-value 
PCA volume 
used 
Median 43.0 22.0 0.057 
Percentile 
25 
20 12  
Percentile 
75 
55 47  
 














3.5.2.4 Supplemental analgesia 
There were 2 patients who required supplemental analgesia in the IT group and 8 patients in 
the PCA group. This difference was statistically significant as indicated in Table 3.12. 
 
3.5.3 Forty-eight (48) hours post-operatively 
3.5.3.1 IT group 
There was 1 incident of itching, 3 incidents of headache, 1 incident of nausea and vomiting 
and 0 incidences of a feeling of heavy breathing (see Table 3.5). 
The average VAS lying still was 3.22 and moving 5.1. The average difference between lying 
still and moving was 1.88. 
 3.5.3.2 PCA group 
There were 0 incidents of itching, 4 incidents of headache, 1 incident of nausea and vomiting 
and 0 incidences of a feeling of heavy breathing (Table 3.5). 
The average VAS lying still was 3.32 and moving 5.21. The average difference between lying 
still and moving was 1.89. 
3.5.3.3 Supplemental analgesia 
There were 5 patients who required supplemental analgesia in the IT group and 8 patients in 
the PCA group (see Table 3.12). 
3.5.3.4 VAS difference over the first 48 hours 
The VAS scores were recorded both when the patient was lying still, and when the patient 
was asked to move. The difference between these two measures is presented in Figure 3.2. 







Figure 3.2: The difference in VAS scores for the IT group (blue line) and the PCA group (red 
line) at 8, 24 and 48 hours 
 
3.5.3.5 VAS sub analysis at 24 hours post-operatively 
When the difference in VAS lying still and VAS moving were compared between the IT and 
PCA groups, and the patients with a BMI of less than 30 were removed (n=14), a statistically 
significant difference occurred in favour of the IT group (p=0.03).  
 
3.5.4 Seventy-two (72) hours post-operatively (n=32) 
3.5.4.1 IT group 
The average VAS lying still was 2.21 and moving 4.14. The average difference between lying 
still and moving was 1.93. 
3.5.4.2 PCA group 
The average VAS lying still was 2.28 and moving 4. The average difference between lying still 





3.5.4.3 Supplemental analgesia 
There was 1 patient who required supplemental analgesia in the IT group and 4 patients in 
the PCA group (see Table 3.12). 
 
3.5.5 Ninety-six (96) hours post-operatively (n=24) 
3.5.5.1 IT group 
The average VAS lying still was 1.56 and moving 3.67. The average difference between lying 
still and moving was 2.11. 
3.5.5.2 PCA group 
The average VAS lying still was 2.67 and moving 4.2. The average difference between lying 
still and moving was 1.53. 
 
3.5.5.3 Supplemental analgesia 
There was 1 patient who required supplemental analgesia in the IT group and 3 patients in 
the PCA group (see Table 3.12). 
 
3.5.6 One-hundred and twenty (120) hours post-operatively (n=20) 
3.5.6.1 IT group 
The average VAS lying still was 1 and moving 2.17. The average difference between lying still 
and moving was 1.17. 
3.5.6.2 PCA group 
The average VAS lying still was 2.64 and moving 3.86. The average difference between lying 
still and moving was 1.21. 
3.5.6.3 Supplemental analgesia 
No patients required supplemental analgesia in the IT group and 2 patients required analgesia 




3.6 Intrathecal injection and morphine side effects 
Patients were assessed for the following possible side effects of the intrathecal injection (with 
or without morphine) and morphine itself: headache, nausea and vomiting, itching and a sense 
of heavy breathing. The incidences are described for each time point (8 hours, 24 hours and 
48 hours) and proved to not be statistically different. 
 
 IT group incidences PCA group 
incidences 
p-value 
8 hours headache 3 3 1.000 
8 hours nausea and 
vomiting 
1 0 1.000 
8 hours itching 4 1 0.340 
8 hours feeling of 
heavy breathing 
1 0 1.000 
24 hours headache 2 2 1.000 
24 hours nausea 
and vomiting 
1 0 1.000 
24 hours itching 5 1 0.180 
24 hours feeling of 
heavy breathing 
0 0 1.000 
48 hours headache 3 4 0.565 
48 hours nausea 
and vomiting 
1 1 0.598 
48 hours itching 1 0 0.486 
48 hours feeling of 
heavy breathing 
0 0 0.311 
 
Table 3.5: Summary of the side effects related to the intrathecal injection and morphine in the 







3.7 VAS scores during study period and supplemental analgesia 
3.7.1 VAS lying still  
The VAS scores lying still over the study period is presented in Table 3.6 and Figure 3.3. There 
was a significant difference at 120 hours post-operatively between the IT and PCA groups 
(p=0.029). 
 
VAS lying still IT PCA p-value 
8 hours 2.26 2.68 0.552 
24 hours 3.16 2.26 0.237 
48 hours 3.22 3.32 0.938 
72 hours 2.21 2.28 0.924 
96 hours 1.56 2.67 0.174 
120 hours 1 2.64 0.029 
 





















3.7.2 VAS moving  
The VAS scores while moving are presented in Table 3.7 and Figure 3.4. There was a 
significant difference at 120 hours post-operatively between the IT and PCA groups (p=0.026). 
When using the median values, a significant difference was also detected at 120 hours 
(p=0.033). 
VAS moving IT PCA p-value 
8 hours 4 4.79 0.422 
24 hours 4.79 4.68 0.953 
48 hours 5.1 5.21 0.835 
72 hours 4.14 4 0.831 
96 hours 3.67 4.2 0.487 
120 hours 2.17 3.86 0.026 
 




















3.7.3 VAS difference  
The difference in VAS scores over the study period is presented in Table 3.8 and Figure 3.5. 
A statistically significant difference was noted at 24 hours favouring the IT group. 
 
VAS difference IT PCA p-value 
8 hours 1.74 2.11 0.507 
24 hours 1.63 2.42 0.034 
48 hours 1.88 1.89 0.810 
72 hours 1.93 1.72  
96 hours 2.11 1.53 
120 hours 1.17 1.21 
 
Table 3.8: The mean difference in VAS values of the IT and PCA groups over the first 120 
hours post-operatively 
 



























8 hours 2.26 2.39 2.68 2.42 0.066 
24 hours 3.16 3.34 2.26 1.65 
48 hours 3.22 3.19 3.32 2.91 
 
Table 3.9: The mean VAS Lying still values for the IT and PCA group for 8, 24 and 48 hours 
post-operatively both before and when corrected for the effect of sitting. The impact of sitting 













8 hours 2.26 2.57 2.68 2.23 0.045 
24 hours 3.16 3.55 2.26 1.43 
48 hours 3.22 3.28 3.32 2.81 
 
Table 3.10: The mean VAS Lying still values for the IT and PCA group for 8, 24 and 48 hours 
post-operatively both before and when corrected for the effect of standing. The impact of 

















8 hours 2.26 2.57 2.68 2.24 0.052 
24 hours 3.16 3.52 2.26 1.45 
48 hours 3.22 3.27 3.32 2.83 
 
Table 3.11: The mean VAS Lying still values for the IT and PCA group for 8, 24 and 48 hours 
post-operatively both before and when corrected for the effect of taking steps. The impact of 
taking steps was not statistically significant (p=0.052) 
 
3.7.4 Supplemental analgesia required 
There was a significant difference in supplemental analgesia use at 24 hours between the 2 
groups. 
 
 IT PCA p-value 
24 hours 2 8 0.02 
48 hours 5 8 0.25 
72 hours 1 4 0.24 
96 hours 1 3 0.57 
120 hours 0 2 0.33 
 










Mobilisation was measured in accordance with targets achieved for each patient. These 
targets were: logroll, sit on the side of the bed, stand next to the bed, mobilise a few steps, 
walk to the bathroom aided, walk to the bathroom unaided, mobilise independently and 
discharge. 
The average length of stay in the IT group was 3.68 days and in the PCA group 5.61 days. 
These results are depicted in Figures 3.6 and 3.7. 
 
 





Figure 3.7: Histogram presenting the PCA group length of stay 
 
The results for each of the individual mobilisation targets are presented in Table 3.13. 
There was a significant difference between the IT and PCA groups for days to mobilising 














PCA  IT  p-value 
Days to logroll Median 1 1 0.988 
Days to sit Median 2 1 0.298 
Days to stand Median 2 2 0.134 
Days to a few steps Median 3 2 0.105 
Days to walking aided Median 3 3 0.480 
Days to walking 
unaided 
Median 4 4 0.126 
Days to mobilising 
independently 
Median 5 4 0.009 
Days to discharge Median 6 4 0.001 
 
Table 3.13: The median days to achieving mobilisation targets for the IT and PCA groups 
 
The individual distributions of mobilisation targets per group is presented in Figure 3.8. 
 




3.9 Blood gas analysis 
 
Blood gas analysis was performed on each patient: every hour for 4 hours, 2-hourly for a 
further 8 hours and then 4-hourly up to 24 hours post arrival in the recovery room after surgery. 
Each patient thus contributed 11 samples post-operatively to the data. A pre-operative blood 
gas analysis was also performed on each patient. 
The following parameters were also assessed at the same time as the blood gas analysis: 
respiratory rate (RR), FiO2 and the opioid induced sedation scale (OISS). 
The following were considered risk factors for respiratory depression: RR less than 10 breaths 
per minute, oxygen saturation (SATS) less than 90%, PaCO2 more than 6kPa, PaO2 less than 
8kPa and an OISS score of 2 or more. The results were also assessed during ICU sleep time 
(22:00 – 06:00) and awake time (06:00 – 22:00) and also if the patient had a BMI of >30kg/m².  
 
3.9.1 Respiratory rate 
Considering a rate of less than 10 breaths per minute as an indicator for respiratory 
depression, very few incidents occurred within the first 24 hours post-operatively in both the 
PCA and IT groups.  
A total of 5 incidents were observed of which 3 were in the IT group and 2 in the PCA group. 
No incidence of RR <10 breaths per minute were recorded prior to 6 hours post-operatively 
(Table 3.14). These 5 incidents were observed in 2 patients (3 incidents in an IT patient, 2 
incidents in a PCA patient). 
The mean respiratory rate (mRR) at each timepoint demonstrated a slightly higher mRR at the 
first hour post-operatively and both groups (PCA and IT) demonstrated a steady increase in 
mRR for the first 24 hours measured (see Figure 3.9). Neither of the groups had any mRR of 










PCA group IT group 
n percentage n percentage 
 1hr  RR<10 0 0.0% 0 0.0% 
2hr  RR<10 0 0.0% 0 0.0% 
3hr  RR<10 0 0.0% 0 0.0% 
4hr  RR<10 0 0.0% 0 0.0% 
6hr  RR<10 1 5.3% 1 5.3% 
8hr  RR<10 0 0.0% 0 0.0% 
10hr  RR<10 1 5.9% 0 0.0% 
12hr  RR<10 0 0.0% 1 5.3% 
16hr  RR<10 0 0.0% 0 0.0% 
20hr  RR<10 0 0.0% 1 5.3% 
24hr  RR<10 0 0.0% 0 0.0% 
 
Table 3.14: Incidences of mean respiratory rate under 10 breaths per minute between the 
PCA and Intrathecal morphine groups over the first 24 hours post-operatively with no 







 Figure 3.9: The mean respiratory rate of the patients in the PCA group (red line) and IT group 
(blue line) as observed over the first 24 hours 
 
3.9.2 Oxygen saturation 
SATS of less than 90% was defined as a parameter for respiratory depression. Seven 
incidents occurred where the SATS decreased to less than  90%. This occurred 4 times in the 
IT group and 3 times in the PCA group (Table 3.15).  
Five of the above occurred while the patient was on supplemental oxygen and 2 occurred on 
room air. Of these 5, 3 occurred in the IT group, and 2 in the PCA group.  
The mean SATS values for both groups demonstrated a sharp rise until 3 hours post-
operatively after which a steady decline took place over the next 24 hours. This subsequent 
decline never decreased to below 95% (Figure 3.10). 
When the parameters of RR and SATS were cross tabulated, no incidents of RR below 10 
breaths per minute and SATS of less than 90% occurred at the same time over the first 24 







n % n % 
 1hr SATS <90 1 5.3% 1 5.3% 
2hr SATS <90 0 0.0% 0 0.0% 
3hr SATS <90 0 0.0% 0 0.0% 
4hr SATS <90 0 0.0% 0 0.0% 
6hr SATS <90 0 0.0% 0 0.0% 
8hr SATS <90 0 0.0% 1 5.6% 
10hr SATS <90 1 5.9% 0 0.0% 
12hr SATS <90 0 0.0% 1 5.3% 
16hr SATS <90 1 5.3% 1 5.3% 
20hr SATS <90 0 0.0% 0 0.0% 
24hr SATS <90 0 0.0% 0 0.0% 
 
Table 3.15: Incidence of SATS being less than 90% between the s PCA and IT groups over 






Figure 3.10: The mean SATS of the patients in the PCA group (red line) and IT group (blue 
line) as observed over the first 24 hours 
 
3.9.3 PaCO2 
PaCO2 of higher than 6kPa was defined as indicative of significant alveolar hypoventilation 
because of central respiratory depression.  This occurred 41 times (19.8%) in the PCA group 
and 57 times (27.9%) in the IT group over the first 24 hours post-operatively. 
In the IT group, 52.6% had PaCO2 in excess of 6kPa at the first hour post-operatively and 
66.7% at hour 2. The percentage gradually decreased over the following 22 hours, yet never 
reached 0%. This gradual decrease is seen in both PCA and IT groups (Table 3.16). 
There was no statistically significant difference detected between the mean PaCO2 in both 
groups (p=0.175). 
When a PaCO2 of higher than 6.5kPa was considered, 21.1% of PCA and 26.3% of IT patients 
exceeded this threshold at the first hour post-operatively (Table 3.17). The PCA group then 
presented a sudden decrease and maintained a low incidence throughout the rest of the 24 
hours. The IT group maintained a higher incidence for the first 8 hours, where after it 
decreased to 0% barring a small spike of 5.3% at 12 hours (Table 3.17).  The total incidence 




The mean PaCO2 of both the PCA and IT group rapidly decreased 4 hours post-operatively 
(Figure 3.11). From 10 hours post-operatively onwards they followed a similar trend. 
The decrease in PaCO2 in the IT group demonstrated a statistically significant decrease 
starting at 4 hours post-operatively and continuing until 24 hours post-operatively and in the 




n % n % 
 1hr PaCO2 >6 6 31.6% 10 52.6% 
2hr PaCO2 >6 6 31.6% 12 66.7% 
3hr PaCO2 >6 6 31.6% 8 42.1% 
4hr PaCO2 >6 4 21.1% 8 42.1% 
6hr PaCO2 >6 4 21.1% 6 33.3% 
8hr PaCO2 >6 1 5.3% 5 27.8% 
10hr PaCO2 >6 4 23.5% 2 11.8% 
12hr PaCO2 >6 4 21.1% 1 5.3% 
16hr PaCO2 >6 4 21.1% 1 5.3% 
20hr PaCO2 >6 1 5.3% 2 10.5% 
24hr PaCO2 >6 1 5.3% 2 10.5% 
Total PaCO2 >6 41 19.8% 57 27.9% 
 
Table 3.16: Incidence of PaCO2 being higher than 6kPa between the PCA and IT groups over 






Figure 3.11: The mean PaCO2 of the patients in the PCA group (red line) and IT group (blue 
















The incidence of a PaCO2 higher than 6.5kPa is presented in Table 3.17. There were 43 
incidences in total (16 in the PCA group and 27 in the IT group). No statistically significant 




n % n % 
 1hr PaCO2 >6.5 4 21.1% 5 26.3% 
2hr PaCO2 >6.5 0 0.0% 6 33.3% 
3hr PaCO2 >6.5 1 5.3% 4 21.1% 
4hr PaCO2 >6.5 1 5.3% 5 26.3% 
6hr PaCO2 >6.5 1 5.3% 3 16.7% 
8hr PaCO2 >6.5 1 5.3% 3 16.7% 
10hr PaCO2 >6.5 2 11.8% 0 0.0% 
12hr PaCO2 >6.5 2 10.5% 1 5.3% 
16hr PaCO2 >6.5 2 10.5% 0 0.0% 
20hr PaCO2 >6.5 1 5.3% 0 0.0% 
24hr PaCO2 >6.5 1 5.3% 0 0.0% 
Total PaCO2 >6.5 16 7.7% 27 13.2% 
 
Table 3.17: Incidence of PaCO2 being higher than 6.5kPa between the PCA and IT groups 








 Time IT group 
p-value 
PCA group        
p-value 
Mean PaCO2 1hr vs 2hr 0.623 0.086 
2hr vs 3hr 0.530 0.241 
3hr vs 4hr 0.807 0.259 
4hr vs 6hr 0.012 0.250 
6hr vs 8 hr 0.004 0.051 
8hr vs 10hr 0.000 0.589 
10hr vs 12hr 0.000 0.247 
12hr vs 16hr 0.000 0.122 
16hr vs 20hr 0.000 0.032 
20hr vs 24 hr 0.000 0.016 
 
Table 3.18: The statistical difference in change in PaCO2 between post-operative time points 
in the intrathecal morphine and PCA groups. A statistically significant decrease in PaCO2 
occurs from 4 hours up to 24 hours post-operatively in the IT group, and from 16 hours up to 













The incidence of a PaCO2 higher than 7kPa is presented in Table 3.19. There were 9 
incidences in total (3 in the PCA group and 6 in the IT group). Four incidents occurred in the 
first 4 hours post-operatively in the IT group, 1 at 8 hours post-operatively and none thereafter. 
The 3 incidences in the PCA group occurred at 1, 12 and 24 hours.  
With regards to the PaCO2 higher than 7kPa in the IT group, the following are individual 
additional details: 
• The first patient had a PaCO2 of 7.2kPa at 1 hour post-operatively. The 
PaO2 was 7.7, the respiratory rate 15 breaths per minute, the SATS 89%, 
the FiO2 0.21 and the OISS was 1. The same patient had a second event 
of PaCO2 of 7.2kPa at 4 hours post-operatively. The PaO2 was 16.9kPa, 
the respiratory rate 15 breaths per minute, the SATS 99%, FiO2 0.4 and the 
OISS was 1.  
• The second patient had a PaCO2 of 7.3kPa at 2 hours post-operatively. The 
PaO2 was 10.3kPa, the respiratory rate 14 breaths per minute, the SATS 
94%, the FiO2 0.4 and the OISS was s (sleeping, easily rousable).  
• The third patient had a PaCO2 of 7.3kPa at 4 hours post-operatively. The 
PaO2 was 16.3kPa, the respiratory rate 13 breaths per minute, the SATS 
98%, the FiO2 0.21 and the OISS was s. 
• The fourth patient had a PaCO2 of 7.1kPa at 4 hours post-operatively. The 
PaO2 was 9.1kPa, the respiratory rate was 15 breaths per minute, the SATS 
92%, the FiO2 0.4 and the OISS was 1. 
• The fifth patient had a PaCO2 of 7.25kPa at 8 hours post-operatively. The 
PaO2 was 8.83, the respiratory rate was 23 breaths per minute, the SATS 
was 89.5%, the FiO2 0.4 and the OISS was 1. 
With regards to the PaCO2 being higher than 7kPa in the PCA group, the following were 
individual additional details: 
• The first patient had a PaCO2 of 7.1kPa at the first hour post-operatively. The 
PaO2 was 10.9kPa, the respiratory rate 16 breaths per minute, the SATS 95%, 
the FiO2 0.4 and the OISS was 1. 
• The second patient had a PaCO2 of 7.2kPa at hour 12 post-operatively. The 
PaO2 was 16kPa, the respiratory rate was 13 breaths per minute, the SATS 
98%, the FiO2 0.4 and the OISS was s. 
• The third patient had a PaCO2 of 7.1kPa at hour 24 post-operatively. The PaO2 
was 10.9kPa, the respiratory rate was 22 breaths per minute, the SATS 95%, 








n % n % 
 1hr PaCO2 >7 1 5.3% 1 5.3% 
2hr PaCO2 >7 0 0.0% 1 5.6% 
3hr PaCO2 >7 0 0.0% 0 0.0% 
4hr PaCO2 >7 0 0.0% 3 15.8% 
6hr PaCO2 >7 0 0.0% 0 0.0% 
8hr PaCO2 >7 0 0.0% 1 5.6% 
10hr PaCO2 >7 0 0.0% 0 0.0% 
12hr PaCO2 >7 1 5.3% 0 0.0% 
16hr PaCO2 >7 0 0.0% 0 0.0% 
20hr PaCO2 >7 0 0.0% 0 0.0% 
24hr PaCO2 >7 1 5.3% 0 0.0% 
 
Table 3.19: Incidences of PaCO2 being higher than 7kPa between the PCA and IT group over 






Figure 3.12: The percentage of PaCO2 in excess of 7kPa in the PCA group (red line) and IT 
group (blue line) as observed over the first 24 hours 
 
3.9.4 Awake and sleep time 
The incidence of the PaCO2 being in excess of 6kPa was correlated with the occurrence 
thereof in day time (06:00 – 22:00) and during sleep time (22:00 – 06:00). In the PCA group, 
the total incidence was 21.1% during day time and 16.4% during sleep. In the IT group, the 
incidence was 32.5% in the day time and 14% during sleep time. The breakdown for all the 













n % n % 
 1hr  awake time 6am - 10pm PaCO2 <=6 12 66.7% 9 47.4% 
>6 6 33.3% 10 52.6% 
sleep time 10pm - 6am PaCO2 <=6 1 100.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
2hr  awake time 6am - 10pm PaCO2 <=6 12 66.7% 6 33.3% 
>6 6 33.3% 12 66.7% 
sleep time 10pm - 6am PaCO2 <=6 1 100.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
3hr  awake time 6am-10pm PaCO2 <=6 12 66.7% 11 57.9% 
>6 6 33.3% 8 42.1% 
sleep time 10pm - 6am PaCO2 <=6 1 100.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
4hr  awake time 6am - 10pm PaCO2 <=6 14 77.8% 11 61.1% 
>6 4 22.2% 7 38.9% 
sleep time 10pm - 6am PaCO2 <=6 1 100.0% 0 0.0% 
>6 0 0.0% 1 100.0% 
6hr  awake time 6am - 10pm PaCO2 <=6 12 75.0% 11 73.3% 
>6 4 25.0% 4 26.7% 
sleep time 10pm - 6am PaCO2 <=6 3 100.0% 1 33.3% 
>6 0 0.0% 2 66.7% 
8hr  awake time 6am - 10pm PaCO2 <=6 10 90.9% 10 76.9% 
>6 1 9.1% 3 23.1% 
sleep time 10pm - 6am PaCO2 <=6 8 100.0% 3 60.0% 
>6 0 0.0% 2 40.0% 
10hr  awake time 6am - 10pm PaCO2 <=6 5 83.3% 7 87.5% 




sleep time 10pm - 6am PaCO2 <=6 8 72.7% 8 88.9% 
>6 3 27.3% 1 11.1% 
12hr  awake time 6am - 10pm PaCO2 <=6 1 100.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
sleep time 10pm - 6am PaCO2 <=6 14 77.8% 18 94.7% 
>6 4 22.2% 1 5.3% 
16hr  awake time 6am - 10pm PaCO2 <=6 6 75.0% 5 83.3% 
>6 2 25.0% 1 16.7% 
sleep time 10pm - 6am PaCO2 <=6 9 81.8% 13 100.0% 
>6 2 18.2% 0 0.0% 
20hr  awake time 6am - 10pm PaCO2 <=6 18 94.7% 17 89.5% 
>6 1 5.3% 2 10.5% 
sleep time 10pm - 6am PaCO2 <=6 0 0.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
24hr  awake time 6am - 10pm PaCO2 <=6 18 94.7% 17 89.5% 
>6 1 5.3% 2 10.5% 
sleep time 10pm - 6am PaCO2 <=6 0 0.0% 0 0.0% 
>6 0 0.0% 0 0.0% 
Total  awake time 6am - 10pm PaCO2 <=6 120 78.9% 104 67.5% 
>6 32 21.1% 50 32.5% 
sleep time 10pm - 6am PaCO2 <=6 46 83.6% 43 86.0% 
>6 9 16.4% 7 14.0% 
 
Table 3.20: Incidence of PaCO2 being higher than 6kPa between the PCA and IT group during 







The incidence of SATS decreasing below 90% was analysed with reference to it occurring in 
day time or night time. The overall incidence of SATS below 90% in the PCA group during day 
time was 2% and during sleep time 1.4%. In the IT group during the day time the incidence 
was 1.3% and during sleep time 2%.  
The incidence of RR decreasing below 10 breaths per minute was analysed for day and night 
time. This occurred twice in both the PCA and IT groups during day and only once in the IT 
group during sleep compared to no events in the PCA during sleep. 
A crosstabulation of RR less than 10 breaths per minute and PaCO2 higher than 6kPa revealed 
no co-occurrence.  
When RR, SATS and PaCO2 higher than 6kPa were compared, 5 incidents were identified 
where SATS was below 90% together with PaCO2 in excess of 6kPa. In all these events the 
RR remained more than 10 breaths per minute.  
• The first patient was in the PCA group and had SATS of 88%, PaCO2 of 6.1kPa 
and a RR of 20 breaths per minute on room air (FiO2 0.21). This occurred at 
hour 1 after arrival in the recovery room. The OISS was 1 (awake and alert). 
• The second patient was in the IT group and had SATS of 89%, PaCO2 of 
7.2kPa and a RR of 15 breaths per minute. This also occurred 1 hour after 
arrival in the recovery room whilst the patient was on room air (FiO2 0.21). The 
OISS was 1 (awake and alert). 
• The third patient was in the IT group and had 2 episodes. The first was at hour 
8 post-surgery with SATS of 89.5% and PaCO2 of 7.25kPa. The RR was 23 
breaths per minute, the FiO2 0.4 and the OISS was 1 (awake). The second 
episode in this patient occurred at hour 12 post-surgery. The SATS was 89.9%, 
the PaCO2 was 6.51kPa, FiO2 0.4 and the RR 15 breaths per minute. The OISS 
was 1 (awake and alert). 
• The fourth patient was in the IT group and had SATS of 88%, PaCO2 of 6.1kPa, 











The OISS was recorded while arterial blood gas was taken for analysis. Each patient had 11 
recordings over the first 24 hours post-operatively. Three patients in the PCA group collectively 
had 19 events of OISS of 2, no episodes in the IT group were recorded. There were no values 
of 3 or 4 recorded. 
• The first patient was in the PCA group and had all 11 time points recorded 
as 2 on the OISS. At each of these time points both the SATS and PaCO2 
were over 90% and under 6kPa. In 2 of the 11 episodes, the RR was below 
10 breaths per minute. 
• The second patient was in the PCA group and had 7 time points recorded 
as OISS 2. At all those time points, the SATS were more than 90%, the 
PaCO2 equal or less than 6kPa and the respiratory rate in excess of 10 
breaths per minute. There were 2 episodes of PaCO2 being 6kPa exactly. 
• The third patient was in the PCA group and the event was recorded (OISS 
of 2) hour 1 post-operatively. The SATS was 98% on room air and the 



















A PaO2 value of less than 8kPa was considered abnormal. This occurred 3 times (1.8%) in 
the PCA group and 4 times (2%) in the IT group (see Table 3.21).  One patient had 2 episodes 
of PaO2 being less than 8kPa.  
• The first patient had a PaO2 of 7.5kPa at 1 hour in the PCA group. The 
PaCO2 was 6.1kPa, the SATS 88%, the RR 20 breaths per minute and the 
OISS 1. The FiO2 was 0.21. 
• The second patient had a PaO2 of 7.7kPa at 1 hour in the IT group. The 
SATS was 89%, the PaCO2 7.2kPa, the RR 15 breaths per minute and the 
OISS 1. The FiO2 was 0.21. 
• The third patient had a PaO2 of 7.69kPa 16 hours post-operatively in the 
PCA group. The SATS was 88.6%, PaCO2 4.8kPa, RR 12 breaths per 
minute and OISS 1.  The FiO2 was 0.4.  
• The fourth patient had a PaO2 of 7.3kPa 16 hours post-operatively in the IT 
group. The SATS was 88%, PaCO2 6.1kPa, RR 14 breaths per minute and 
OISS 1. The FiO2 was 0.4. 
• The fifth patient had a PaO2 of 7.7kPa 20 hours post-operatively in the IT 
group. The SATS was 90%, PaCO2 6.4kPa, RR 17 breaths per minute and 
OISS s. The FiO2 was 0.21. This patient had a second incident 1 hour later 
with a PaO2 of 7.5kPa. The SATS remained 90%, the RR increased to 18 
breaths per minute and the OISS was s. The PaCO2 decreased to 6.1kPa. 
• The sixth patient had a PaO2 of 7.6kPa 20 hours post-operatively in the 
PCA group. The SATS was 90%, PaCO2 6.7kPa, RR 16 breaths per minute 
and OISS 1. 
  
A graph comparing the mean PaO2 between the PCA and IT groups demonstrated an increase 
in the mean PaO2 over the first 3 hours post-operatively. There is a decline after that up to the 
24 hours. The PCA group mean PaO2 is consistently below the mean PaO2 of the IT group, 
except for the 20 hour time point  and 6 hour point (Figure 3.13). 
 
Figure 3.14 depicts the mean PaO2 and PaCO2 of the IT group over the first 24 hours post-
operatively. It demonstrates a higher mean PaCO2 than the PCA group (see Figure 3.15) and 
the rapid increase of PaO2 seen up to 3 hours post-operatively did not alter the slow 









n % n % 
 1hr PaO2 <8 1 5.3% 1 5.3% 
2hr PaO2 <8 0 0.0% 0 0.0% 
3hr PaO2 <8 0 0.0% 0 0.0% 
4hr PaO2 <8 0 0.0% 0 0.0% 
6hr PaO2 <8 0 0.0% 0 0.0% 
8hr PaO2 <8 0 0.0% 0 0.0% 
10hr PaO2 <8 0 0.0% 0 0.0% 
12hr PaO2 <8 0 0.0% 0 0.0% 
16hr PaO2 <8 1 5.3% 1 5.3% 
20hr PaO2 <8 1 5.3% 1 5.3% 
24hr PaO2 <8 0 0.0% 1 5.3% 
Total PaO2 <8 3 1.4% 4 2.0% 
 
Table 3.21:  Incidence of the PaO2 lower than 8kPa comparing PCA and IT group over the 







Figure 3.13: The mean PaO2 of the patients in the PCA group (red line) and IT group (blue 








Figure 3.14: The mean PaO2 (red line) and mean PaCO2 (blue line) in the IT group over the 
first 24 hours post-operatively 
 
Figure 3.15: The mean PaO2 (red line) and mean PaCO2 (blue line) in the PCA group over 






A BMI of 30kg/m² was considered a risk factor which could affect respiration. The incidents 
where BMI equals or is more than 30kg/m² and PaCO2 higher than 6kPa occurred together 
are presented in Table 3.22.  
There were 33 incidences of both occurring in the PCA group (23.2% of cases) and 38 in the 




n % n % 
BMI <30 PaCO2 <=6 
kPa 
57 87.7% 66 77.6% 
>6kPa 8 12.3% 19 22.4% 
>=30 PaCO2 <=6 
kPa 
109 76.8% 81 68.1% 
>6kPa 33 23.2% 38 31.9% 
 
Table 3.22: The incidents of BMI less and more than 30kg/m² together with PaCO2 less and 












3.9.8 Alveolar oxygen tension   
The partial pressure of oxygen in the alveoli (PAO2) is calculated with the abbreviated alveolar 
gas equation: PAO2 (mm Hg) = (Patm - PH2O) FiO2 - PaCO2 / RQ. 
Both groups followed a similar trend with a peak between 2 and 3 hours post-operatively, a 
steady trend up to 12 hours post-operatively and then a rapid decline with the PCA group 
decline at 24 hours being much more than the IT decline (see Figure 3.16). 
 
 
Figure 3.16: The alveolar partial pressure of oxygen (PAO2) in mm Hg for the PCA (red line) 










3.9.9 PaO2 / FiO2 ratio 
The mean PaO2 / FiO2 ratio is presented in Figure 3.17 for the first 24 hours post-operatively. 
Both groups followed s similar trend over the first 24 hours with a peak at 3 hours and a gradual 
increase up to 24 hours. 
 
 
Figure 3.17: The mean PAO2 (mm Hg)/ FiO2 ratio for the IT group (blue line) and PCA group 












3.9.10 A-a gradient 
The A-a gradient is calculated as PAO2 – PaO2. The mean A-a gradient in both IT and PCA 
group follow a similar trend with an initial spike at 1 to 3 hours post-operatively, followed by a 
dip between 3 and 6 hours post-operatively. It then remains steady until a gradual decrease 
up to 24 hours with the PCA group presenting a more profound decrease (Figure 3.18). 
 
 
Figure 3.18: The mean A-a gradient ratio for the IT group (blue line) and PCA group (red line) 
over the first 24 hours post-operatively 
 










 PCA IT 
PAO2 PaO2/FiO2 
A-a 
gradient PAO2 PaO2/FiO2 
A-a 
gradient 
 Pre-op Mean 221.11 73.56 27.28 220.26 87.72 -34.21 
Standard 
deviation 
123.78 54.89 136.51 80.10 36.37 98.38 
1hr Mean 173.06 38.78 86.39 177.64 37.26 89.24 
Standard 
deviation 
69.28 13.19 65.26 67.42 8.88 56.16 
2hr Mean 196.78 37.14 104.25 196.85 38.82 96.75 
Standard 
deviation 
58.47 10.21 53.39 56.40 13.43 56.74 
3hr Mean 185.21 45.16 78.76 199.95 43.27 88.57 
Standard 
deviation 
61.26 13.99 56.34 55.95 15.37 57.00 
4hr Mean 181.10 40.70 85.45 185.09 40.34 88.59 
Standard 
deviation 
60.65 8.76 49.47 66.19 14.18 63.65 
6hr Mean 188.65 40.17 90.74 192.26 39.54 95.00 
Standard 
deviation 
60.01 9.01 50.56 61.15 15.37 63.60 
8hr Mean 191.08 38.86 98.05 194.26 39.59 96.35 
Standard 
deviation 
61.21 11.36 57.46 61.28 13.78 60.73 
10hr Mean 188.70 39.96 92.88 189.05 41.05 88.96 
Standard 
deviation 
60.14 11.23 54.55 62.70 12.13 55.25 
12hr Mean 190.22 38.42 97.09 192.67 42.33 89.66 
Standard 
deviation 
57.17 10.52 50.43 62.19 13.55 58.10 






60.21 9.37 51.09 66.81 14.04 63.66 
20hr Mean 164.68 42.75 71.74 156.97 41.93 72.09 
Standard 
deviation 
62.92 9.80 49.95 68.15 13.70 63.70 
24hr Mean 116.33 45.75 38.68 150.76 43.10 67.35 
Standard 
deviation 
33.33 8.10 29.46 67.46 13.66 65.30 
 
 
Table 3.23: The mean PAO2, PaO2 / FiO2 ratio and A-a gradient for the IT and PCA groups 




















3.10 Post-operative scoring results 
3.10.1 QVAS 
Pre-operative QVAS scores (pain right now, pain on average, pain at its best, pain at its worst) 
is described in Table 3.2. 
The follow-up time points were at 6 weeks, 3 months and 6 months. 
 
3.10.1.1 QVAS at 6 weeks 
The 6-week QVAS scores are presented in Table 3.24. There was no statistical difference 
noted between any of the parameters assessed.  
 
PCA 
group IT group 
6wk QVAS Pain right now Median 1 2 
6wk QVAS Pain on average Median 2.0 2.0 
6wk QVAS Pain at its best Median 0 0 
6wk QVAS Pain at its worst Median 3 4 
 
Table 3.24: The median values for 6-week QVAS scores with no statistically significant 











3.10.1.2 QVAS at 3 months 
The 3-month QVAS scores are presented in Table 3.25. There was no statistical difference 
noted between any of the parameters assessed. Six patients, 3 per group, were lost to the 3-




group IT group  
3m QVAS Pain right now Median 1 1  
3m QVAS Pain on average Median 2 2  
3m QVAS Pain at its best Median 0 0  
3m QVAS Pain at its worst Median 3 3  
 
Table 3.25: The median values for 3-month QVAS scores with no statistically significant 
difference between the groups on all parameters 
 
3.10.1.3 QVAS at 6 months 
The 6-month QVAS scores are presented in Table 3.26. There was no statistical difference 
noted between any of the parameters assessed. Six patients, 3 per group, were lost to the 6-




group IT group  
6m QVAS Pain right now Median 0 1  
6m QVAS Pain on average Median 1 2  
6m QVAS Pain at its best Median 0 0  
6m QVAS Pain at its worst Median 2 3  
 
Table 3.26: The median values for 6-month QVAS scores with no statistically significant 




The median QVAS (pain right now) is presented in Figure 3.19. There was a statistically 
significant improvement in both groups between the pre-operative values and the 6 weeks, 3 
months and 6 months values. 
 
 
Figure 3.19: The median QVAS (pain right now) presented for the IT group (blue line) and 












The median QVAS (pain on average) is presented in Figure 3.20. There was a statistically 
significant improvement in both groups between the pre-operative values and the 6 weeks, 3 
months and 6 months values. 
 
 
Figure 3.20: The median QVAS (pain on average) presented for the IT group (blue line) and 
PCA group (red line) for the time periods: pre-operative, 6 weeks,3 months and 6 months. The 












The median QVAS (pain at its best) is presented in Figure 3.21. There was a statistically 
significant improvement in both groups between the pre-operative values and the 6 weeks, 3 
months and 6 months values. The values were identical for both groups (IT and PCA). 
 
Figure 3.21: The median QVAS (pain at its best) presented for the IT group (blue line) and 
PCA group (red line) for the time periods: pre-operative, 6 weeks, 3 months and 6 months. 













The median QVAS (pain at its worst) is presented in Figure 3.22. There was a statistically 
significant improvement in both groups between the pre-operative values and the 6 weeks, 3 
months and 6 months values. 
 
Figure 3.22: The median QVAS (pain at its worst) presented for the IT group (blue line) and 
















The best/worst health state as depicted in a vertical line ranging from 0 to 100 (best health 
state = 100) provided a significant improvement in the score between pre-operative, 6 weeks, 
3 months and 6 months. There was a statistical significance between the pre-operative values 




Figure 3.23: The median EQ-5 best/worst health state values presented for the IT group (blue 












The ODI is expressed as a percentage with a higher value indicating more disability. 
The values significantly drop from pre-operative up to 6 weeks and are then maintained up to 
6 months in both groups. There is no statistical difference between the 2 groups (Figure 3.24). 
 
Figure 3.24: The median ODI values presented for the IT group (blue line) and PCA group 














The RM collates a value out of 18 with a higher value indicating increased disability. The mean 
values in both groups demonstrate a significant drop from pre-operative values up to 6 weeks 
which then gradually declines further up to 6 months. No significant difference was noted 
between the 2 groups (Figure 3.25). 
 
Figure 3.25: The median RM values presented for the IT group (blue line) and PCA group 
(red line) for the time periods: pre-operative, 6 weeks, 3 months and 6 months  
 
 
3.11 Retrospective review 
A departmental surgical database was interrogated for first lumbar spine surgery single level 
fusion patients. Thirty-seven patients were identified. Four were removed from the dataset as 
they had prolonged stay (1 re-operation and 3 social circumstances preventing them from 
going home). 






3.12 Direct cost 
The direct cost involved were calculated according to the billing practices of Tygerberg 
Hospital. 
The management of the patients in both groups were standardized therefore the following 
costs were the same: pre-operative imaging, intraoperative cost, spinal implants and ICU stay. 
The length of stay in the general ward differed where the IT group stayed 2 full days less than 
the PCA group (see section 3.8). The percentage cost saving on general ward stay was 
43.5%. The overall saving was 5%. The costs for both groups are expressed in Table 3.27. 
 
 
Cost description IT group PCA group Percentage 
difference 
Total Surgical ward  3172 5612 43.5 
Total ICU 1688.80 1688.80 0 
Pre-operative imaging 222 222 0 
Intraoperative cost 21572.60 21572.60 0 
Spinal implants 19526.50 19526.50 0 
Total cost (Rand) 46181.9 48621.90 5 
 


















The rationale behind this study is based on the ever-increasing pressure exerted by the vast 
volume of patients requiring tertiary medical care in the South African public health service, in 
general, and the Western Cape Department of Health, in particular. This pressing need for 
health services, coupled with a trauma epidemic, is placing available resources under 
significant pressure and is fuelling the need to create solutions whereby scarce resources, 
such as ICU and general ward beds, could be optimised. When opioid analgesia is the only 
effective option for post-operative analgesia, patients often require a high care or ICU 
environment in order to monitor for opioid related side-effects and complications.  
The single level spinal fusion patient fits the profile of a patient who is suffering from a 
debilitating condition which requires surgery. The use of systemic opioid analgesia is 
associated with significant challenges in mobilizing and discharging patients due to the extent 
of the surgery and the associated pain. 
The author noted that, in the past the use of intrathecal morphine has resulted in patients 
apparently mobilising quicker. However, dose and safety concerns have always remained a 
serious consideration. Unfortunately, in the author’s opinion, literature does not address these 
issues satisfactorily. A prospective, double-blind randomised controlled trial was thus 
designed in an attempt to prove the efficacy and safety of intrathecal morphine when 
compared to the more standard analgesic approach of patient controlled analgesic (PCA).  
The primary hypothesis stated that a proposed dose of 0.005mg/kg intrathecal morphine, 
up to a maximum dose of 0.45mg, would be effective in ensuring earlier mobilisation and 
earlier discharge from hospital. Generally, in the public health sector where no step-down 
facilities are available, discharge from hospital occurs between 5 to 7 days after surgery. 
Furthermore, but also of significant importance, it was hypothesised that the proposed 
intrathecal morphine dose would be safe and effective in controlling pain. When considering 
safe and effective analgesia as well as early mobilisation, it was envisaged that this approach 
could result in cost savings to the health system. 
The number of patients that needed to be operated to prove these hypotheses were calculated 
at 72 in consultation with a biostatistician. As this was a prospective trial, the study was 
subjected to an interim analysis which was done after 40 patients had been operated on. The 




(IT) and 5 patient-controlled analgesia (PCA) patients. In addition, the study had progressed 
past the half-way point at this time.  
An independent statistician was appointed to review the available data and to consequently 
recommend whether or not the study should continue. The data were unblinded and results 
indicated that the primary hypothesis had already been proven as both groups had equal 
distribution and the study was powered at 90% with a significance level of 0.001. It was 
therefore decided to terminate the study at the interim point. 
 
4.2 Mobilisation and discharge 
The challenge when performing a single level fusion procedure of the spine lies in effectively 
managing the initial pathology of the patient and thereby relieve the symptoms.  
To a large extent, degenerative spine disease is associated with advanced age and hence the 
patient profile is often that of an older patient who presents with medical co-morbidities 
(Andersson, 1999). The ideal would be an effective procedure which not only relieves the 
patient’s symptoms but also enables him/her to mobilise rapidly in order to reduce morbidity 
and cost to the patient (Dagenais, 2005). Effective analgesia is mandatory as it aids in 
mobilisation, but it should not negatively influence the result of the index procedure.  
A patient may experience several limitations to post-operative mobilisation after spinal 
surgery. The most prominent limitation is pain which stems from the procedure itself. Pain is 
an entity which clinicians should be able to control (Somerville, 1982; Brennan, 2007), but 
some otherwise effective analgesics, such as non-steroid anti-inflammatory analgesics 
(NSAID), could significantly affect the outcome of bony fusion. The use of these drugs as an 
effective analgesic option are thus limited (Thaller, 2005). 
The very nature of the initial presenting pathology is an instability between two lumbar 
vertebrae which results in neurological impairment. In principle, management of the primary 
cause for the symptoms and signs is to unite (fuse) these vertebrae and maintain the union. 
The surgical technique involves pedicular screws in each vertebra, connected by a rod and 
secured with locking caps, resulting in a scaffold which creates immediate stability between 
the vertebrae. Care should however be taken to decorticate the transverse processes and 
pars interarticularis for the effective grafting of autologous bone, usually harvested during the 
decompression of the spinous processes and laminae. The new bone will ultimately form and 
unite the vertebrae. The screws, if unsupported by new bone formation, will break and result 




bone (i.e. removal of all soft tissues to create the largest possible surface area of cancellous 
bone) and preparation of the transverse processes and pars interarticularis by decorticating 
them as much as possible.  
The effect of NSAIDs on post-operative fusion has been repeatedly discussed in the literature 
(Riew, 2003; Reuben, 2005; Li, 2011). Li et al. conducted a meta-analysis on the deleterious 
effects of NSAIDS on spinal fusion rates which highlighted a significant reduction in fusion rate 
when accompanied by high doses of Ketorolac. The authors, however, were ambivalent 
regarding normal dosages and short periods of use (Li, 2011). A statistically significant 
association between NSAID use and decrease in bony fusion could not be established. 
However, they did report a wide confidence interval, ranging from 0.74 - 2.61, and concluded 
that there might be a dose-dependent inverse relationship between NSAID dose and fusion 
rates. The same finding was reported in a further meta-analysis of NSAID’s use and it’s 
relationship with spinal fusion highlighting dose- and duration dependency (Sivaganesan, 
2017). 
The data itself creates an ethical conundrum as there now is a known effect of NSAID’s on 
bone fusion (Thaller, 2005, Riew, 2003) and therefore, to study a possible dose dependant 
relationship, with non-union as a potential outcome, would be ethically unacceptable. This is 
further highlighted by the fact that impairment of bone formation as a result of NSAID’s is 
effectively used to curb heterotopic ossification in hip arthroplasty surgery (Fransen, 2013).   
The surgeon is ethically bound to maximise the possible outcome for the patient, in this case 
bone formation. Certain factors which affect bony fusion such as age, nutrition and smoking 
are, to some extent, beyond the control of the surgeon and thus he/she should implement 
factors which can be controlled. One of the factors which lie within the surgeon’s sphere of 
control is the choice of drugs to be used. As such, the choice should be carefully considered 
to avoid a negative impact on the formation of bone in spinal surgery. Effective analgesia, as 
obtained from NSAIDs, can thus no longer be considered a completely safe option. Therefore, 
it is becoming increasingly important to identify effective and safe alternative/s in the opioid 









4.2.1 Disability of patients 
Pre-existing morbidity was assessed through the use of several scoring systems. As explained 
in Chapter 1.3.1, these scoring systems were used to define the disability of the patient (ODI, 
RM and EQ-5) as well as ascertain their pain (VAS). These scoring systems are key in 
establishing the effect of spinal instability and neurological fallout on the patient. In addition, 
they help to ascertain the effect/s of the intervention (surgery) on the patient/s. The power of 
these scoring systems lies in their repetition to monitor a trend (Wewers, 1990; Hawker, 2011; 
Fairbank, 2000; The EuroQOL Group, 1990; Beurskens, 1996). 
The ODI was chosen as it interrogates activities associated with daily living. Irrespective of 
the age of the patient, the ODI provides a relevant score which relates to that particular patient 
(Fairbank, 1980). Similarly, the RM reviews physical disability (Roland, 2000), specifically as 
it relates to the lower back. This scoring system was thus particularly appropriate to this study 
cohort which included older patients who are more prone to degenerative or age-related 
conditions of the spine. It is known that a correlation exists between the ODI and RM 
questionnaires (Beurskens, 1996). One would thus expect a similar response to the procedure 
and the same degree of disability post-surgery. 
The mean pre-operative ODI for the IT group was 63.79% and 63.47% for the PCA group, 
thus placing them in the severe disability group (Fairbank, 2000). The same pre-operative 
level of disability was expressed in the RM scores with the mean being 16.11 in the IT group 
and 16.37 in the PCA group out of a total of 18 questions posed (Roland, 2000). The very fact 
that both groups ticked nearly all the disability related questions in the RM questionnaire 
highlights the extent to which the pre-operative condition affected patient profiles as reflected 
with the ODI. The status quo was echoed by the EQ-5 health state in which a value is assigned 
out of a possible total of 100 with a score of 100 denoting the best possible state of health for 
a patient (The EuroQOL Group, 1990). Both groups recorded values averaging in the 30s with 
the IT group scoring 34.21 and the PCA group 36.05. 
All three these modalities were clinically significant for pre-operative disability and 
demonstrated appropriate indications for surgical intervention. The two groups demonstrated 
near similar levels of disability for all three questionnaires. This suggests that the starting point 
for the study was similar for the two arms of the study. 
To facilitate the appropriate assessment of the IT and PCA morphine interventions, the index 
procedure should remove potential confounders including pre-operative pain as the ideal post-
operative score must reflect surgically inflicted pain only. Similarly, the pain created by the 




This was evident in the post-operative scoring done during follow-up at 6 weeks, 3 months 
and 6 months post-operatively.  As illustrated in Figures 3.19 to 3.25, there was a significant 
clinical and statistical decrease in the disability experienced by both groups when compared 
to the pre-operative scoring. There was no statistical difference between the 2 groups, 
indicating that the procedure was effective in treating the initial pathology. It must be noted 
that the pre-operative scores were similar i.e. the groups started with a similar disability. The 
equal decrease in disability, as measured at 6 weeks, 3 months and 6 months post-surgery in 
both arms of the study, suggests that the procedure itself was successful and that the 2 groups 
did not experience significantly different outcomes. This is not surprising as patients admitted 
to the study were carefully selected in accordance with accepted criteria, the surgical 
procedures were similar, and the patients were properly randomised.  
One would not expect a long-term advantage from immediate post-operative analgesia. The 
hypothesis stated that post-operative mobility and pain would favour the intrathecal group but 
once the patient had been mobilised, this shorter term advantage would fall away. 
Despite the IT group mobilising quicker, no long-term difference was noted between the 2 
groups. This could most likely be ascribed to factors which affect rehabilitation at home as 
different socio-economic environments either add to or detract from rehabilitation. This is 
especially apt when considering all modalities which quantify disability in the ODI, for example 
sleep, lifting weights, standing, walking and sitting, as per Figure 1.2. These variables will 
naturally differ between patients but due to effective randomisation and sufficient power in the 
number of patients analysed, one can safely assume that the variables would be equally 
distributed between the two arms of the study. 
The results indicate that the index procedure effectively addressed the primary pathology. In 
addition, any difference/s noted in early mobilisation and post-operative analgesia did not carry 











4.2.2 Pain  
The QVAS score captured patients’ pain as associated with the pre-existing condition. This 
score includes the conventional VAS methodology of a horizontal line depicting a score 
between 0 and 10. In addition, it reflects the best, worst and average pain experienced by the 
patient. Each of the entities is depicted on a separate line which illustrates the degree in which 
the patient is experiencing the disabling primary pathology as translated into pain.  
It is important to note that the conducted VAS scores were numbered, thus effectively 
converting the scale into a numeric rating scale (NRS). This differs very little from a traditional 
VAS score. A numerical value on the horizontal line, familiar to the patient and easy to 
correlate with his/her experience of the pain, is used as an indication of said pain (Hawker, 
2011). The numerical values were added to facilitate easier recording of the score. In the 
traditional VAS the patient is asked to make a mark on a 100mm unnumbered line to indicate 
his/her pain.  A drowsy patient or one that is experiencing pain or who is unwilling to write at 
that specific time can seriously affect this process. The NRS allows a patient to verbalise and 
define the intensity of the pain, especially if they cannot or choose not to write at that time. It 
can thus be specifically helpful in the context of potential sedation as a result of morphine 
(Karcioglu 2018). Both scores measure pain intensity in addition to being reproducible and 
reliable per patient (Hawker, 2011). It is still referred to as VAS in the discussion. 
Pre-operative scores in 3 QVAS modalities (pain right now, pain on average, pain at its worst) 
were in excess of 6 out of 10 (Table 3.2). There was no significant difference between the 2 
groups, once again confirming both the proper randomisation of patients and equal starting 
point for the study. The pain at its best scores were under 4 in both groups and no difference 
between groups could be demonstrated. 
When the patients were counselled on how to complete the VAS scores, a value of 4 was 
used to indicate pain which needed treatment by injection. This same value was used as a 
trigger for supplemental analgesia in the post-operative period should the patient require 
additional analgesia. 
The VAS score is also valuable as a repetitive measurement. Changes of 1.9 out of 10 is 
considered a clinically significant difference, whether reflecting more, or less pain (Hägg, 
2003). This change was evident in all 4 modalities when the 6 weeks, 3 month and 6 month 
scores were collated as per Figures 3.19 to 3.22. A clinically and statistically significant change 
was noted in the values, thus echoing results observed in the scores measuring disability (EQ-
5, RM, ODI). These values reflect the effect of the procedure on the initial pathology. It also 




result of muscle and surgical trauma related to the procedure itself rather than remaining 
primary pathology (radiculopathy and instability). Selection criteria for the study also dictated 
that the index procedure be the first lumbar spinal surgery undergone by the patient. The 
patient’s post-operative pain would thus be a new experience, devoid of any previous 
reference, which could possibly then create a subjective expectation. 
Direct vision of the nerve roots intra-operatively would confirm that they are free from 
compression thus resolving the radiculopathy. The pain generated by instability (mechanical 
backache) would also be resolved as the 2 unstable vertebrae would now be united. However, 
the decompression requires bony excision which, in itself, can be a pain generator, albeit 
short-lived. This implies that the main sources of immediate post-operative pain would be 
surgical trauma to the musculature, to facilitate access, and surgical trauma to the bone as a 
result of the decompression. These should occur equally between the 2 groups.  
During the post-operative period the VAS score was assessed for 2 scenarios: lying still and 
moving in bed. Pain is a unique and individual experience. A pain score of 2 out of 10 for one 
person might thus very well be a 4 out of 10 for another person (Wewers,1990). During pre-
operative counselling, attempts were made to educate patients regarding the use of the VAS 
to help in standardising the scale. However, this proved difficult due to the subjective nature 
of pain. A value of 4 out of 10 was determined to indicate a level at which pain would usually 
require an injection. In addition, the advantage of the study was that every patient acted as 
his/her own control. This implied that the psychological aspect of pain probably did not differ. 
The surgical procedure resolved the pre-existing pathological pain, yet it also inflicted pain. 
This was most prominently as a result of the erector spinae and multifidus muscles undergoing 
dissection off their medial attachments and being mobilised to access the transverse 
processes and facet joints. Even though they remained physically intact, these injured muscles 
present a significant generator of pain. This is particularly true in the first 2 post-operative days 
when the bruised muscles need to be used to effect mobilisation. 
Activation of these trunk muscles will be a significant pain generator and will thus hamper 
mobilisation. The muscles controlling the trunk have been grouped into 2: those muscles that 
control spinal segmental stabilisation (multifidus, internal oblique and transversus abdominus) 
and those muscles controlling gross trunk movement (erector spinae, rectus abdominus and 
external oblique) (Bergmark, 1989). The erector spinae muscles, or pain generators, are not 
as active when the patient is sitting but play an important role in maintaining posture. These 
muscles are thus strongly activated when standing and mobilising to the erect position 
(O’Sullivan, 2002). It then stands to reason that in the relaxed position (or when lying still), the 




movement is being attempted. In accordance with this tenet, VAS was measured when the 
patient was lying still in bed and when the patient was moving. This was done in an attempt 
to quantify the intensity of the pain given the perspective set out above. 
As illustrated in Table 3.8, the difference in VAS for the first 48 hours post-operatively 
demonstrated a lesser difference (and thus less pain) in the IT group, significantly so at 24 
hours. After 48 hours this relationship reversed. As per Figure 3.5, the difference in VAS 
scores were less in the PCA group than in the IT group from 48 hours onwards up to 120 
hours post-operatively. 
Considering the earlier mobilisation noted in the IT group, these patients should naturally have 
experienced more discomfort when activating the erector spinae muscles, particularly in trying 
to stand for the first time post-operatively. The direct comparison of the mean VAS lying still 
favours the PCA group, yet the values become near equal at 48 hours and follow the same 
trend up to 72 hours where the IT group continues with a downward trend and demonstrated 
a statistical difference at 120 hours (Table 3.6 and Figure 3.3).  
In the VAS moving analysis, a non-significant difference favouring the IT group is seen up to 
24 hours, after which both groups followed a similar trend up to 72 hours, upon which the 
groups once again deviated to a statistical difference favouring IT at 120 hours (refer Table 
3.7 and Figure 3.4).  
At first glance it would seem as if the scores did not differ that much and the question therefore 
begs to be asked: Why did one group then mobilise significantly faster than the other, 
considering that nearly all variables were accounted for? This can be explained by the fact 
that the actual mobilisation itself generates pain by activating the core muscles, specifically 
the first attempt at standing upright which would activate the erector spinae muscles, argued 
to be the main muscle used in maintaining standing posture and hence the biggest pain 
generator (O’Sullivan, 2002). 
One must then consider the impact that the quicker mobilisation had on the pain itself as well 
as pondering the question whether the VAS scores of the groups are, in fact, comparable. The 
IT group fully mobilised a mean of 1.93 days earlier than the PCA group which was statistically 
significant in days to independent mobilisation as per Table 3.10. A multivariate analysis was 
conducted which included 3 mobilisation end-points (sitting, standing, taking a few steps) 
which were the most likely actions to impact the VAS scores in first 48 hours when the 
difference in the interventions are deemed to be most pronounced. 
There was no statistical evidence using VAS lying still or moving of a differential treatment 




However, when mobilisation targets were considered, it demonstrated that the act of standing 
significantly affected the apparent non-significant mean VAS values (Table 3.10). This would 
imply that standing after a single level fusion procedure has a significant impact on 
mobilisation and that intrathecal morphine provided a statistically significant advantage over 
the conventional PCA regimen. The acts of sitting and taking steps also provided near-
significant advantages over the PCA and merits reporting (Tables 3.9 - 3.11). 
The fact that the act of standing significantly influenced the pain perceived by the patient, 
supports the argument that the erector spinae muscles were the biggest pain generators in 
the first 48 hours post-operatively. This is where the strong segmental analgesia associated 
with the intrathecal morphine provided advantage when compared to the more central effects 
of the intravenous morphine. This makes for a compelling argument as to the use of IT 
morphine.  
Overall, the results indicate that the direct measures of VAS, as observed in the VAS lying still 
and VAS moving groups, seem equal. Yet, the scores are significantly affected by the 
mobilisation attempts of the patient.  In effect, the use of the IT allowed for earlier mobilisation 
and although this comes at a price, namely an increase in pain, this method of analgesia was 
still effective to ensure acceptable analgesia while obtaining the advantage of earlier 
mobilisation. This important concept and the interrelationship between attempting to obtain 
early mobilisation but, at the same time, provide effective analgesia is, in the author’s view, 
an important concept supporting the use of IT morphine. Specific qualification of this 
interaction is difficult to achieve but, on a conceptual basis, the author argues that this view 
and conceptual interpretation of the data are valid. 
When the VAS difference values were compared (a measure of the intensity of pain), a 
statistically significant difference at 24 hours favouring the IT group was noted (Table 3.8). 
This difference between the values directly reflects the ability of a patient to mobilise as the 
patient is experiencing the pain associated with the movement i.e. originating from the muscles 
involved.  In the IT group, the experience of pain was similar to the pain experienced when 
lying still (keep in mind the additional pain generator). The acceptable pain levels during 
movement will also bolster the patient’s confidence to mobilise without fearing the pain usually 
associated with movement. 
In addition, as to the impact of mobilisation on the VAS scores, one must consider 
supplemental analgesia use between the groups. The PCA group, as per Table 3.9, used 
significantly more supplemental analgesia than the IT group in the first 24 hours post-
operatively. The use of supplemental analgesia is a clinical validator which indicates whether 




the PCA group who required supplemental analgesia had a BMI in excess of 30kg/m2 (the 
remaining patient’s BMI was 29.5kg/m2). 
This finding underscores the fact that excessive adipose tissue does not form part of the 
pharmacologically active mass.  It can, however, absorb morphine and thus potentially yield a 
less effective result (Linares, 2009). In addition, the administration of morphine in obese 
patients can be dangerous. The calculation of the correct dose is a challenging endeavour 
which needs to take into account the delayed release of morphine from the adipose tissues 
which can result in dangerous levels of morphine in the blood (Coetzee, 2010).  
Therefore, when interpreting the results, one must recognise the impact of supplemental 
analgesia on the VAS values as well as the lack of mobilisation in the PCA group. Despite 
additional analgesia, mobilisation targets were still achieved significantly quicker in the IT 
group as illustrated in Table 3.10. 
A sub-analysis was performed in which all patients with a BMI of less than 30kg/m2 were 
removed. The results demonstrated a statistically significant difference in the VAS difference 
scores at 24 hours between the groups, favouring the IT group. The intravenous morphine 
group (PCA) experienced analgesia from the interaction of the morphine with the cranial µ-
receptors whilst the intrathecal morphine group experienced strong segmental analgesia. In 
the obese group of patients, adipose tissue does not form part of the pharmacologically active 
tissues. However, the partly lipophilic nature of morphine could result in absorption of the drug 
(Linares, 2009) thus affecting the available drug at the target receptors. This consideration 
emphasises the idea that the effectiveness and accuracy of analgesia could be enhanced by 
adopting an intrathecal route for morphine delivery (i.e. at the locus of pain) thus rendering 
considerations as to the effect of excess adipose tissue obsolete.  
In summary, the results showed that mobilisation was indeed achieved at 24 hours earlier in 
the intrathecal morphine group. The pain associated with this mobilisation process remained 
at acceptable pain levels. The author would speculate that this earlier mobilisation would 
increase patient confidence which, in turn, would motivate them to continue with the 
mobilisation. For reasons explained earlier, the advantage seems to be more pertinent in the 








4.2.3 Mobilisation  
The primary hypothesis of the study was that the IT group would fully mobilise and be 
discharged quicker than the PCA group. The IT group were fully mobilised and discharged 
home after a mean of 3.68 days and the PCA group after 5.61 days. 
The mobilisation regime was standardised for all patients with several targets which had to be 
achieved. The attainment of each of the mobilisation gaols was recorded and included: log-
roll in bed, sit on the side of the bed, stand next to the bed, mobilise a few steps, walk aided, 
walk unaided and ultimately discharged with full independent mobilisation having been 
achieved. It is noteworthy that some steps in the mobilisation regime are generally easier to 
achieve as they cause less pain and discomfort.  These steps relate to activities which facilitate 
the activation of the trunk muscles when erect (erector spinae) and their relaxing in passive 
positions such as sitting. However, when sitting the multifidus muscle, another pain generator 
which was influenced by surgery, is activated. Thus, a log roll, by inference, would use very 
few of the surgically affected muscles whilst sitting and standing upright would mobilise most 
muscle groups (O’Sullivan, 2002). 
Most patients thus easily achieved a log roll in bed on day 1 post-operatively as per Table 
3.10. Sitting up and sitting upright on the side of the bed does not require significant weight 
bearing and result in limited activation of the back muscles, particularly the erector spinae 
(Bergmark, 1989). Although painful at times, it is generally regarded as bearable. Standing 
upright next to the bed is considered a full weightbearing activity which results in full activation 
of the posterior lumbar muscles. In the recently operated patient, especially when one 
considers the extent of muscle mobilisation in lumbar fusion surgery, this is associated with 
significant pain (O’Sullivan, 2002; Bergmark, 1989).  
As per Figure 3.8, the mobilisation pattern noted in the 2 groups started diverging when 
patients were required to stand next to the bed and/or take a few steps. The data in a 
multivariate analysis showed that mobilisation significantly affected the VAS reported by the 
patients (Tables 3.9 to 3.11). The relationship between the pain scores and level of 
mobilisation achieved can be ascribed to mobilisation resulting in additional pain. This 
occurrence had to be considered when interpreting VAS and analgesia requirements.  
The difference in VAS, viewed as an indication of pain intensity, was most pronounced at 24 
hours with the IT group displaying significantly better pain control at this point. This was 
illustrated by the significant difference in VAS scores with the IT group attaining 1.63 and the 
PCA group attaining 2.42. This difference can be ascribed to the efficacy of the IT on the µ-




which directly relate to the surgical site with direct administration of morphine into the 
intrathecal space reaching high concentrations at that target site (Bujedo, 2012). This 
advantage is further emphasised when one considers the increased expression of the µ-
receptors in the presence of inflammation (Linares, 2009).  
 
PCA administration results in a blood concentration of the opiate which must cross the blood-
brain barrier to reach the effected site in order to deliver pain relief. Due to its hydrophilic 
nature, morphine does not have a strong tendency to diffuse into the fatty neural tissue and it 
thus remains available in the cerebrospinal fluid in order to bind to the µ-receptors. In addition, 
it remains in the cerebrospinal fluid for a longer period of time thus resulting in a prolonged 
action when compared to a single bolus dose of morphine administered intravenously or 
intramuscularly (Hindle, 2008). 
Intrathecal morphine is also in direct contact with the µ-receptors. In the author’s opinion, this 
assists in earlier mobilisation as all nociceptive nerve traffic from the afferent sensory neurons, 
responding to painful triggers, is effectively suppressed and controlled (Linares, 2009). 
Patients also quickly learn and obtain confidence that they will not be in severe pain when 
they start moving if they had intrathecal morphine. Given human nature and the power wielded 
by experience, patients would probably find it easier to overcome anxiety associated with the 
unknown once they had experienced that moving did not result in severe pain if intrathecal 
analgesia had been administered. Apart from the reality of pain itself, the fear of pain is a 
significant limiting factor in making progress to mobilisation. The fear of pain can even prompt 
patients to use the PCA device in the absence of pain (Johnson, 1989). Hence, effective 
analgesia, obtained through the use of intrathecal morphine, made it physically easier for 
patients to start mobilising. Once these patients were up and experiencing effective pain relief, 
they gained confidence which, in turn, assisted in further mobilisation. 
This does not imply that the PCA did not provide reasonable analgesia. However, once it 
reaches beyond the blood-brain barrier, it is dispersed throughout the central nervous system 
rather than being concentrated at the spinal target site, as is the case with intrathecal morphine 
introduced into the lumbar thecal sac. In the event of systemic opiates, the general dispersion 
would affect all susceptible areas in the brain. However, a simple and straight comparison of 
the 2 techniques, as well as the concentration of morphine achieved in the cerebrospinal fluid 
at the level of the brain, is beyond the scope of this study. It could, however, be considered as 




The calculation of an effective dose also gains relevance with the increase of adipose tissue, 
associated with a higher BMI, as noted in most of the trial patients. The higher BMI could very 
well interfere with the availability of systemically administered morphine (Linares, 2009). 
It is estimated that the intrathecal dose would be effective for approximately 24 hours 
(Sjöström, 1987). At this point the PCA device would have been removed and both groups 
would have been placed on the same analgesic regime. Sidebotham et al. demonstrated that 
the use of a PCA device was most effective in the first 24 hours post-operatively, irrespective 
of the type of surgery performed. The device was therefore removed after 24 hours in an 
attempt to standardise the effect of the interventions (Sidebotham, 1997). 
The expected difference between the 2 groups would be most pronounced in the first 48 hours 
post-operatively as both groups received the same standardised analgesic regimen from 24 
hours post-operatively onwards. The effects of the initial analgesic intervention would wear off 
by 48 hours. 
The argument has been made that sitting up, standing and taking a few steps would be most 
challenging to the patient as these activities directly involve muscles which had recently been 
mobilised during surgery. These muscles thus act as pain generators and, as such, their use 
would hinder mobilisation. 
The VAS scores, both in lying still and moving, did not demonstrate significant differences 
between the groups. The difference in VAS between moving and not moving was however 
significant. 
Discharge within the public service does not usually involve step-down facilities. This means 
that patients have to be able to return home and essentially care for themselves within the 
broader context of their local support system. The mandate for physiotherapy was that the 
patient must be able to mobilise independently on oral analgesics alone, and that he/she 
should be able to repeat the activities at home within limits of pain.  The final discharge, after 
physiotherapy had cleared the patient, was done by the surgeon who inspected the wound, 









4.2.4 Efficacy of the intrathecal morphine dose  
A first-time lumbar surgery, single level fusion procedure was used in an attempt to 
standardise surgical injury to patients and thus facilitate comparable pain responses when 
comparing intrathecal vs PCA morphine interventions. In addition, this selection guaranteed 
that the patient had not previously undergone a lumbar rehabilitation and mobilisation 
programme. 
As evident from Table 3.1, a significant difference in BMI existed between the groups. The 
mean BMI in the intrathecal morphine group was 29.18kg/m2 and in the PCA group 
34.31kg/m2. The median values, 30.9kg/m2 in the intrathecal group and 33kg/m2 in the PCA 
group, represented a more accurate value as outliers were accounted for. This significance 
was not evident in the mean body fat percentage of the groups implying that either patients’ 
length or an increased muscle component affected the BMI as BMI cannot distinguish between 
larger than normal muscle mass or adipose tissue (Green, 2004). In both groups these 
patients were classified as obese. As Table 3.1 illustrates, no statistical difference could be 
detected between body fat percentage and body muscle percentage in the 2 groups. 
The fact that the median BMI values in both groups classified them as obese, played a 
significant role in attempting to find the safe morphine dose.  Although morphine is primarily 
hydrophilic, the excess adipose tissue still needs to be considered along with the 
pharmacokinetics of the drug when administered intravenously (Coetzee, 2010). As obesity is 
considered a growing epidemic (Agha, 2017), this becomes a very relevant consideration in a 
frequently used drug such as morphine.  
One of the dangers in attempting to calculate a safe dose is that the administered dose may 
not effectively control pain, and this may very well prompt the use of rescue analgesia. In doing 
so, a compound effect could occur which could result in delayed onset respiratory depression 
and other side-effects (Coetzee, 2013).  
For the intrathecal group, a dose of 0.005mg/kg up to a maximum of 0.45mg intrathecal 
morphine was proposed and used by the author. This implied that a patient with a weight of 
90kg and/or more would have received the same dose of intrathecal morphine.  
In general, it is the author’s view that above 90kg the percentage body fat becomes more 
significant unless the person is a particular large and muscular individual. This value of 90kg 
was chosen based on the average height of males which resides at 168cm in South Africa 
and up to 183cm in the Netherlands (Average height of men and women worldwide [Internet]). 
When one correlates this with a standard BMI table, the corresponding weight prior to being 




In addition, available literature on the intrathecal use of morphine in spinal surgery afforded 
some insight into potentially dangerous and effective doses (Boezaart, 1999; O’Neill, 1985; 
Ross, 1991). 
Intuitively, one would expect a dose-response relationship to intrathecal morphine. This is 
however only partially true. To fully understand this relationship, or lack thereof, one must 
carefully scrutinise the pharmacokinetics and dynamics of morphine when administered both 
intravenously and intrathecally.  
The effect that the opioid has on the pain sensation is based on its interaction with µ-receptors 
situated in the dorsal horn where it enters the spinal cord, as well as centrally in both the 
midbrain (periaqueductal grey matter) and the medulla (pre-Bötzinger complex). The latter 
area is also associated with opioid induced respiratory depression (Montandon, 2011). 
Nausea, vomiting and pruritis are side-effects which stem from the central action of morphine 
(Gulhas, 2007). 
 
In order to be effective, one must appreciate the obstacles which the drug has to overcome to 
reach these target sites. Segmental spinal analgesia will be achieved through interaction with 
the µ-receptors at the dorsal horn in the spinal cord. This is the safe target and will yield an 
ideal result as effective interaction here will have no significant side effects such as respiratory 
depression. It will thus provide post-surgical analgesia related to the surgical site, in this case 
the lumbar spine.  
 
The physiochemical properties of the drugs inter alia dictate the efficacy and side-effect profile 
of the opioids. The effect of the drug is determined by the cerebrospinal fluid and spinal cord 
concentrations of the freely diffusible opioid as these conditions are favoured by more 
hydrophilic drugs (Ummenhofer, 2000). Morphine is (mostly) a hydrophilic drug and has a 
strong affinity to the µ-receptors. These receptors are situated in the grey matter of the spinal 
cord which contains no myelin and thus pose no obstacle for the more hydrophilic drug. The 
opposite is true for the white matter which, as a result of the myelin sheaths, is made up of up 
to 80% lipids (Bernards, 2002; Hindle, 2008). Therefore, once the drug arrives at the spinal 
cord, by whichever route, the more hydrophilic drug will diffuse through the extracellular space 
of the white matter cells and reach its target receptors. Hardly any of the morphine will partition 
into the white matter therefore resulting in an increased bioavailability to the receptors, as long 
as the drug is not actively cleared (Bernards, 2002).  It has been shown that meningeal 
permeability is inversely proportional to the hydrophilic nature of a drug, implying that 




within the CSF space (Ummenhofer, 2000). This characteristic is useful if prolonged analgesia 
is required.  
.  
The high affinity of morphine to the µ-receptor provides effective analgesia mainly in relation 
to the spinal segments where the drug is inserted. If a discrete concentration of morphine 
remains available, it would suggest prolonged analgesia until the available concentration of 
morphine becomes negligible. Morphine effect-site pharmacokinetics could differ from 
cerebrospinal fluid pharmacokinetics implying that, despite the cerebrospinal fluid morphine 
being eliminated, morphine at the receptor level can persists (Bernards, 2002). This ensures 
that a clinical effect is present for up to 12 hours (Hindle, 2008). Ummenhofer demonstrated 
the extracellular spinal cord bioavailability of morphine at level L2/3, even after 6 hours post-
intrathecal injection (Ummenhofer, 2000). 
 
For intravenous morphine to reach this site, it must cross the layers of the meninges. The dura 
mater has a rich capillary network of which the endothelial cells will act as a barrier to more 
hydrophilic drugs (Bernards, 2002). This capillary network is also an important site for 
clearance of the drug from the cerebrospinal space. This also favours the more hydrophilic 
drug if the intention is for the drug to remain in the cerebrospinal fluid for as long as possible. 
Hence, morphine would be the more ideal drug to use.  
 
Despite the dura mater being the thickest layer of the meninges, the arachnoid mater accounts 
for 90% of resistance to drug diffusion. It is also impermeable to cerebrospinal fluid and thus 
contains the cerebrospinal fluid and its contents in the subarachnoid space, unless being 
actively cleared (Bernards, 1990). The arachnoid has tightly junctioned flat epithelial cells 
which pose resistance to more hydrophilic drugs (Nabeshima, 1975). Both these layers will 
provide an obstacle to the diffusion of morphine if the drug arrives at the spinal cord via the 
intravenous route.  
 
The pia mater consists of a single cellular layer and it poses very little resistance. There is no 
difference between opioids injected directly into the cerebrospinal fluid space and those 
arriving through diffusion, therefore, once in the cerebrospinal fluid, the effect will be 
comparable (Bernards, 2002), although dependent on the concentration present. 
 
As regards the dose-response relationship of intrathecal morphine, Jiang demonstrated a 
clear dose-response relationship for doses ranging from 0.025 - 0.125mg regarding the 




did have a longer effect well in excess of the expected cerebrospinal fluid half-life of morphine. 
At the same time, increased incidents of pruritis were observed with increased doses which 
would support the contention of a supraspinal effect of intrathecal morphine in larger doses. It 
then stands to reason that the clinical analgesic effect, observed beyond the expected duration 
at the spinal segmental level, is due to the interaction of morphine with the central receptors.  
 
Palmer et al. assessed different doses of intrathecal morphine in post-caesarean section 
patients ranging from 0.0mg as placebo up to 0.5mg with supplementary PCA morphine use 
noted as a measure of effective pain relief. Their initial hypothesis was that an expected 
inverse linear dose-response relationship would be present. However, they were surprised to 
observe a ceiling for analgesia (or similar PCA morphine use) of doses starting at 0.075mg up 
to 0.5mg. They did however notice an increase in pruritis, nausea and vomiting as the dose 
increased. Because the study was not designed to assess respiratory depression, they did not 
offer comments on this important topic (Palmer, 1999). They concluded that an increase in 
dose beyond 0.025mg will not provide an increase in the quality of analgesia. They concluded 
that the analgesia provided by the intrathecal dose was not perfect and that even their 
maximum intrathecal dose of 0.5mg was not sufficient to activate supraspinal mediated 
analgesia via cephalad spread. They recommended that PCA morphine support should be 
considered in addition to the intrathecal dose (even 0.5mg) to provide a supraspinal analgesic 
effect.  
 
The latter conclusion can, however, be disputed as the cerebrospinal fluid terminal elimination 
half-life of morphine has been demonstrated to be between 42 and 136 minutes (Sjöström, 
1987). Thus, a supraspinal analgesic effect had to occur if pain relief had lasted 24 hours, as 
per the study, most likely due to supraspinal spread of the morphine in the cerebrospinal fluid. 
This potential misinterpretation could be explained by PCA morphine use being adopted as a 
measure of pain rather than the pain scores themselves. This approach is fraught with 
inaccuracies (Johnson, 1989; Ferrante, 1988; Macintyre, 2001). In addition, the dose-related 
increase in pruritis, nausea and vomiting described in the study would suggest cephalad 
spread of the intrathecal morphine due to the interaction with the 5HT3 receptors in the 
trigeminal cervical nucleus for pruritis (Kerhonen, 2003) and the chemoreceptor trigger zone 
in the floor of the fourth ventricle for nausea and vomiting (Smith, 2014).  
 
These supraspinal, or central effects of morphine can be used to the clinician’s advantage 
when prolonged and effective analgesia is being sought, although achieved against the 






The method by which intrathecal morphine is introduced can also play a role in the movement 
of morphine to the medulla and other supraspinal areas. The main method of cephalad spread 
is bulk cerebrospinal fluid flow resulting from the pulsating brain and cyclical thoracic pressure 
associated with respiration (Kroin, 1993; Hindle, 2008).  
 
The pharmacokinetics of morphine in the cerebrospinal fluid is poorly understood and 
hampered by the logistics of studying the subject i.e. taking repeated fluid samples. This 
procedure will potentially dilute the available intrathecal drug and repeated samples of spinal 
cord tissue and fluid cannot be obtained in clinical practice (Ummenhofer, 2000). Kroin et al. 
studied the distribution of a hydrophilic compound along the length of the spinal cord. They 
demonstrated a 57% decrease in concentration over the length of the thoracic spinal cord 
(20cm). Considering minimal capillary losses due to the hydrophilic nature of the compound, 
they ascribed the change in concentration to the increase in volume the drug is exposed to as 
well as a two-compartment model of cerebrospinal fluid interchange involving the spinal and 
cranial spaces (Kroin, 1993).  
 
In a cadaveric study, Parese et al. demonstrated that the overall length of the spinal cord 
varied ranging from 36.2 to 45.7cm (Parese, 1959).  Effectively, the key in predicting a dose 
that would be effective both in the spinal and cranial areas would be linked to the length of the 
patient which is an indirect reflection of the length of the spinal cord and spinal canal 
cerebrospinal fluid volume. As the relationship between length and weight is generally defined 
in BMI (Agha, 2017), it stands to reason that a weight based dose should be effective to 
manage the supraspinal effects of the intrathecal morphine, reverting back to the original 
proposed dose of 0.005mg/kg up to a maximum of 0.45mg.  Given the variance in achieving 
the BMI, i.e. for instance being very short and very fat vs being tall and fat, will obviously result 
in different cord lengths. Based on this observation, one can perhaps argue that the patient’s 
length may very well be an equally good, if not better, determinant for the dose. This topic has 
not been examined but provides an interesting topic for further research. 
 
A further uncertainty which affects the calculation of intrathecal morphine doses is the question 
of whether or not any relationship exists between the body’s fat component and the volume of 
the CSF. The author believes that this is unlikely, and that CSF volume more closely relates 
to ideal body weight rather than total body weight. The already speculative and tenuous 
relationship between the cerebrospinal fluid and total body weight will probably become even 




in fact, described a smaller total spinal cerebrospinal fluid volume in obese patients as a result 
of raised intra-abdominal pressure (Hogan, 1996).  
Matsumae et al. could demonstrate a mean difference of 21cm3 of total cranial CSF volume 
between males and females.  However, in both sexes the total cerebrospinal fluid volume 
amounted to 11.4% of the total intracranial volume (Matsumae, 1996). These findings were 
not coupled to length, yet it seems as if a relationship existed between total cranial 
cerebrospinal fluid volume and length with males being generally taller than females.  
The PCA device was primed with a 1mg/ml concentration of morphine in normal saline. The 
device delivered a 1mg bolus intravenously on demand with a 7-minute lockout period. This 
would allow a patient up to 8mg of intravenous morphine per hour. Owen et al. compared the 
concentrations of 0, 5, 1 and 2mg/ml of morphine in normal saline and concluded that 1mg/ml 
is optimal and effective for post-operative analgesia (Owen, 1989; Macintyre, 2001). The 
recommended lockout period for morphine PCA is 7 - 11 minutes (Macintyre, 2001). This 
concentration and total potential dose per hour also conform to the institutional standard of 
care at Tygerberg Academic Hospital.    
The efficacy of the doses was evident in the VAS scores assessed throughout the study. The 
difference in VAS lying still and VAS moving, as a measure of pain intensity, demonstrated 
efficacy of the proposed dose. Moreover, the earlier mobilisation emphasised this conclusion 
as well. During the retrospective review, prior to embarking on this study, the average stay 
was 6.23 days for the same surgery in the department of Neurosurgery at Tygerberg Academic 
Hospital. This was similar to the length of stay in the PCA group (5.61 days). 
The volume of PCA used was more in the PCA group compared to the intrathecal group (which 
was primed with normal saline as placebo), yet this was not deemed statistically significant 
(p=0.057). The box and whisker plot (Figure 3.1) demonstrate outliers affecting the median 
volume which was used. The fact that the median PCA volume used in the intrathecal group 
was 22ml, emphasises the point made by Johnson that fear of potential pain may well drive 
the use of the PCA (Johnson, 1989). Given that the placebo was normal saline, it could 
however not influence the pain scores.  
In the intrathecal group, the quicker mobilisation achieved in a short time is testament to 
adequate analgesia. However, the fear of potential pain should not be underestimated. Even 
if present, the early mobilisation targets achieved are remarkable considering patients’ 
potential fear. The fact that minimal rescue analgesia was requested, despite the mobilisation, 
supports the contention that the dose of intrathecal morphine was effective and that the 
particular level VAS could be accepted as an indication that patients were not experiencing 




The double-blinded nature of the study assured that the PCA volume used was an acceptable 
indirect reflection of both the pain experienced by a patient as well as the fear of possible pain. 
Given that the latter is a uniquely individual experience, and as such not quantified in this 
study, the author asserts that the total pain perception of any particular patient needs to be 
addressed by the attending doctor who has to consider both the physical manifestation of pain 
as well as the psychological component of his/her patient. In addition, the volume of morphine 
used in the PCA group could also be less than potentially necessary as the sedative effect of 
morphine could result in a patient falling asleep and waking only when the pain becomes 
excessive (Coetzee, 2013). However, one has to keep in mind that the patient with significant 
pain is unlikely to fall asleep in the first instance. 
All these factors make a compelling argument that when opioid analgesia is relied upon, the 


















4.3 Safety of the intrathecal injection of morphine 
The use of morphine, both via the intravenous and intrathecal routes, will expose the patient 
to certain risks concerning the side effects of the drug.  
 
The bioavailability of a drug refers to its ability to distribute from its site of injection to its site 
of action and, in the case of spinal surgery, spinal segmental analgesia is the goal. This is 
easily achieved when introducing the drug intrathecally as the calculated dose will be delivered 
directly to the target site.  
 
Morphine, administered intravenously, will be distributed throughout various body 
compartments. The working of the drug will also be influenced by other tissues, such as fat 
(Bernards, 2002), where the physiochemical properties of the opioid and those of the tissue 
determine the interaction. The volume of distribution (Vd) is defined as the distribution of a 
medication between the plasma and the rest of the body. It can be expressed in the following 
formula: 
 
Vd = total amount of the drug in the body / total amount of drug in the plasma 
 
The Vd of morphine is 1 - 6L/kg which implies that it will be absorbed in other tissues of the 
body as well (Glare, 1991). Even though it is considered a mostly hydrophilic drug, it will be 
partially absorbed in adipose tissue (Linares, 2009). Should this component of the body 
habitus be significant, it could affect the bioavailability of the drug to target receptors. This will 
affect the efficacy of the drug and prompt the use of rescue analgesia or result in persistent 
and higher volume PCA use. A potential build-up of the drug should thus be considered along 
with later than expected clinical effects and, specifically, side-effects (Coetzee, 2010).  
Once distributed in the plasma, the drug will become available to all areas of target receptors 
with equal amounts being available to both the spinal and cranial µ-receptors. Considering 
that the respiratory control centre and receptors in the spinal cord would be affected, it follows 
that an increased dose, or cumulative doses, would increase the potential for side-effects. 
This, in contrast to the intrathecal route of administration, could present with earlier onset 
significant side-effects where the exposure of intrathecally introduced morphine to the cranial 
receptors only occur at a later stage. 
 
The key, when using intrathecal morphine, would then be to administer an effective dose which 




and medulla, however, the ideal is that it would be sufficiently diluted to not cause significant 
side-effects such as respiratory depression and excessive somnolence.  
 
Based on the above rationale, morphine is the better choice for intrathecal use as: it has a 
high affinity for the µ-receptors at the injection site, it does not absorb into the fatty myelin and 
it will persist in the cerebrospinal fluid for a lengthy period of time. However, it will have 
cephalic spread in the cerebrospinal fluid which is an unavoidable occurrence. The accurate 
calculation of a safe dose in a safe volume thus becomes imperative. The safety of the dose 
should be critically evaluated in accordance to parameters related to respiratory depression 
and level of consciousness.  
 
In order to critically evaluate the effects of the intrathecal opiates on the brain, as opposed to 
the spinal cord, blood gas analysis, monitoring of the respiratory rate, the determination of the 
OISS and FiO2 were done at various time intervals. These observations were done at 11 
predetermined time points post-operatively over the first 24 hours. It was envisaged that this 
exercise would define the risk in addition to providing valuable information to be used in 
suggesting a safe approach to the use of the intrathecal morphine. 
 
 
4.3.1 Intra-operative injection 
Initially there was some concern that intrathecal administration could result in a cerebrospinal 
fluid leak which could potentially affect the patient’s recovery and result in the loss of some 
morphine which was, in fact, supposed to remain in the CSF. 
The intrathecal injection was performed once the pedicular screws had been placed and the 
decompression had been completed. This allowed adequate time for the drug to work 
considering the remaining steps in the procedure and emergence from anaesthesia.  
To minimise the risk of a potential CSF leak, the author used a blunt instrument to depress 
the thecal sac in the midline at the border of the thecal sac and the cranial lamina within the 
surgical field. The injection was performed with a sterile insulin needle and syringe which is 
the smallest bore needle available. The anaesthetist was asked to prepare a solution of 
1mg/ml of morphine in normal saline and the surgeon drew the correct dose as it related to 
millilitres with 1ml being 1mg of morphine.  
The rationale for this injection site is that the inherent pressure within the thecal sac would 
tamponade the small puncture site onto the ventral surface of the lamina, thus reducing the 




which could then be mobilised gently, or the needle could be passed through said fatty tissue 
to further minimise a potential leak, as per Figure 2.2. 
By using a small volume (no more than 0.45ml for the maximum dose), the volume added to 
the thecal content is minimal and therefore it does not affect the pressure in the thecal sac. 
Consequently, it is thus extremely unlikely to perpetuate a leak. The expectation was further 
that the small volume added to the existing cerebrospinal spaces would limit the immediate 
rostral ascension of the drug. It is important to keep the needle in situ for approximately 30 
seconds to allow the injected content to disperse as it is a small volume with a high 
concentration of morphine. Cerebrospinal fluid pulsation associated with the normal cardiac 
cycle will allow the content to disperse locally within that time and when the needle is removed, 
the potential small flush of cerebrospinal fluid will unlikely contain a high concentration of 
morphine. Considering the small volume that is introduced into the thecal sac and knowing 
that spinal cord concentrations could be maintained up to 12 hours, it is important not to lose 
some of the morphine in this small back flush (Hindle, 2008).  
Once the injection had been performed, the rods were placed and secured, and the autologous 
bone graft was placed in the decorticated lateral gutters prior to commencing closure. This 
resulted in an average time from injection until skin closure of 28.21 minutes. It has been 
shown that maximum concentrations of intrathecal morphine are achieved at the target 
receptors in the spinal cord between 5 and 30 minutes post-injection (Sjöström, 1987). This 
does not mean that optimal analgesia has been achieved as the morphine still has to bind to 
the µ-receptor. This makes it even more important that the anaesthetist titrate analgesia in the 
recovery room should the patient be uncomfortable. Morphine has a high affinity for the µ-
receptor which makes this time short and the approximate 45 minutes it would take from 
injection until emergence of the patient from anaesthesia should be sufficient time for the 
administered dose to take effect.  
Complications related to cerebrospinal fluid leak include headache and a cerebrospinal fluid 
leak through the surgical site. In this study, no patient presented with a cerebrospinal fluid 
leak. Six incidents of headache were recorded at 8 hours, 4 at 24 hours and 7 at 48 hours 
post-operatively. Whether these headaches were related to a potential cerebrospinal fluid leak 
is uncertain.  
The surgical site drain was assessed for clotting in the draining tube towards the reservoir and 
if clotted, it was removed. All drains were removed after 24 hours.  
This technique has proved to be safe in limiting cerebrospinal fluid leak and related 





4.3.2 Respiratory depression 
Rhythmic breathing, generated by a complex neuronal network found in the brainstem, is 
essential to life (Montandon, 2011). The rhythm generated by the pre-Bötzinger complex found 
in the medulla is thus considered critical for maintaining breathing (Gray, 2001) and, ultimately, 
for the oxygenation of tissues. Opioids have a dose-dependent interaction with this area in the 
medulla which consequently affects the rhythm of breathing and which may result in a 
decrease in respiratory drive (Montandon, 2011). Not only do opioids effect the rhythm of 
breathing, they also influence the respiratory system and airway as they decrease the 
genioglossus muscle tone. This could cause potential airway obstruction and result in a 
sedatory effect which decreases response to stimuli (Coetzee, 2013) whilst, on the other hand, 
wakefulness is a stimulus to normal breathing (Talbot, 2003).  
In addition, a patient who is sleeping normally could present with rhythm disturbances related 
to rapid eye movement (REM) and non-REM phases of sleep. Krieger et al. studied 20 young 
(average age 24 years) and 20 older (average age 65.5 years) healthy patients with no 
previous history of sleep disturbances (Krieger, 1983). Hypopnea was defined as a 50% 
decrease in tidal volume in 1 minute compared to the tidal volume recorded during quiet 
wakefulness for a 3 minute period. Apnoea, defined as a complete cessation of air flow, was 
divided into central or obstructive apnoea. The authors reported a decrease in tidal volume for 
all patients during light sleep and a further decrease during deeper sleep. Hypopnea was 
demonstrated in 85% of the older group (more than 5 events per sleep hour) and apnoea in 
35%. Hypopnea was seen in 65% of the younger group and apnoea in 55%. They concluded 
that advanced age was a risk factor for sleep related respiratory events. Given the influence 
which sleep exerts on the respiratory system it follows that the presence of opiates, with their 
well-defined depressing effect on the respiratory control system, would introduce a heightened 
risk of severe respiratory depressive effects during sleep. In the light of this, it is specifically 
important to monitor patients during sleep periods when they are being exposed to opiate 
therapy. 
In the event of opioid related respiratory depression, the primary result is hypercarbia. This 
can be explained at the hand of the following formula: 
PaCO2 = k X VCO2/VA   (Equation 4.1) 
Where VCO2 is carbon dioxide production (which remains relatively constant) and VA refers 
to alveolar ventilation (Talbot, 2003). If the alveolar ventilation decreases, as seen in 




The question is whether this hypercarbia is dangerous to the patient. Permissive hypercapnia 
has long since been an accepted strategy in managing acute respiratory distress syndrome 
(ARDS) where the low-stretch ability of the lung prevents clearance of CO2 (Kregenow, 2002). 
Systemic effects of hypercarbia include, amongst others: increased ventilatory stimulation, 
cerebral vasodilation, increased sympathetic tone and it can also lead to reduced oxygen 
consumption (Kregenow, 2002). Hence, one can safely conclude that mild hypercarbia is not 
a life-threatening condition and that it only becomes such if and when hypoxia ensues.  The 
interaction between hypercarbia and hypoxia is best illustrated with reference to the 
abbreviated alveolar gas equation: 
PAO2 = FiO2(PB – PH2O) – PaCO2/0.8 (Equation 4.2) 
Where PAO2 = alveolar oxygen tension (in mm Hg), PB = barometric pressure, PH2O the 
saturated vapor pressure in the alveolus which is taken as a constant of 47mm Hg at 37oC 
and PaCO2 is the arterial carbon dioxide tension in mm Hg. With regards to the latter, the 
assumption is (correctly) made that the alveolar and arterial carbon dioxide tension are 
approximately similar. Note that a gradient exists from the alveolar PO2 to the capillary and 
arterial PO2 but, for the purposes of this discussion, this is assumed to remain constant. 
From this equation it is clear that as the alveolar ventilation decreases and the carbon dioxide 
increases (Equation 4.2), the alveolar PAO2 will decrease in a ratio of 1.2 i.e. for every 1 unit 
increase in PaCO2 there will be n decrease in PAO2 of 1.2. Hence, if alveolar ventilation is 
significantly depressed, the patient may become hypoxic. Hypoxia, for purposes of clinical 
medicine and in patients with normal lungs, is defined as a PaO2 less than 60mm Hg (or 
7.99kPa) based on the assumption that the oxyhaemoglobin dissociation curve is normal when 
this level of oxygenation is associated with a saturation of 90%. 
From Equation 4.2 it is also clear that, within limits, arterial oxygen partial pressure and thus 
saturation may well be maintained if inspired oxygen is raised.   
Furthermore, in wards and units where saturation is constantly displayed, staff and 
practitioners use the 90% cut off with impunity as the measurement is available and physiology 
is known to be normal. However, if the oxyhaemoglobin dissociation curve is shifted, with 
either a decrease or increase in P50, the relationship between the saturation and the partial 
pressure for oxygen will change. In the presence of uncompensated hypercarbia, the P50 will 
increase and the critical PaO2 will be associated with a lower saturation (less than 90%). 




Therefore, when assessing the side-effects of morphine, specifically for respiratory 
depression, one must carefully evaluate individual parameters but also appraise them within 
the broader context of facilitating a pain free, comfortable and safe patient. 
 
4.3.3 Respiratory rate (RR) 
When trying to assess the safe use of morphine, respiratory rate is often one of the factors 
closely monitored. However, the definition of bradypnea is not clear-cut and often varies 
across studies referencing morphine and the safe usage thereof (Ko, 2003). The challenge in 
using RR to define respiratory depression is that its monitoring usually forms part of hourly 
observations in a high care unit or at an even longer intervals in a general ward. Once 
assessed by nursing staff, respiratory rate represents, at best, a snapshot in time of a 
ventilatory pattern which may very well vary between observations.   
Similarly, the action of assessing RR or the mere presence of the nurse may disturb, or wake, 
the patient resulting in a less depressed state being recorded which, in reality, confounds the 
actual state of sedation. The inadequacies of this monitoring method have been highlighted 
before and recommendations have been made that this phenomenon not be used as a single 
or reliable reflection of respiratory depression (Coetzee, 2013).  
Only 5 incidents of low respiratory rate were recorded in this study and none prior to 6 hours 
post-operatively (Table 3.14). These low respiratory rates were not associated with a decrease 
in saturation below 90% nor an increase in PaCO2 over 6kPa. The OISS in the IT patient did 
not signify any dangerous sedation, yet a score of 2 was noted in the PCA patient during both 
incidents of bradypnea. This illustrates a sedate patient, yet the PaCO2 remained below 6kPa 
throughout the 24 hours observed. Additionally, the patient presented with a PaO2 of 11.6 and 
13.5kPa implying good oxygenation despite the low respiratory rate. It is thus justified to ask 
whether a “snapshot” count of respiratory rate could truly represent any form of respiratory 
distress or wellbeing.  
The value, or lack thereof, of considering RR can be placed in perspective by considering 
Equation 4.2 and the role of, for instance, elevated inspired oxygen. 
If one assumes the A-a gradient to be normal (healthy lungs) in association with a FiO2 supply 
of 0.21, then to achieve the minimal acceptable PAO2 of 60mm Hg (or 8kPa), the PaCO2 must 
rise to 72mm Hg (or 9.6kPa)! This was not the case in incidents observed in the study with a 
RR less than 10 breaths per minute. This emphasised the fact that all abnormal values were 




at the time. In real terms this implies that minute ventilation must be reduced by approximately 
50% over a period of time, once again emphasising the limitation of intermittent counting of 
respiration. 
It is safe to say that a low RR (less than 10 breaths per minute) is always concerning and 
requires prompt verification. Data garnered from this study, however, does not support RR to 
be of positive predictive value i.e. indicating severe hypercarbia and associated hypoxia. The 
author suggests that this parameter should be used as but one in a battery of observations 
continuously applied when monitoring the respiratory effects of opiates (Coetzee, 2013). 
The mean respiratory rates for both groups demonstrated a steady increase over 24 hours 
post-operatively. This increase was noted to start between 6 and 8 hours post-operatively, as 
per Figure 3.9. As wakefulness is a stimulus for respiration (Talbot, 2003), the steady increase 
is most-likely a reflection of increased activity in the ICU the following morning after the 
procedure at approximately 16 hours post-operatively on average. At this stage nursing 
activities would intensify in the ICU with patients being washed and active attempts at 
mobilisation being initiated.  
However, an increase in observed mean RR commences at more or less 6 to 8 hours post-
operatively, thus effectively during the night for most patients. This could indicate that during 
the first 6 to 8 hours post-operatively, the effect of morphine may well have played a role in 
the pattern of respiration. A decreasing trend is noted in both groups up to 3 hours post-
operatively. Admittedly, this mean rate is between 15 and 16 breaths per minute with the PCA 
group showing a decrease, albeit briefly, below 15 breaths per minute between 3 and 4 hours 
post-operatively. The mean RR for the PCA group is consistently less than that of the 
intrathecal group over the initial 24 hours post-operatively. The upward trend which was noted, 
particularly from 10 hours onwards, suggests that RR will no longer be a real concern from 10 
hours post-surgery. 
After 6 hours, a steady increase in mean RR for both groups was noted. Overall, however, the 
checking of RR did not contribute significantly to the successful monitoring of the effect of the 
opiates on the respiratory drive. In summary, little difference was noted between the 
intrathecal and PCA morphine groups. Perhaps the RR trend is noteworthy inasmuch as RR 
increased from 10 hours onwards thus suggestive of a diminished opiate effect at this time 







The OISS is not a direct measure of respiratory depression but rather focuses on the level of 
sedation of a patient. Sedation is a central action, or side-effect, of morphine and would thus 
indicate, in the case of intrathecal morphine, that a cranial spread of the drug had occurred 
(Kroin, 1993). 
Its association with respiratory depression is two-fold. Firstly, less opioids are required to affect 
sedation than respiratory depression. Sedation, therefore, could be considered an early 
warning sign for respiratory depression (Coetzee, 2013). Secondly, in obese patients, 
increased fat deposition in the pharyngeal wall will cause a smaller pharyngeal volume which 
when relaxed, such as in the case of sedation, can cause potential airway collapse and 
compromise (Benumof, 2001).  
As argued by Coetzee et al., the use of a sedation scale should be afforded preference over 
counting the RR and should be used in the monitoring of all patients who have received opioids 
(Coetzee, 2010). The values of s (asleep, easily aroused) and 1 (awake and alert) indicate 
patients not experiencing sedatory effects. In the study population used for this thesis, only 3 
patients recorded a value of 2 and no values of 3 or 4 were documented. These occurred only 
in the PCA group and amounted to 19 events. The benefit of this study is that during the 
evaluation of sedation (OISS), an arterial blood gas analysis was also performed which 
accurately defined the impact on PaO2 and PaCO2.  
One patient was evaluated as a 2 at 11 time-points, yet at no point did saturation register 
under 90% and PaCO2 remained in excess of 6kPa. The respiratory rate decreased to below 
10 breaths per minute at 2 of these time points. This patient was comfortable and had no 
subsequent deleterious effects related to the opioids received, but his RR certainly warranted 
close observation. The FiO2 was 0.4 throughout the first 23 hours and at 24 hours it was 
recorded at 0.21. The second patient recorded OISS 2 at 7 time-points, yet no events of 
saturation, RR and PaCO2 were noted which would suggest possible respiratory depression. 
The same applied to the third patient who had a single OISS value of 2. This patient had 
normal saturation and RR, yet an elevated PaCO2 (6.9kPa) was noted.  
The fact that very few of the parameters which suggest respiratory depression occurred in the 
abnormal range verifies that patients can experience the sedatory effect of morphine without 
suffering respiratory depression. However, if the scale does indicate that a patient is suffering 
from the sedatory effects of an opioid, it is imperative that monitoring be continuous and that 
other parameters be carefully evaluated as well. The opinion of the author in this regard is that 




that arterial blood gas (in particular) should be done to place the occurrence of sedation within 
the correct perspective. 
No patient in the IT group recorded any OISS values beyond 1. The conclusion is that there 
was limited cranial spread of the intrathecal morphine in the doses used. To some extent this 
is a reassuring observation as, already discussed, patients experienced effective analgesia at 
the doses used. Therefore, it seems as if the elected dose was not excessive inasmuch as it 
resulted in significant cranial spread in the cerebrospinal fluid.  
 
4.3.5 Oxygen saturation 
The use of oxygen saturation, as a single observation, to detect respiratory depression is a 
dangerous practice. If an opioid induced respiratory depression does take place, alveolar 
ventilation is affected, and this could result in hypoxia, hypercarbia and desaturation. In this 
cascade of events, once desaturation does occur as a late warning sign, the patient would 
already be in significant danger. This already dire situation could be compounded when 
oxygen is supplemented as this procedure could mask potential depression with, what may 
well appear to be, an acceptable saturation while, in fact, significant respiratory depression is 
occurring as per Equation 4.2 (Fu, 2004). 
The mean saturation in both groups demonstrated the same trend of a sharp rise until 3 hours 
post-operatively with a steady decline up to 24 hours post-operatively. This could represent 
the use of supplemental oxygen on arrival in the neurosurgical ICU for the first few hours 
(Figure 3.10).  
When cross-tabulated, no incidents of RR decreasing below 10 breaths per minute coinciding 
with saturation of less than 90% occurred. However, in view of the elevated PaCO2 which was 
commonly noted (19.8% incidence overall), respiratory depression had, in fact, occurred but 
it was either not severe enough and/or the effect on oxygenation was masked by an elevated 
inspired oxygen (Fu, 2004).  
Of the saturations below 90%, 5 were supplemented with oxygen at the time (FiO2 0.4). None 
of these were associated with bradypnea. In all 5 these cases, the A-a gradient ranged 
between 151 and 182.52 mm Hg suggesting abnormal lung parenchymal function, most likely 
related to a decreased functional residual capacity secondary to atelectasis post-anaesthetic. 
It highlights the fact that vigilance is required even in the absence of potential respiratory 




Another aspect worth considering with pulse oximetry is a possible poor contact between the 
patient’s finger and the sensor or inadequate pulsatile flow being registered for a number of 
reasons. If the contact is poor, a false measurement will be noted. This is a common 
occurrence in ICUs where nursing staff become desensitised to the alarms and, consequently 
a decrease in saturation may be wholly disregarded or the response to a monitor alarm may 
not be as prompt as one would wish.  
In this study the author had the advantage of monitoring blood gases. Generally, saturation, a 
parameter which is continuously available, was tracked to indicate whether effective 
oxygenation was taking place.  
 
4.3.6 PaCO2 
A PaCO2 in excess of 6kPa in a normal patient is indicative of some depression of the alveolar 
ventilation if not associated with an elevated standard bicarbonate and normal pH, in which 
case it would, from a physiological perspective, be regarded as a normal value. It should be 
reiterated that type 2 respiratory failure, in a patient with prior normal lungs, is defined in terms 
of an elevation of the PaCO2 in excess of 8kPa. An elevated PaCO2 must be considered in 
the context of how it relates to the alveolar ventilation.  Equation 4.1 (PaCO2 = k X VCO2/VA) 
indicates that a rise in PaCO2 would directly be as a result of alveolar hypoventilation. The 
latter can either be as a result of a decreased tidal volume, or slow RR, or a combination of 
these two. This deduction rests on the assumption that the VCO2 remains constant (which it 
usually does) and that only in conditions of hypermetabolism (such as an elevated 
temperature, thyroid toxicosis or excessive metabolism of fat) would the VCO2 increase per 
se. However, notwithstanding these possible explanations, the chemoreceptors in the brain 
monitor pH and the maintenance of a normal pH is a priority in human physiology. Given that, 
according to the Henderson Hasselbalch equation (Po, 2001) pH is mainly determined by the 
HCO3/PaCO2 ratio, it follows that in cases where the production of carbon dioxide thus 
increases, the onus rests on the brain to increase the minute ventilation to maintain the PaCO2 
within the normal range.  
Equation 4.2 summarises the relationship between PaCO2 and alveolar oxygenation and thus 
arterial oxygenation. 
As per Figure 3.11, the graph depicting the mean PaCO2 values between the PCA and 
intrathecal morphine groups demonstrate a rapid decrease in values from 4 hours post-
operatively and onwards. This implies that in both groups, vigilance is required and, where 




administered in the first 4 hours post-operatively. A similar trend of gradual decrease is noted 
from 10 hours onwards with the mean PaCO2 of both groups recorded below 6kPa. In an 
attempt to pinpoint a period of risk associated with hypoventilation, statistical analysis 
indicates a significant decrease in the mean PaCO2 in the IT group from 4 hours up to 24 
hours post-operatively for every time-point’s data collected (Table 3.18). The mean PaCO2 in 
the PCA group had a statistically significant decrease from 16 hours up to 24 hours post-
operatively. This significance supports the use of supplemental oxygen to counter any 
deleterious effects of potentially elevated PaCO2 for the first 4 hours post-operatively in the IT 
group. 
Crosstabulation between incidences of bradypnea and elevated PaCO2 (higher than 6kPa) 
revealed no coinciding events. This is comforting as it shows that an adequate RR was 
maintained in all instances of an elevated PaCO2. These results have to be considered in the 
context of respiratory rate being a snapshot in a ventilatory pattern which could, potentially, 
include episodes of bradypnea (Catley, 1985). It also raises queries as to why the PaCO2 was 
elevated if the RR was maintained. The only explanations being that the tidal volume 
decreased and/or the VCO2 increased and was not matched by the increase in tidal volume 
(McCrimmon, 2003). 
Furthermore, in nearly all ICU settings the diurnal cycle of a patient is respected, with a 
designated “sleep time” thus being set to ensure maximum rest. In the Neurosurgery ICU at 
Tygerberg Academic Hospital, this “sleep time” is from 22:00 until 06:00 the following day. 
During this time every attempt is made to curb noise within the ICU and to minimise activity in 
an effort to ensure that patients obtain adequate sleep. However, all essential and prescribed 
monitoring activities continue. It is this prolonged period of sleep that could pose a risk to 
patients, especially if they are obese (Rose, 1994; Benumof, 2001).  Nurse observations are 
sometimes fragmentary during the sleep period and staff often hesitate to wake a patient to 
check on his/her level of sedation. Hence, nursing staff often rely on the RR and saturation, 
with both of these having clear limitations. Not checking the sedation level though may very 
well constitute the omission of a crucial part of a required set of observations if patients with 
opiate analgesia are to be successfully protected against the risky effects of the morphine. 
Obese patients possess an additional chest weight which could potentially restrict normal 
respiration and thus result in shallower breathing. If the rate does not accommodate the 
smaller tidal volume, the potential for heightened PaCO2 increases. This, if occurring in 
combination with potential respiratory depression, could pose an additional risk to the patient. 
When incidences of increased PaCO2 (as defined by a PaCO2 higher than 6kPa) were 




in excess of 6kPa during the day time for both groups (PCA 21.1%, intrathecal morphine 
32.5%). These values were both higher than the sleep time percentages of 16.4% in the PCA 
group and 14% in the intrathecal morphine group. This is an unexplained but reassuring 
finding because the median BMI was in excess of 30kg/m2 in both groups, suggesting that 




Hypoxia is the biggest danger when using drugs that could interfere with respiratory control 
mechanisms.  Effectively, the elevation of PaCO2 (within limits) is not dangerous in itself and 
the body normally responds to the elevated levels by increasing respiratory drive in the short 
term and bicarbonate retention in the longer term (Kregenow, 2002). It is when the respiratory 
drive is decreased, as the case may be when opioids are administered, that hypoxia could 
become a significant risk.  
As previously explained, Equation 4.2 the abbreviated alveolar gas equation, summarises the 
risk associated with alveolar hypoventilation in the following way: PAO2 (mm Hg) = (PB – PH2O) 
FiO2 - PaCO2/RQ. This implies that once the PAO2 has decreased to dangerous levels, 
considered to be less than 8kPa or 60mm Hg, the PaCO2 increases to severe levels. This 
interaction is, as already mentioned, subject to the level of inspiratory oxygen which could 
serve to overcome the effect of hypercarbia on the arterial oxygen tension but may also mask 
the depression of the alveolar ventilation in the presence of opiates. The attending practitioner 
must understand this interaction when considering the alveolar gas equation. 
There were only 7 incidences of PaO2 decreasing below 8kPa in both study groups with 3 
instances in the PCA group and 4 in the intrathecal morphine group. Of these 7 incidents, 2 
occurred in the first post-operative hours and the other 5 occurred at hours 16 (n=3) and 20 
(n=2) post-operatively. 
• The first instance was in the PCA group at the first hour post-operatively with a PaO2 
of 7.5kPa. This occurred in the high care unit in an awake patient with a RR of 20 
breaths per minute with the warning sign being a saturation of 88%. The patient was 
on room air. It seems as if the low PaO2 was not related to the opioid as no apparent 
sedation was present, nor was the PaCO2 markedly elevated (6.1kPa). This patient’s 
FiO2 was increased to 0.4 which improved the PaO2 to 16.4kPa and the saturation to 




• The second case belonging to the intrathecal group, with a PaO2 of 7.7kPa, presented 
at one hour post-operatively. This was a similar presentation where the only parameter 
suggesting concern was a saturation of 89%. The RR was 15 breaths per minute and 
the patient was awake and not sedated. The patient was on room air. The PaCO2 
showed an increase to 7.2kPa. The patient’s FiO2 was increased to 0.4 resulting in the 
PaO2 increasing to 21.3 kPa and the saturation to 99%. 
With both incidents occurring in the first post-operative hour, the probability exists that the 
functional residual capacity of the lungs was decreased due to the recent anaesthesia which 
is known to reduce the FRC (Hewlett, 1974; Rutherford, 1994; Don 1972). In addition, age and 
body habitus may also have played a role (Nunn, 2006). The saturation was the only 
measurable warning sign and appropriate action (increasing the FiO2) had the appropriate 
result i.e. improved oxygenation. The fact that both patients were awake would suggest that 
very little central action of morphine was present.  
The remaining 5 incidents of PaO2 less than 8kPa all occurred at either 16 or 20 hours post-
operatively.  
• The third patient was in the PCA group and at 16 hours presented a PaO2 of 7.69kPa. 
The patient was awake, had a RR of 12 and FiO2 was 0.4. The saturation was 88.6%. 
The PaCO2 was normal at 4.8kPa. The following blood gas one hour later revealed a 
PaO2 of 20.33kPa and saturation of 99% with FiO2 of 0.4. Minimal change in the other 
parameters was noted. The low PaO2 at the 16 hour mark was not due to alveolar 
hypoventilation (i.e. a central respiratory drive effect) as the PaCO2 was normal. The 
A-a gradient was 182.52mm Hg which would suggest a decreased FRC as a cause for 
the hypoxia. 
• Two other patients, one in the PCA and one in the intrathecal group, presented at 20 
hours post-operatively with PaO2 less than 8kPa. In both cases there was no 
bradypnea and no evidence of sedation. The saturations were 90% in both patients on 
room air. In both cases the PaCO2 was elevated (6.7 and 6.4kPa). The patient in the 
intrathecal group did not receive supplementary oxygen. One hour later there still was 
no bradypnea, no sedation was noted, and saturation remained 90%. The PaCO2 
decreased to 6.1kPa. The patient in the PCA group did not receive supplemental 
oxygen, was not sedated, had no bradypnea and the saturation improved to 94% with 
the PaCO2 decreasing to 5.6kPa. In both these cases alveolar hypoventilation played 
a small role in the reduction of the PaO2, but this can only explain a small portion of 
the reduced oxygenation. The remainder can probably be ascribed to residual 
reduction in the FRC which was initiated during anaesthesia and carried over into the 




Clinical parameters set to prompt responses for ICU nursing staff were: RR, OISS and 
saturation. Considering that neither of these elements were abnormal, no action was taken. In 
hindsight, it is important to reflect on the saturation of 90% and the low PaO2 which is 
associated with it. Firstly, it relates to the relationship between oxygen tension and saturation 
via the oxyhaemoglobin dissociation curve which, as already alluded to, may vary depending 
on the P50. Secondly it will be prudent to rather select a saturation of 92 to 94% as a cut-off 
criterion in light of the fact that the decrease in saturation will be a relatively late marker of 
impending problems. 
 
• The sixth patient was in the intrathecal group and whilst on 40% facemask oxygen, a 
desaturation to 88% was noted. The RR was 14 breaths per minute and the OISS 1. 
The PaO2 was 7.3kPa and PaCO2 6.1kPa. The next saturation improved to 92% and 
the RR remained unchanged. However, one hour later, the FiO2 was recorded as 0.21 
and the OISS remained 1. The patient was fully awake and cooperative. In this 
instance the alveolar hypoventilation did play a role in the reduction of the PaO2 and it 
could have been addressed with ease if the inspired oxygen had been sufficiently 
elevated. 
It is evident that the clinical parameters set to recognise hypoxia might not be stringent 
enough. In hindsight, all parameters were close to the thresholds set for alerts. One must 
appreciate that there is a slow deterioration in these parameters and in an environment where 
alarms measure absolute values and not trends (such as decreasing RR or saturation over 
time), a hypo-ventilating patient could present rather suddenly in the absence of prior 
warnings. In addition, it may be prudent to supply a minimum of 28% oxygen in the post-
operative period and the prescription issued by the practitioner must clearly state the remedy 
if and when the saturation decreases below say 92%. The remedy is simply to increase the 
inspired oxygen to 40% and continuously observe the patient. 
None of the patients in which PaO2 less than 8kPa was measured had evidence of sedation 
which is regarded as a constant finding when opioid induced respiratory depression is present 








4.4 Direct cost 
The direct costs involved in the complete management of the patients in both groups only 
differed in length of stay in the general wards. The pre-admission, surgical procedure and ICU 
stay was standardized and the same for each patient. 
The billing practices at each institution differs and thus it is very difficult to provide an accurate 
figure to the general l saving generated by the earlier mobilization and discharge as was 
demonstrated in the earlier discharge of 2 days. The data represented here applies to our 
institution and obviously the 2 days saving will depend on the cost per ward day of any 
particular institution. 
The cost saved per day in the ward, amounts to 43.5 % saving on the ward day cost. However, 
in the total cost per procedure, the cost saved was 5%. The cost saving favoured the IT group. 
This however is in context of the heavily subsidized public service pricing model implying that 
the cost of a general ward stay is much less than for example the surgical implants and this 
will differ between institutions and both private and public facilities. However, if the total 
number of procedures are considered, it may well amount to a large cumulative value.  
The 2 day saving is not only important as a cost saver.  In an environment where bed 
availability is progressively becoming more problematic, making beds available are of 
enormous importance. Approximately 60 such procedures are annually performed at 
Tygerberg Hospital which will translate in 120 available bed days in the neurosurgical service.  

















The purpose of this study was to evaluate the safety, efficacy and cost-effectiveness of a 
proposed dose of intrathecal morphine when comparing it to the standard of care practice at 
a tertiary public service hospital in South Africa. This was tested in first time, single level 
lumbar spinal fusion surgery in a prospective, double blind, randomized placebo controlled 
fashion. 
The first question was whether the proposed dose of 0.005mg/kg of intrathecal morphine up 
to a maximum dose of 0.45mg was effective. The intervention was compared to the standard 
of care which is a patient controlled analgesia device able to deliver 1mg of intravenous 
morphine every 7 minutes.  The primary hypothesis that the proposed dose will result in faster 
mobilization and shorter hospital stay was proven when the intrathecal morphine (IT) group 
mobilized a statistically significant 1.93 days faster than the patient controlled analgesia (PCA) 
group. This was ascribed to the interaction of the directly introduced morphine to the µ-
receptors in the spinal cord resulting in segmental analgesia to counter painful stimuli from the 
surgical site.  
The visual analogue scores (VAS) were recorded when the patient was lying still and moving 
during the post-operative course. The difference between these scores represented the 
intensity of pain when moving. A statistically significant difference was noted at 24 hours post-
operatively in favour of the IT group. This was further emphasized when the effect of 
mobilization on the VAS demonstrated a statistically significant effect in favour of the IT group 
implying that despite the active mobilization occurring in the group, the IT morphine group had 
better pain control at 24 hours. It must be emphasized that the PCA group also had excellent 
analgesia with mean VAS lying still values always less than 3 for the first 24 hours post-
operatively. 
The second question of safety of the proposed dose was evaluated by clinically assessing the 
known side-effects of morphine which included nausea and vomiting, pruritis and respiratory 
depression. The later was clinically assessed by means of the respiratory rate, the oxygen 
saturation and by using an opioid induced sedation scale (OISS). These were further 
supported by 11 arterial blood gas analyses within the first 24 post-operative hours. No 
statistically significant difference could be demonstrated between the two groups when 
nausea and vomiting and pruritis was assessed.  
The mean respiratory rate in both groups demonstrated an increasing trend after 10 hours 




probable effect of the opiates became less). Furthermore, the mean PaCO2 in the IT group 
was initially elevated for up to 4 hours after which a statistically significant decrease was noted 
up to 24 hours. Seven incidents of hypoxia (PaO2 < 8kPa) were observed in 4 of the IT group 
and 3 in the PCA group. All seven incidents could be explained by either a low FiO2 or a 
decreased functional residual capacity, as demonstrated by the A-a gradient, and some 
degree of hypoventilation i.e. the effect of the opiate. In none of the patients where the PaO2 
less than 8kPa were recorded, were the patients overtly sedated. These findings highlighted 
the fact that the conventional lowest acceptable oxygen saturation level of 90% should be 
higher in order to define patients at risk at an earlier stage. Similarly, supplemental oxygen is 
advised for all patients, irrespective of the analgesic technique used, for up to 10 hours post-
operatively. Monitoring should include no single parameter, but a combination of respiratory 
rate, saturation and sedation as no single entity warned of the risk of desaturation. 
 
The third question of a direct economic impact was answered when calculating the effect of 
an earlier mobilization on both the patient and the hospital. Due to the fact that the admission 
time, surgical procedure and ICU stay were equal for both groups, the saving occurred in the 
general ward stay which translated to 43.5% in favour of the IT group.  
In addition, the saving of two ward days occupancy has profound implications for a burdened 
public service where these beds can be utilized for the next patient requiring surgical 
admission and intervention. An estimated 120 bed-days per year are expected to be saved by 
means of the intrathecal morphine intervention in the Department of Neurosurgery at 
Tygerberg Academic Hospital. 
 
The study proved that the proposed intrathecal morphine dose of 0.005mg/kg up to a 
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